<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hum Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Hum. Genet</journal-id>
<journal-title-group>
<journal-title>Human Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0340-6717</issn>
<issn pub-type="epub">1432-1203</issn>
<publisher>
<publisher-name>Springer Berlin Heidelberg</publisher-name>
<publisher-loc>Berlin/Heidelberg</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28213670</article-id>
<article-id pub-id-type="pmc">5370280</article-id>
<article-id pub-id-type="publisher-id">1766</article-id>
<article-id pub-id-type="doi">10.1007/s00439-017-1766-y</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Emerging genotype–phenotype relationships
in patients with large <italic>NF1</italic> deletions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3398-5913</contrib-id>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>Hildegard</given-names>
</name>
<address>
<phone>0049 731 50065421</phone>
<email>hildegard.kehrer-sawatzki@uni-ulm.de</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mautner</surname>
<given-names>Victor-Felix</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cooper</surname>
<given-names>David N.</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9748</institution-id><institution-id institution-id-type="GRID">grid.6582.9</institution-id><institution>Institute of Human Genetics, </institution><institution>University of Ulm, </institution></institution-wrap>Albert-Einstein-Allee 11, 89081 Ulm, Germany </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution>Department of Neurology, </institution><institution>University Hospital Hamburg Eppendorf, </institution></institution-wrap>20246 Hamburg, Germany </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0807 5670</institution-id><institution-id institution-id-type="GRID">grid.5600.3</institution-id><institution>Institute of Medical Genetics, School of Medicine, </institution><institution>Cardiff University, </institution></institution-wrap>Cardiff, CF14 4XN UK </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>17</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>17</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2017</year>
</pub-date>
<volume>136</volume>
<issue>4</issue>
<fpage>349</fpage>
<lpage>376</lpage>
<history>
<date date-type="received">
<day>27</day>
<month>12</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>8</day>
<month>2</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the
terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in
any medium, provided you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if changes
were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>The most frequent recurring mutations in neurofibromatosis type 1
(NF1) are large deletions encompassing the <italic>NF1</italic>
gene and its flanking regions (<italic>NF1</italic>
microdeletions). The majority of these deletions encompass 1.4-Mb and are associated
with the loss of 14 protein-coding genes and four microRNA genes. Patients with
germline type-1 <italic>NF1</italic> microdeletions frequently
exhibit dysmorphic facial features, overgrowth/tall-for-age stature, significant
delay in cognitive development, large hands and feet, hyperflexibility of joints and
muscular hypotonia. Such patients also display significantly more cardiovascular
anomalies as compared with patients without large deletions and often exhibit
increased numbers of subcutaneous, plexiform and spinal neurofibromas as compared
with the general NF1 population. Further, an extremely high burden of internal
neurofibromas, characterised by &gt;3000 ml tumour volume, is encountered
significantly, more frequently, in non-mosaic <italic>NF1</italic>
microdeletion patients than in NF1 patients lacking such deletions. <italic>NF1</italic> microdeletion patients also have an increased risk of
malignant peripheral nerve sheath tumours (MPNSTs); their lifetime MPNST risk is
16–26%, rather higher than that of NF1 patients with intragenic <italic>NF1</italic> mutations (8–13%). <italic>NF1</italic> microdeletion patients, therefore, represent a high-risk group for
the development of MPNSTs, tumours which are very aggressive and difficult to treat.
Co-deletion of the <italic>SUZ12</italic> gene in addition to
<italic>NF1</italic> further increases the MPNST risk in
<italic>NF1</italic> microdeletion patients. Here, we summarise
current knowledge about genotype–phenotype relationships in <italic>NF1</italic> microdeletion patients and discuss the potential role of the genes
located within the <italic>NF1</italic> microdeletion interval
whose haploinsufficiency may contribute to the more severe clinical
phenotype.</p>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer-Verlag Berlin Heidelberg 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p>Neurofibromatosis type 1 (NF1; MIM#162200) is a tumour predisposition
syndrome with an incidence at birth of 1 in 2000–3000 (Crowe et al. <xref ref-type="bibr" rid="CR33">1956</xref>; Lammert et al. <xref ref-type="bibr" rid="CR104">2005</xref>; Uusitalo et al. <xref ref-type="bibr" rid="CR224">2015</xref>). The hallmark features of NF1 are
café-au-lait spots (CALS) and the pathognomonic neurofibromas. The majority of NF1
patients are characterised by mutations residing within the boundaries of the
<italic>NF1</italic> gene, which spans 287-kilobases (kb) of
chromosome 17q11.2 and comprises 57 constitutive and 3 alternatively spliced
exons.</p>
<p>Only a few genotype–phenotype correlations in NF1 have been identified
to date. One of these relates to spinal neurofibromatosis (SNF) which is
characterised by bilateral neurofibromas located at all 38 spinal nerve roots. The
risk of having SNF versus NF1 without spinal neurofibromas, or NF1 with
neurofibromas affecting only some but not all spinal nerve roots, is significantly
increased in individuals harbouring <italic>NF1</italic> missense
mutations (Ruggieri et al. <xref ref-type="bibr" rid="CR186">2015</xref>).
Furthermore, the recurrent three base-pair in-frame deletion, c.2970-2972 delAAT,
within exon 17 of the <italic>NF1</italic> gene leads to the loss
of a single amino acid (p.Met992del) and is associated with a relatively mild NF1
phenotype that is characterised by the occurrence of CALS and skinfold freckling but
a lack of externally visible cutaneous or plexiform neurofibromas (Upadhyaya et al.
<xref ref-type="bibr" rid="CR223">2007</xref>). The second well-established
genotype–phenotype correlation in NF1 is associated with missense mutations
affecting codon p.Arg1809. Individuals with these very specific missense <italic>NF1</italic> mutations exhibit CALS (with or without freckling)
and Lisch nodules, but no externally visible plexiform neurofibromas or cutaneous
neurofibromas (Pinna et al. <xref ref-type="bibr" rid="CR168">2015</xref>;
Rojnueangnit et al. <xref ref-type="bibr" rid="CR185">2015</xref>).
Approximately, 25% of the individuals with missense mutations affecting codon
p.Arg1809 have Noonan-like features including pulmonic stenosis and short stature
whilst 50% of them exhibit developmental delay and/or learning disability
(Rojnueangnit et al. <xref ref-type="bibr" rid="CR185">2015</xref>). However,
missense mutations affecting codon p.Arg1809 appear to be quite rare, since they
were observed in only 1.2% of the cohort of 7000 NF1 patients with identified
mutations. In the same cohort of patients, the prevalence of the recurrent one amino
acid deletion (p.Met992del) was 0.8% (Rojnueangnit et al. <xref ref-type="bibr" rid="CR185">2015</xref>).</p>
<p>The third genotype–phenotype relationship evident in NF1 is that
associated with large <italic>NF1</italic> deletions and is the
topic of this review. An estimated 4.7–11% of all NF1 patients have large deletions
encompassing the entire <italic>NF1</italic> gene and its flanking
regions at 17q11.2 (Cnossen et al. <xref ref-type="bibr" rid="CR27">1997</xref>; Rasmussen et al. <xref ref-type="bibr" rid="CR175">1998</xref>; Kluwe et al. <xref ref-type="bibr" rid="CR95">2004</xref>; Zhang et al. <xref ref-type="bibr" rid="CR261">2015</xref>). Large deletions of the <italic>NF1</italic> gene and its flanking regions (generally termed ‘<italic>NF1</italic> microdeletions’) are frequently associated with a
severe clinical manifestation of NF1 as described below.</p>
<p>Altogether, four types of large <italic>NF1</italic>
deletion (type-1, 2, 3 and atypical) have been identified that are distinguishable
in terms of their size and breakpoint location, by the number of genes located
within the deletion region or by the frequency of somatic mosaicism with normal
cells not harbouring the deletion. Most frequent are the type-1 <italic>NF1</italic> deletions which encompass 1.4-Mb and include 14
protein-coding genes as well as four microRNA genes (Fig. <xref ref-type="fig" rid="Fig1">1</xref>) (Dorschner et al. <xref ref-type="bibr" rid="CR44">2000</xref>; Jenne et al. <xref ref-type="bibr" rid="CR79">2001</xref>; López-Correa et al. <xref ref-type="bibr" rid="CR121">2001</xref>). Type-1 deletions account for 70–80% of all large <italic>NF1</italic> deletions and usually occur as germline deletions
that are present in all cells of the affected patients (Messiaen et al. <xref ref-type="bibr" rid="CR136">2011</xref>). Most type-1 <italic>NF1</italic> deletions are caused by interchromosomal non-allelic homologous
recombination (NAHR) during maternal meiosis (López-Correa et al. <xref ref-type="bibr" rid="CR120">2000</xref>; Steinmann et al. <xref ref-type="bibr" rid="CR206">2008</xref>). The NAHR events causing type-1 <italic>NF1</italic> deletions are mediated by the low-copy repeats,
NF1-REPa and NF1-REPc. Within these low-copy repeats, recurrent breakpoints have
been detected within two NAHR hotspots, termed paralogous recombination sites 1 and
2 (Forbes et al. <xref ref-type="bibr" rid="CR56">2004</xref>; De Raedt et al.
<xref ref-type="bibr" rid="CR38">2006</xref>; Bengesser et al. <xref ref-type="bibr" rid="CR15">2014</xref>; Hillmer et al. <xref ref-type="bibr" rid="CR70">2016</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Schema of the genomic region at 17q11.2 harbouring the <italic>NF1</italic> gene and its flanking genes included within
the boundary of the type-1 <italic>NF1</italic> deletion
interval encompassing 1.4-Mb (<italic>red bar</italic>).
The <italic>arrows</italic> given subsequent to the
symbols of the genes denote their transcriptional orientation. <italic>SUZ12P1</italic> and <italic>LRRC37B</italic>-<italic>P</italic> are
non-functional pseudogenes. <italic>cen</italic>
centromeric direction, <italic>tel</italic> telomeric
direction</p></caption><graphic id="MO1" xlink:href="439_2017_1766_Fig1_HTML"></graphic></fig>
</p>
<p>In contrast to type-1 <italic>NF1</italic>
deletions, type-2 deletions encompass only 1.2-Mb and are associated with
hemizygosity for 13 protein-coding genes since the <italic>LRRC37B</italic> gene is absent from the deleted region (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). At least 10% of large <italic>NF1</italic> deletions are type-2 but this is very likely to be an
underestimate (Messiaen et al. <xref ref-type="bibr" rid="CR136">2011</xref>).
Type-2 deletions are also mediated by NAHR but in contrast to type-1 <italic>NF1</italic> deletions, their breakpoints are located within
<italic>SUZ12</italic> and its highly homologous pseudogene
<italic>SUZ12P1</italic> which flank NF1-REPc and NF1-REPa,
respectively (Fig. <xref ref-type="fig" rid="Fig1">1</xref>) (Petek et al.
<xref ref-type="bibr" rid="CR165">2003</xref>; Vogt et al. <xref ref-type="bibr" rid="CR242">2012</xref>). Type-2 <italic>NF1</italic> deletions are frequently of postzygotic origin, mediated by
mitotic NAHR, and hence are associated with somatic mosaicism of normal cells
lacking the deletion (Kehrer-Sawatzki et al. <xref ref-type="bibr" rid="CR89">2004</xref>; Steinmann et al. <xref ref-type="bibr" rid="CR205">2007</xref>; Roehl et al. <xref ref-type="bibr" rid="CR182">2010</xref>, <xref ref-type="bibr" rid="CR183">2012</xref>).</p>
<p>Type-3 <italic>NF1</italic> deletions are very rare;
these 1.0-Mb deletions occur in only 1-4% of all patients with gross <italic>NF1</italic> deletions and are mediated by NAHR between NF1-REPb
and NF1-REPc leading to hemizygosity for a total of nine protein-coding genes
(Fig. <xref ref-type="fig" rid="Fig1">1</xref>) (Bengesser et al. <xref ref-type="bibr" rid="CR14">2010</xref>; Pasmant et al. <xref ref-type="bibr" rid="CR160">2010</xref>; Zickler et al. <xref ref-type="bibr" rid="CR264">2012</xref>). As their name suggests, atypical large
<italic>NF1</italic> deletions do not exhibit recurrent
breakpoints and are quite heterogeneous in terms of their size and the number of
genes located within the deleted region (Upadhyaya et al. <xref ref-type="bibr" rid="CR221">1996</xref>; Cnossen et al. <xref ref-type="bibr" rid="CR27">1997</xref>; Dorschner et al. <xref ref-type="bibr" rid="CR44">2000</xref>; Kehrer-Sawatzki et al. <xref ref-type="bibr" rid="CR88">2003</xref>, <xref ref-type="bibr" rid="CR90">2005</xref>, <xref ref-type="bibr" rid="CR91">2008</xref>; Venturin
et al. <xref ref-type="bibr" rid="CR231">2004a</xref>; Gervasini et al.
<xref ref-type="bibr" rid="CR61">2005</xref>; Mantripragada et al.
<xref ref-type="bibr" rid="CR127">2006</xref>; Pasmant et al. <xref ref-type="bibr" rid="CR158">2008</xref>, <xref ref-type="bibr" rid="CR159">2009</xref>, <xref ref-type="bibr" rid="CR160">2010</xref>; Vogt et
al. <xref ref-type="bibr" rid="CR243">2014</xref>). It has been estimated that
8–10% of all large <italic>NF1</italic> deletions are atypical
(Pasmant et al. <xref ref-type="bibr" rid="CR160">2010</xref>; Messiaen et al.
<xref ref-type="bibr" rid="CR136">2011</xref>). Atypical <italic>NF1</italic> deletions may occur as germline mutations but can
also be of postzygotic origin and hence may be associated with somatic mosaicism
with normal cells (Taylor Tavares et al. <xref ref-type="bibr" rid="CR214">2013</xref>; Vogt et al. <xref ref-type="bibr" rid="CR243">2014</xref>). Atypical <italic>NF1</italic> deletions
are not only highly heterogeneous in terms of their length but also in terms of
their underlying mutational mechanisms which may involve aberrant DNA double strand
break repair and/or replication and retrotransposon-mediated mechanisms (Vogt et al.
<xref ref-type="bibr" rid="CR243">2014</xref> and references therein). The
architecture of the genomic regions flanking the <italic>NF1</italic> gene in 17q11.2, characterised by low-copy repeats, predisposes to
large deletions mediated by various different mutational mechanisms occurring in the
germline of an unaffected parent or during mitotic postzygotic cell
divisions.</p>
<p>
<italic>NF1</italic> microdeletions are important from the
clinical standpoint because, as noted above, they are often associated with more
severe manifestations of NF1 than those noted in patients with intragenic <italic>NF1</italic> mutations. One interpretation of this observation is
that some of those genes co-deleted with <italic>NF1</italic>
exert an influence on the clinical manifestation of the disease in patients with
<italic>NF1</italic> microdeletions. In the following, we shall
review current knowledge about <italic>NF1</italic> microdeletions
in terms of potential genotype–phenotype relationships and the putative modifier
role of genes located within the <italic>NF1</italic>
microdeletion interval.</p>
</sec>
<sec id="Sec2">
<title>Genotype–phenotype relationships in patients with <italic>NF1</italic> microdeletions</title>
<p>The <italic>NF1</italic> gene was identified more
than 25 years ago (Viskochil et al. <xref ref-type="bibr" rid="CR238">1990</xref>; Wallace et al. <xref ref-type="bibr" rid="CR245">1990</xref>). Genotype–phenotype analyses suggested from very early on
that patients with <italic>NF1</italic> microdeletions often
exhibit a more severe clinical phenotype than patients with intragenic <italic>NF1</italic> mutations; the former are frequently characterised by
dysmorphic facial features and severe developmental delay (Kayes et al. <xref ref-type="bibr" rid="CR85">1992</xref>, <xref ref-type="bibr" rid="CR86">1994</xref>; Wu et al. <xref ref-type="bibr" rid="CR251">1995</xref>,
<xref ref-type="bibr" rid="CR252">1997</xref>, <xref ref-type="bibr" rid="CR253">1999</xref>; Riva et al. <xref ref-type="bibr" rid="CR180">1996</xref>, <xref ref-type="bibr" rid="CR181">2000</xref>; Upadhyaya
et al. <xref ref-type="bibr" rid="CR221">1996</xref>, <xref ref-type="bibr" rid="CR222">1998</xref>; Leppig et al. <xref ref-type="bibr" rid="CR112">1997</xref>; Tonsgard et al. <xref ref-type="bibr" rid="CR218">1997</xref>; Valero et al. <xref ref-type="bibr" rid="CR226">1997</xref>; Rasmussen et al. <xref ref-type="bibr" rid="CR175">1998</xref>; Streubel et al. <xref ref-type="bibr" rid="CR208">1999</xref>; Dorschner et al. <xref ref-type="bibr" rid="CR44">2000</xref>; Kobayashi et al. <xref ref-type="bibr" rid="CR97">2012</xref>).</p>
<p>Subsequent follow-up studies confirmed that these deletions
frequently lead to severe clinical manifestations of the disease including a high
tumour load and cardiovascular anomalies (Venturin et al. <xref ref-type="bibr" rid="CR232">2004b</xref>; Mensink et al. <xref ref-type="bibr" rid="CR135">2006</xref>; Pasmant et al. <xref ref-type="bibr" rid="CR160">2010</xref>; Zhang et al. <xref ref-type="bibr" rid="CR261">2015</xref>). Although, as a group, <italic>NF1</italic> microdeletion patients tend to exhibit a
comparatively severe form of NF1, some variability of clinical symptoms has
nevertheless been observed when comparing individuals with <italic>NF1</italic> microdeletions. These clinical phenotypic differences may be
influenced by the variable expressivity of NF1 characteristic of all NF1 patients,
irrespective of the type of <italic>NF1</italic> gene mutation
involved (Sabbagh et al. <xref ref-type="bibr" rid="CR187">2009</xref>;
reviewed by Pasmant et al. <xref ref-type="bibr" rid="CR162">2012</xref>).
However, a certain proportion of the phenotypic variability exhibited by patients
with <italic>NF1</italic> microdeletions who were investigated in
the above-mentioned studies may have been due to differences in deletion size and
breakpoint location which together determine the number of genes included within the
deletion interval.</p>
<p>Somatic mosaicism with cells not harbouring the <italic>NF1</italic> microdeletion in question is likely to have a
disproportionately large impact upon the manifestations of disease (Rasmussen et al.
<xref ref-type="bibr" rid="CR175">1998</xref>; Tinschert et al. <xref ref-type="bibr" rid="CR217">2000</xref>; Maertens et al. <xref ref-type="bibr" rid="CR125">2007</xref>; Kehrer-Sawatzki and Cooper <xref ref-type="bibr" rid="CR87">2008</xref>; Roehl et al. <xref ref-type="bibr" rid="CR183">2012</xref>; Kehrer-Sawatzki et al. <xref ref-type="bibr" rid="CR92">2012</xref>). This is particularly relevant since some types of <italic>NF1</italic> microdeletion, such as the type-2 and atypical
<italic>NF1</italic> deletions, are frequently of postzygotic
origin and hence occur as mosaic deletions alongside normal cells in the body of an
affected patient (Steinmann et al. <xref ref-type="bibr" rid="CR205">2007</xref>; Vogt et al. <xref ref-type="bibr" rid="CR243">2014</xref>). By contrast, type-1 <italic>NF1</italic>
deletions are only very rarely of postzygotic origin (Messiaen et al. <xref ref-type="bibr" rid="CR136">2011</xref>). This notwithstanding, in many of the
reported studies of genotype–phenotype correlations in patients with <italic>NF1</italic> microdeletions, neither deletion size nor somatic
mosaicism has been specifically taken into consideration.</p>
<p>To refine the genotype–phenotype analysis of <italic>NF1</italic> microdeletions, Mautner et al. (<xref ref-type="bibr" rid="CR132">2010</xref>) investigated 29 NF1 patients with non-mosaic type-1 (1.4-Mb)
<italic>NF1</italic> deletions. A combination of
breakpoint-spanning PCRs and/or polymorphic marker analysis confirmed that the
deletion breakpoints were located within specific regions of the NF1-REPs. Thus, all
29 patients studied were hemizygous for the same number of genes at 17q11.2
(Fig. <xref ref-type="fig" rid="Fig1">1</xref>). The clinical analysis of these
29 patients with type-1 <italic>NF1</italic> microdeletions served
to confirm that several clinical phenotypic features were relatively frequent in
patients with <italic>NF1</italic> microdeletions but less common
(or even not identifiable) in the general NF1 population (as may be concluded from
the studies listed in Table <xref ref-type="table" rid="Tab1">1</xref>). These
features included facial dysmorphism, overgrowth/tall-for-age stature, significant
delay in cognitive development, scoliosis, bone cysts, large hands and feet with
excessive soft tissue, hyperflexibility of joints of hands and feet and pronounced
muscular hypotonia. Further, patients with type-1 <italic>NF1</italic> microdeletions exhibited a variety of features that were markedly
more frequent than in the general NF1 population including intellectual disability,
high numbers of subcutaneous and spinal neurofibromas, and the occurrence of
plexiform neurofibromas (Table <xref ref-type="table" rid="Tab1">1</xref>). An
increased frequency of optic gliomas was however not observed in patients with
type-1 <italic>NF1</italic> deletions as compared to the general
NF1 population. In the studies listed in Table <xref ref-type="table" rid="Tab1">1</xref> that compared the frequency of clinical features, NF1 patients
were analysed irrespective of the type of <italic>NF1</italic>
mutation they harboured; these patients are therefore referred to as the ‘general
NF1 population’. Such comparisons will tend to err on the conservative side since
4.7–11% of the individuals in the general NF1 population harbour <italic>NF1</italic> microdeletions.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Frequency of clinical symptoms in patients with type-1 <italic>NF1</italic> microdeletions investigated by Mautner et al.
(<xref ref-type="bibr" rid="CR132">2010</xref>) and in the general
NF1 population</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Clinical features</th><th align="left">Frequency in patients with type-1 <italic>NF1</italic> deletions, (%)</th><th align="left" colspan="2">Frequency in the general NF1 population (reference),
(%)</th></tr></thead><tbody><tr><td align="left">Facial dysmorphism</td><td align="left">90</td><td align="left">n.d.</td><td align="left"></td></tr><tr><td align="left">Hypertelorism</td><td align="char" char=".">86</td><td align="left">n.d.</td><td align="left"></td></tr><tr><td align="left">Facial asymmetry</td><td align="char" char=".">28</td><td align="left">8<break></break>6</td><td align="left">(Friedman and Birch <xref ref-type="bibr" rid="CR58">1997</xref>)<break></break>(Sbidian et al. <xref ref-type="bibr" rid="CR190">2012</xref>)</td></tr><tr><td align="left">Coarse face</td><td align="char" char=".">59</td><td align="left">n.d.</td><td align="left"></td></tr><tr><td align="left">Broad neck</td><td align="char" char=".">31</td><td align="left">n.d.</td><td align="left"></td></tr><tr><td align="left">Tall-for-age stature</td><td align="char" char=".">46</td><td align="left">n.d.</td><td align="left"></td></tr><tr><td align="left">Macrocephaly<sup>a</sup>
</td><td align="char" char=".">39</td><td align="left">45<break></break>29<break></break>43<break></break>24</td><td align="left">(Huson et al. <xref ref-type="bibr" rid="CR72">1988</xref>)<break></break>(Riccardi <xref ref-type="bibr" rid="CR177">1992</xref>)<break></break>(North <xref ref-type="bibr" rid="CR148">1993</xref>)<break></break>(Sbidian et al. <xref ref-type="bibr" rid="CR190">2012</xref>)</td></tr><tr><td align="left">Large hands and feet</td><td align="char" char=".">46</td><td align="left">n.d.</td><td align="left"></td></tr><tr><td align="left">Pes cavus</td><td align="char" char=".">17</td><td align="left">n.d.</td><td align="left"></td></tr><tr><td align="left">Café-au-lait spots</td><td align="char" char=".">93</td><td align="left">87<break></break>95<break></break>86<break></break>99</td><td align="left">(McGaughran et al. <xref ref-type="bibr" rid="CR133">1999</xref>)<break></break>(Friedman <xref ref-type="bibr" rid="CR57">1999</xref>)<break></break>(Duong et al. <xref ref-type="bibr" rid="CR47">2011</xref>)<break></break>(Sbidian et al. <xref ref-type="bibr" rid="CR190">2012</xref>)</td></tr><tr><td align="left">Axillary and inguinal freckling</td><td align="char" char=".">86</td><td align="left">86<break></break>89</td><td align="left">(Duong et al. <xref ref-type="bibr" rid="CR47">2011</xref>)<break></break>(Plotkin et al. <xref ref-type="bibr" rid="CR170">2012</xref>)</td></tr><tr><td align="left">Lisch nodules</td><td align="char" char=".">93</td><td align="left">63<break></break>93<break></break>50<break></break>45</td><td align="left">(McGaughran et al. <xref ref-type="bibr" rid="CR133">1999</xref>)<break></break>(Huson et al. <xref ref-type="bibr" rid="CR72">1988</xref>)<break></break>(Friedman <xref ref-type="bibr" rid="CR57">1999</xref>)<break></break>(Sbidian et al. <xref ref-type="bibr" rid="CR190">2012</xref>)</td></tr><tr><td align="left">Significant delay in cognitive development</td><td align="char" char=".">48</td><td align="char" char=".">17</td><td align="left">(Klein-Tasman et al. <xref ref-type="bibr" rid="CR94">2014</xref>)</td></tr><tr><td align="left">General learning difficulties</td><td align="char" char=".">45</td><td align="left">45<break></break>47<break></break>32<break></break>39<break></break>31</td><td align="left">(North et al. <xref ref-type="bibr" rid="CR151">1995</xref>)<break></break>(Brewer et al. <xref ref-type="bibr" rid="CR20">1997</xref>)<sup>b</sup>
<break></break>(Hyman et al. <xref ref-type="bibr" rid="CR74">2006</xref>)<break></break>(Krab et al. <xref ref-type="bibr" rid="CR100">2008</xref>)<sup>c</sup>
<break></break>(Plotkin et al. <xref ref-type="bibr" rid="CR170">2012</xref>)</td></tr><tr><td align="left">IQ &lt; 70</td><td align="char" char=".">38</td><td align="left">8<break></break>7</td><td align="left">(Ferner et al. <xref ref-type="bibr" rid="CR53">1996</xref>)<break></break>(Hyman et al. <xref ref-type="bibr" rid="CR73">2005</xref>)</td></tr><tr><td align="left">Attention deficit hyperactivity disorder</td><td align="char" char=".">33</td><td align="left">49<break></break>38</td><td align="left">(Mautner et al. <xref ref-type="bibr" rid="CR130">2002</xref>)<break></break>(Hyman et al. <xref ref-type="bibr" rid="CR73">2005</xref>)</td></tr><tr><td align="left">Skeletal anomalies</td><td align="char" char=".">76</td><td align="char" char=".">31</td><td align="left">(Plotkin et al. <xref ref-type="bibr" rid="CR170">2012</xref>)</td></tr><tr><td align="left">Scoliosis</td><td align="char" char=".">43</td><td align="left">26<break></break>12<break></break>10<break></break>20<break></break>25<break></break>28</td><td align="left">(Friedman and Birch <xref ref-type="bibr" rid="CR58">1997</xref>)<break></break>(McGaughran et al. <xref ref-type="bibr" rid="CR133">1999</xref>)<break></break>(Riccardi <xref ref-type="bibr" rid="CR178">1999a</xref>)<break></break>(North <xref ref-type="bibr" rid="CR150">2000</xref>)<break></break>(Duong et al. <xref ref-type="bibr" rid="CR47">2011</xref>)<break></break>(Plotkin et al. <xref ref-type="bibr" rid="CR170">2012</xref>)</td></tr><tr><td align="left">Pectus excavatum</td><td align="char" char=".">31</td><td align="left">50<break></break>12</td><td align="left">(Riccardi <xref ref-type="bibr" rid="CR179">1999b</xref>)<break></break>(Castle et al. <xref ref-type="bibr" rid="CR23">2003</xref>)</td></tr><tr><td align="left">Bone cysts</td><td align="char" char=".">50</td><td align="char" char=".">1</td><td align="left">(Plotkin et al. <xref ref-type="bibr" rid="CR170">2012</xref>)</td></tr><tr><td align="left">Hyperflexibility of joints</td><td align="char" char=".">72</td><td align="left">n.d.</td><td align="left"></td></tr><tr><td align="left">Excess soft tissue in hands and feet</td><td align="char" char=".">50</td><td align="left">n.d.</td><td align="left"></td></tr><tr><td align="left">Congenital heart defects</td><td align="char" char=".">29</td><td align="left">2<break></break>1.6–2</td><td align="left">(Friedman and Birch <xref ref-type="bibr" rid="CR58">1997</xref>)<break></break>(Lin et al. <xref ref-type="bibr" rid="CR116">2000</xref>)</td></tr><tr><td align="left">Epilepsy</td><td align="char" char=".">7</td><td align="left">7<break></break>4<break></break>13<break></break>4</td><td align="left">(Huson et al. <xref ref-type="bibr" rid="CR72">1988</xref>)<break></break>(North <xref ref-type="bibr" rid="CR148">1993</xref>)<break></break>(Ferner et al. <xref ref-type="bibr" rid="CR53">1996</xref>)<break></break>(Kulkantrakorn and Geller <xref ref-type="bibr" rid="CR102">1998</xref>)</td></tr><tr><td align="left">Muscular hypotonia</td><td align="char" char=".">45</td><td align="char" char=".">27</td><td align="left">(Wessel et al. <xref ref-type="bibr" rid="CR248">2013</xref>)</td></tr><tr><td align="left">Speech difficulties</td><td align="char" char=".">48</td><td align="left">25<break></break>20–55</td><td align="left">(North <xref ref-type="bibr" rid="CR149">1999</xref>
n.d.)<break></break>(Alivuotila et al. <xref ref-type="bibr" rid="CR3">2010</xref>)<sup>d</sup>
</td></tr><tr><td align="left">Subcutaneous neurofibromas</td><td align="char" char=".">76</td><td align="char" char=".">48</td><td align="left">(Tucker et al. <xref ref-type="bibr" rid="CR220">2005</xref>)</td></tr><tr><td align="left">Cutaneous neurofibromas</td><td align="char" char=".">86</td><td align="left">38–44<break></break>59<break></break>85<break></break>76<break></break>84</td><td align="left">(Friedman and Birch <xref ref-type="bibr" rid="CR58">1997</xref>)<break></break>(McGaughran et al. <xref ref-type="bibr" rid="CR133">1999</xref>)<break></break>(Tucker et al. <xref ref-type="bibr" rid="CR220">2005</xref>)<break></break>(Duong et al. <xref ref-type="bibr" rid="CR47">2011</xref>)<break></break>(Plotkin et al. <xref ref-type="bibr" rid="CR170">2012</xref>)</td></tr><tr><td align="left">Plexiform neurofibromas</td><td align="char" char=".">76</td><td align="left">15<break></break>44<break></break>50<break></break>30<break></break>54</td><td align="left">(McGaughran et al. <xref ref-type="bibr" rid="CR133">1999</xref>)<break></break>(Waggoner et al. <xref ref-type="bibr" rid="CR244">2000</xref>)<break></break>(Ferner et al. <xref ref-type="bibr" rid="CR54">2007</xref>)<break></break>(Duong et al. <xref ref-type="bibr" rid="CR47">2011</xref>)<break></break>(Plotkin et al. <xref ref-type="bibr" rid="CR170">2012</xref>)</td></tr><tr><td align="left">Malignant peripheral nerve sheath tumours</td><td align="char" char=".">21</td><td align="left">2–5<break></break>7</td><td align="left">(Ferner and Gutmann <xref ref-type="bibr" rid="CR51">2002</xref>)<break></break>(Duong et al. <xref ref-type="bibr" rid="CR47">2011</xref>)</td></tr><tr><td align="left">Spinal neurofibromas</td><td align="char" char=".">64</td><td align="left">30<break></break>24</td><td align="left">(Tucker et al. <xref ref-type="bibr" rid="CR220">2005</xref>)<break></break>(Plotkin et al. <xref ref-type="bibr" rid="CR170">2012</xref>)</td></tr><tr><td align="left">Optic pathway gliomas</td><td align="char" char=".">19</td><td align="left">15<break></break>19<break></break>14<break></break>11<break></break>18</td><td align="left">(Lewis et al. <xref ref-type="bibr" rid="CR113">1984</xref>)<break></break>(Listernick et al. <xref ref-type="bibr" rid="CR117">1997</xref>)<break></break>(Duong et al. <xref ref-type="bibr" rid="CR47">2011</xref>)<break></break>(Plotkin et al. <xref ref-type="bibr" rid="CR170">2012</xref>)<break></break>(Millichap <xref ref-type="bibr" rid="CR137">2015</xref>;
Prada et al. <xref ref-type="bibr" rid="CR171">2015</xref>)</td></tr><tr><td align="left">T2 hyperintensities</td><td align="char" char=".">45</td><td align="left">34<break></break>77<break></break>79<break></break>71</td><td align="left">(Ferner et al. <xref ref-type="bibr" rid="CR52">1993</xref>)<break></break>(Itoh et al. <xref ref-type="bibr" rid="CR78">1994</xref>)<break></break>(Sevick et al. <xref ref-type="bibr" rid="CR195">1992</xref>)<break></break>(Hyman et al. <xref ref-type="bibr" rid="CR75">2007</xref>)</td></tr></tbody></table><table-wrap-foot><p>
<italic>n.d.</italic> not determined; these features are
either absent or rare in the general NF1 population</p><p>
<sup>a</sup>The evaluation criteria in these studies included
a definition of macrocephaly as an occipitofrontal circumference greater than
the 98th centile or two standard deviations above the mean. Despite consistent
evaluation criteria having been employed, a high degree of variability in
terms of the frequency of macrocephaly has been observed</p><p>
<sup>b</sup>39% of the children with NF1 analysed by Brewer et
al. (<xref ref-type="bibr" rid="CR20">1997</xref>) exhibited general
learning disabilities whereas an additional 14% exhibited
visuospatial-construction deficiencies (specific learning
disabilities)</p><p>
<sup>c</sup>39% of the children with NF1 investigated by Krab
et al. (<xref ref-type="bibr" rid="CR100">2008</xref>) had general
learning disabilities whilst an additional 39% had specific learning
disabilities</p><p>
<sup>d</sup> Alivuotila et al. (<xref ref-type="bibr" rid="CR3">2010</xref>) investigated the speech characteristics of 62 NF1
patients (40 adults and 22 children) and compared them with those observed in
24 control individuals. Patients with NF1 exhibited deviations in voice
quality (35% of the adult NF1 patients and 55% of the children with NF1),
problems in regulating pitch (53% of the adult NF1 patients and 55% of the
children), deviant nasality (20% of the adult NF1 patients and 45% of the
children) and disfluency (20% of the adult NF1 patients and 41% of the
children)</p></table-wrap-foot></table-wrap>
</p>
<p>In addition to the previously mentioned clinical features, type-1
<italic>NF1</italic> microdeletion patients were found to have
an increased risk of malignant peripheral nerve sheath tumours (MPNSTs) (De Raedt et
al. <xref ref-type="bibr" rid="CR37">2003</xref>; Mautner et al. <xref ref-type="bibr" rid="CR132">2010</xref>) (Table <xref ref-type="table" rid="Tab1">1</xref>). These findings confirmed that patients with non-mosaic type-1
<italic>NF1</italic> deletions exhibit, as a group, a severe
form of NF1. However, even within this group of patients that are hemizygous for the
same number of genes, some variability in expression of the clinical symptoms has
been detected (Mautner et al. <xref ref-type="bibr" rid="CR132">2010</xref>).
Hence, the phenotype associated with <italic>NF1</italic>
microdeletions is likely to be influenced to a certain degree by the genetic
background (e.g. the expression level of non-deleted genes), as well as by
environmental factors.</p>
<p>It should be emphasised that many of the studies that have addressed
the question of whether or not specific disease features occur disproportionately
more frequently in patients with <italic>NF1</italic>
microdeletions have employed, for the purposes of comparative analysis, frequency
values for these clinical features that were derived from the general NF1 population
obtained in different studies. More appropriate would have been a methodical
comparative analysis of a large number of age-matched patients with and without
germline type-1 <italic>NF1</italic> deletions investigated by
standardised analytical tools. Although such comparative analyses have been
attempted to assess differences in height (Ning et al. <xref ref-type="bibr" rid="CR147">2016</xref>), cognitive capability (Descheemaeker et al.
<xref ref-type="bibr" rid="CR41">2004</xref>) or the frequency of
cardiovascular anomalies (Nguyen et al. <xref ref-type="bibr" rid="CR144">2013</xref>), they have not as yet been performed methodically in the
context of the number of neurofibromas and other <italic>NF1</italic> microdeletion-associated clinical features.</p>
<p>In the following, the clinical features associated with type-1
<italic>NF1</italic> microdeletions are explored in greater
detail.</p>
<sec id="Sec3">
<title>High number of neurofibromas in patients with <italic>NF1</italic> microdeletions</title>
<p>Several studies have suggested that <italic>NF1</italic> microdeletion patients frequently exhibit a disproportionately
high number of cutaneous and subcutaneous neurofibromas (Mensink et al.
<xref ref-type="bibr" rid="CR135">2006</xref> and references therein;
Pasmant et al. <xref ref-type="bibr" rid="CR160">2010</xref>). Indeed, the 29
patients with type-1 <italic>NF1</italic> microdeletions
investigated by Mautner et al. (<xref ref-type="bibr" rid="CR132">2010</xref>) exhibited significantly increased numbers of subcutaneous but
also spinal neurofibromas by comparison with the general NF1 population as
concluded from some of the studies listed in Table <xref ref-type="table" rid="Tab1">1</xref>. Additionally, externally visible plexiform neurofibromas are
significantly more frequent in patients with <italic>NF1</italic> microdeletions than in the general NF1 population
(Table <xref ref-type="table" rid="Tab1">1</xref>; Mautner et al. <xref ref-type="bibr" rid="CR132">2010</xref>). Remarkably, 10 of 20 (50%) of the adult
type-1 <italic>NF1</italic> microdeletion patients investigated
by Mautner et al. (<xref ref-type="bibr" rid="CR132">2010</xref>) exhibited a
very high number of cutaneous neurofibromas (<italic>N</italic> &gt; 1000). Such a high burden of cutaneous neurofibromas may also
be present in some patients with intragenic <italic>NF1</italic>
mutations but the precise frequency of this feature in this subgroup of NF1
patients is currently unknown. Plotkin et al. (<xref ref-type="bibr" rid="CR170">2012</xref>) reported that 13% of 141 NF1 patients exhibited more than
500 cutaneous neurofibromas, but the precise proportions of patients harbouring
either <italic>NF1</italic> microdeletions or intragenic
<italic>NF1</italic> mutations among the 141 NF1 patients
investigated had not been determined. A detailed comparison between both patient
groups, involving the careful age-matching of patients, would be necessary to
clarify whether a very high load of cutaneous neurofibromas (<italic>N</italic> &gt; 1000) is encountered significantly more
frequently in patients with type-1 <italic>NF1</italic>
microdeletions as compared to patients with intragenic <italic>NF1</italic> mutations. In passing, it should be pointed out that counting
neurofibromas one by one in NF1 patients who may have thousands of such tumours is
likely to be subject to considerable intra- and inter-examiner variability, and
hence the precise number of neurofibromas in each patient should always be
regarded as a rough estimate. In an attempt to improve upon this state of affairs,
Cunha et al. (<xref ref-type="bibr" rid="CR35">2014</xref>) developed a new
method using paper frames to quantify cutaneous neurofibromas. Combined with
computerised analysis, this method could yet prove to be very useful for the
comparative quantification of cutaneous neurofibromas in patients with <italic>NF1</italic> microdeletions and those lacking such
deletions.</p>
<p>Several studies have suggested that patients with <italic>NF1</italic> microdeletions not only exhibit a high number of
cutaneous neurofibromas but also an early (pre-pubertal) onset of cutaneuous
neurofibroma growth (Kayes et al. <xref ref-type="bibr" rid="CR85">1992</xref>, <xref ref-type="bibr" rid="CR86">1994</xref>; Mensink
et al. <xref ref-type="bibr" rid="CR135">2006</xref>; Leppig et al.
<xref ref-type="bibr" rid="CR112">1997</xref>; Dorschner et al.
<xref ref-type="bibr" rid="CR44">2000</xref>). However, a comprehensive
analysis of age-matched children has not yet been performed to ascertain whether
an early (pre-pubertal) onset in growth of multiple cutaneous neurofibromas is
significantly more prevalent in children with <italic>NF1</italic> microdeletions as compared to children with intragenic <italic>NF1</italic> mutations.</p>
<p>In addition to tumours that are visible by external investigation,
NF1 patients may also possess internal neurofibromas (mostly of the plexiform
type) which would only be detectable by magnetic-resonance imaging (MRI). Kluwe et
al. (<xref ref-type="bibr" rid="CR96">2012</xref>) showed that an extremely
high burden of internal neurofibromas, characterised by &gt;3000 ml tumour volume
as determined by whole-body MRI, was significantly more frequent in non-mosaic
type-1 and type-2 <italic>NF1</italic> microdeletion patients
than in NF1 patients with intragenic lesions (13 vs. 1%). Consequently, a readily
identifiable subgroup of NF1 patients with germline <italic>NF1</italic> microdeletions is likely to exhibit an extremely high burden of
internal tumours. These patients require special attention in terms of clinical
care and surveillance since a strong association has been observed between the
presence of internal neurofibromas and the occurrence of malignant peripheral
nerve sheath tumours (MPNSTs) (Tucker et al. <xref ref-type="bibr" rid="CR220">2005</xref>; Mautner et al. <xref ref-type="bibr" rid="CR131">2008</xref>; Nguyen et al. <xref ref-type="bibr" rid="CR145">2014</xref>). MPNSTs are very aggressive, have a poor prognosis and
frequently arise in pre-existing plexiform neurofibromas (Ferner and Gutmann
<xref ref-type="bibr" rid="CR51">2002</xref>) which are often diagnosed
before the age of 5, suggesting that they are congenital lesions (Waggoner et al.
<xref ref-type="bibr" rid="CR244">2000</xref>). This postulate receives
strong support from the observation that children with NF1 who do not exhibit
plexiform neurofibromas upon first MRI examination are unlikely to develop new
plexiform neurofibromas later in life (Nguyen et al. <xref ref-type="bibr" rid="CR143">2012</xref>). Hence, a high burden of internal
neurofibromas may well be strongly associated with an increased MPNST risk and
this should be taken into account when planning the clinical care of patients with
<italic>NF1</italic> microdeletions.</p>
</sec>
<sec id="Sec4">
<title>Increased risk of MPNSTs in patients with <italic>NF1
</italic>microdeletions</title>
<p>MPNSTs are rare soft tissue sarcomas occurring with an incidence of
0.001% in the overall (general) population (Ducatman et al. <xref ref-type="bibr" rid="CR46">1986</xref>) and are known to have an association with
NF1. Thus, some 28–52% of patients with MPNSTs also have NF1 (Ducatman et al.
<xref ref-type="bibr" rid="CR46">1986</xref>; Evans et al. <xref ref-type="bibr" rid="CR48">2002</xref>). The estimated lifetime risk of an MPNST
in all NF1 patients is 8–13% (Evans et al. <xref ref-type="bibr" rid="CR48">2002</xref>, <xref ref-type="bibr" rid="CR49">2012</xref>) or 15.8%
according to Uusitalo et al. (<xref ref-type="bibr" rid="CR225">2016</xref>).
However, individuals with <italic>NF1</italic> microdeletions
have an even higher lifetime MPNST risk, in the range of 16–26% (De Raedt et al.
<xref ref-type="bibr" rid="CR37">2003</xref>; Mautner et al. <xref ref-type="bibr" rid="CR132">2010</xref>). Further, MPNSTs may occur significantly
earlier in patients with <italic>NF1</italic> microdeletions as
compared with NF1 patients with intragenic mutations (De Raedt et al. <xref ref-type="bibr" rid="CR37">2003</xref>). These findings clearly indicate that
patients with <italic>NF1</italic> microdeletions constitute a
high-risk group for the development of MPNSTs. Hence patients with <italic>NF1</italic> microdeletions should be under regular surveillance
from an early age.</p>
<p>MPNSTs are difficult to treat, particularly if they are at an
advanced stage and have already metastasized. The complete surgical excision of
non-metastatic MPNSTs represents the mainstay of an effective therapy but this is
only possible if the tumour is detected at an early stage (reviewed by Karajannis
and Ferner <xref ref-type="bibr" rid="CR84">2015</xref>). MPNSTs represent
the biggest contributory factor to reduced life expectancy in NF1 (Evans et al.
<xref ref-type="bibr" rid="CR49">2012</xref>). It may well be that an
<italic>NF1</italic> microdeletion and high internal tumour
load are independent risk factors for MPNST. Thus, patients with an <italic>NF1</italic> microdeletion and a high internal tumour load could
represent an ultra-high risk group for MPNST. For this group of patients,
long-term follow-up investigations using whole-body MRI and serial
<sup>18</sup>Fluorodeoxyglucose positron emission tomography
(PET) scans are likely to be critically important to identify malignant
transformation at an early stage (Salamon et al. <xref ref-type="bibr" rid="CR188">2015</xref>).</p>
</sec>
<sec id="Sec5">
<title>Intellectual disability in patients with <italic>NF1</italic> microdeletions</title>
<p>An estimated, 4.8–8% of all NF1 patients are characterised by
intellectual disability (mean full-scale IQ (FSIQ) &lt;70), a somewhat higher
proportion than the 2% observed in the normal population (Ferner et al.
<xref ref-type="bibr" rid="CR53">1996</xref>; reviewed by North et al.
<xref ref-type="bibr" rid="CR152">1997</xref>). Several studies have
suggested that intellectual disability occurs disproportionately more frequently
in <italic>NF1</italic> microdeletion patients than in the
general NF1 population (Kayes et al. <xref ref-type="bibr" rid="CR86">1994</xref>; Rasmussen et al. <xref ref-type="bibr" rid="CR175">1998</xref>; Korf et al. <xref ref-type="bibr" rid="CR98">1999</xref>; Venturin et al. <xref ref-type="bibr" rid="CR232">2004b</xref>; reviewed by Mensink et al. <xref ref-type="bibr" rid="CR135">2006</xref>). However, some of the early studies were biassed by
including mostly patients with a particularly severe phenotype and uncharacterised
deletion size. Only in two studies, the frequency of intellectual disability has
been analysed systematically by including exclusively non-mosaic patients with
<italic>NF1</italic> microdeletions of the same size (type-1
deletions spanning 1.4-Mb) (Descheemaeker et al. <xref ref-type="bibr" rid="CR41">2004</xref>; Mautner et al. <xref ref-type="bibr" rid="CR132">2010</xref>). Intellectual disability was evident in eight of 21
patients (38%) with type-1 <italic>NF1</italic> deletions
analysed by Mautner et al. (<xref ref-type="bibr" rid="CR132">2010</xref>)
and in two of 11 patients with type-1 <italic>NF1</italic>
microdeletions (18%) investigated by Descheemaeker et al. (<xref ref-type="bibr" rid="CR41">2004</xref>). Taken together, these findings indicate
that intellectual disability is markedly more frequent in patients with type-1
<italic>NF1</italic> microdeletions as compared to patients
with intragenic <italic>NF1</italic> mutations. Furthermore,
borderline intellectual disability, characterised by a full-scale IQ (FSIQ) higher
than 70 but lower than 85 (70 ≤ FSIQ ≤ 85), was noted in seven (33%) of the 21
type-1 <italic>NF1</italic> microdeletion patients analysed by
Mautner et al. (<xref ref-type="bibr" rid="CR132">2010</xref>) and in nine of
the 11 type-1 <italic>NF1</italic> microdeletion patients (82%)
investigated by Descheemaeker et al. (<xref ref-type="bibr" rid="CR41">2004</xref>).</p>
<p>Patients with NF1, irrespective of their mutation type, have a mean
FSIQ of 88-99 which is in the range of one standard deviation lower than the FSIQ
of the general population (100 ± 15) (North et al. <xref ref-type="bibr" rid="CR152">1997</xref>; Krab et al. <xref ref-type="bibr" rid="CR100">2008</xref>). A mean FSIQ of 76.9 was documented in the 21 type-1
<italic>NF1</italic> microdeletion patients investigated by
Mautner et al. (<xref ref-type="bibr" rid="CR132">2010</xref>). This is
similar to the mean FSIQ of 76.0 ascertained in the 11 type-1 <italic>NF1</italic> microdeletion patients analysed by Descheemaeker et
al. (<xref ref-type="bibr" rid="CR41">2004</xref>). By comparison, a mean
FSIQ of 88.5 was determined in 106 NF1 patients without an <italic>NF1</italic> deletion (Descheemaeker et al. <xref ref-type="bibr" rid="CR41">2004</xref>). Despite the relatively small numbers of individuals
available in these studies, the tentative conclusion to be drawn from them is that
the mean FSIQ in patients with type-1 <italic>NF1</italic>
microdeletions is markedly lower than the mean FSIQ in patients with intragenic
<italic>NF1</italic> mutations. However, Descheemaeker et al.
(<xref ref-type="bibr" rid="CR41">2004</xref>) noted a considerable overlap
regarding the range of the FSIQ observed in patients with <italic>NF1</italic> microdeletions (65–85) as compared with the range observed in
patients without microdeletions (54–126), even though the average intelligence (as
measured by FSIQ) of type-1 <italic>NF1</italic> microdeletion
patients is generally lower than that of NF1 patients without large
microdeletions.</p>
</sec>
<sec id="Sec6">
<title>Overgrowth associated with <italic>NF1</italic>
microdeletions</title>
<p>Stature is reduced to some extent in virtually all patients with
intragenic <italic>NF1</italic> mutations. On average,
adolescents and adults with NF1 are one standard deviation shorter than would be
expected for their age and sex (Clementi et al. <xref ref-type="bibr" rid="CR25">1999</xref>; Szudek et al. <xref ref-type="bibr" rid="CR211">2000</xref>). Short stature, characterised by a height of more than two
standard deviations below the predicted mean, is evident in 8–13% of children with
NF1 (Szudek et al. <xref ref-type="bibr" rid="CR211">2000</xref>; Sbidian et
al. <xref ref-type="bibr" rid="CR190">2012</xref>; Soucy et al. <xref ref-type="bibr" rid="CR202">2013</xref>) whilst a body height below the third
percentile has been observed in 15% of children with NF1 (Clementi et al.
<xref ref-type="bibr" rid="CR25">1999</xref>).</p>
<p>Short stature in children with NF1 and intragenic <italic>NF1</italic> mutations has been suggested to be caused by a
paucity of growth hormone as a consequence of abnormal hypothalamic–pituitary axis
function (Vassilopoulou-Sellin et al. <xref ref-type="bibr" rid="CR229">2000</xref>). Support for this hypothesis comes from the phenotype
observed in conditional knockout mice with specific <italic>Nf1</italic> gene inactivation in neuroglial progenitor cells using the brain
lipid-binding protein promoter (Hegedus et al. <xref ref-type="bibr" rid="CR68">2008</xref>). These mice exhibit significantly reduced body weight and
anterior pituitary gland size caused by the loss of neurofibromin expression in
the hypothalamus, leading to reduced production of growth hormone releasing
hormone, pituitary growth hormone and liver-expressed insulin-like growth factor-1
(IGF1). Thus, it would appear that neurofibromin plays a critical role in
hypothalamic–pituitary axis function and hence its loss may cause growth
abnormalities in patients with NF1 (Hegedus et al. <xref ref-type="bibr" rid="CR68">2008</xref>).</p>
<p>In contrast to the reduced stature observed in most patients with
intragenic <italic>NF1</italic> mutations, tall stature in
adults and childhood overgrowth has been reported to occur frequently in patients
with <italic>NF1</italic> microdeletions (van Asperen et al.
<xref ref-type="bibr" rid="CR227">1998</xref>; Spiegel et al. <xref ref-type="bibr" rid="CR203">2005</xref>; Mensink et al. <xref ref-type="bibr" rid="CR135">2006</xref>; Pasmant et al. <xref ref-type="bibr" rid="CR160">2010</xref>). Tall-for-age stature, with height
measurements at or above the 94th percentile, was noted in 46% of patients with
germline type-1 <italic>NF1</italic> deletions (Mautner et al.
<xref ref-type="bibr" rid="CR132">2010</xref>). Since intragenic <italic>NF1</italic> mutations lead to shorter height, and total loss of
the <italic>NF1</italic> gene plus flanking genes often results
in tall-for-age stature, it may be concluded that haploinsufficiency of a gene or
genes co-deleted in patients with <italic>NF1</italic>
microdeletions causes this overgrowth phenotype (Mautner et al. <xref ref-type="bibr" rid="CR132">2010</xref>). In a study of 21 patients with type-1
<italic>NF1</italic> microdeletions, overgrowth was most
evident in preschool children (2–6 years, <italic>n</italic> = 10) (Spiegel et al. <xref ref-type="bibr" rid="CR203">2005</xref>). These findings were confirmed by Ning et al. (<xref ref-type="bibr" rid="CR147">2016</xref>) who performed longitudinal growth
measurements in 56 NF patients with <italic>NF1</italic>
microdeletions and 226 NF1 patients with intragenic <italic>NF1</italic> mutations. Most height measurements in 2–18-year-old boys and
girls with <italic>NF1</italic> microdeletions were greater than
the median observed in non-deletion NF1 patients. However, extreme body height
(more than three standard deviations above the mean) was still unusual among
patients with <italic>NF1</italic> microdeletions (Ning et al.
<xref ref-type="bibr" rid="CR147">2016</xref>). These authors also showed
that children with <italic>NF1</italic> microdeletions were
usually much taller than non-deletion NF1 patients after the age of 2 years. In
early infancy, before the age of 2, the body length of microdeletion and
non-deletion NF1 patients was found to be similar (Ning et al. <xref ref-type="bibr" rid="CR147">2016</xref>). The reasons for these differences in
growth pattern are currently unknown.</p>
</sec>
<sec id="Sec7">
<title>Dysmorphic facial features</title>
<p>Patients with <italic>NF1</italic> microdeletions
frequently exhibit dysmorphic facial features not seen in patients with intragenic
<italic>NF1</italic> mutations. These features include broad
neck, hypertelorism, downslanted palpebral fissures, a broad nasal bridge and a
coarse, sometimes fleshy facial appearance (Mensink et al. <xref ref-type="bibr" rid="CR135">2006</xref> and references therein; Venturin et al.
<xref ref-type="bibr" rid="CR232">2004b</xref>; Pasmant et al. <xref ref-type="bibr" rid="CR160">2010</xref>; Mautner et al. <xref ref-type="bibr" rid="CR132">2010</xref>). A dysmorphic facial appearance is the
most commonly observed feature in patients with <italic>NF1</italic> microdeletions (Table <xref ref-type="table" rid="Tab1">1</xref>)
and is probably caused by haploinsufficiency for a gene or genes located within
the deletion interval. The dysmorphic facial appearance as seen in patients with
<italic>NF1</italic> microdeletions is generally absent in
patients with intragenic <italic>NF1</italic> mutations. Using
<italic>Face2Gene</italic> facial recognition software (<ext-link ext-link-type="uri" xlink:href="http://www.fdna.com">http://www.fdna.com</ext-link>) may be helpful in characterising and quantifying the dysmorphic
facial features observed in patients with <italic>NF1</italic>
microdeletions, particularly if comparison is made with family members lacking the
<italic>NF1</italic> microdeletion.</p>
</sec>
<sec id="Sec8">
<title>Cardiovascular malformations</title>
<p>Several studies have reported the occurrence of heart defects in a
proportion of patients with <italic>NF1</italic> microdeletions
(Kayes et al. <xref ref-type="bibr" rid="CR86">1994</xref>; Tonsgard et al.
<xref ref-type="bibr" rid="CR218">1997</xref>; Wu et al. <xref ref-type="bibr" rid="CR252">1997</xref>; Dorschner et al. <xref ref-type="bibr" rid="CR44">2000</xref>; Riva et al. <xref ref-type="bibr" rid="CR181">2000</xref>; Oktenli et al. <xref ref-type="bibr" rid="CR153">2003</xref>; Mensink et al. <xref ref-type="bibr" rid="CR135">2006</xref>; Venturin et al. <xref ref-type="bibr" rid="CR232">2004b</xref>; De Luca et al. <xref ref-type="bibr" rid="CR36">2007</xref>). However, the overall frequency of such
defects in patients with <italic>NF1</italic> microdeletions has
remained unclear. In the study of Mautner et al. (<xref ref-type="bibr" rid="CR132">2010</xref>), eight (29%) of the 28 type-1 <italic>NF1</italic> deletion patients investigated had cardiovascular anomalies. The
first detailed analysis of the prevalence of heart defects in patients harbouring
<italic>NF1</italic> microdeletions was performed by Nguyen et
al. (<xref ref-type="bibr" rid="CR144">2013</xref>) who observed major
cardiac abnormalities in 6 of 16 <italic>NF1</italic>
microdeletion patients whereas none of 16 patients with intragenic <italic>NF1</italic> mutations exhibited heart defects. Consequently, it
would appear that heart defects are significantly more common in patients with
<italic>NF1</italic> microdeletions as compared to patients
with intragenic <italic>NF1</italic> mutations. However, the
type and frequency of the heart defects observed in patients with <italic>NF1</italic> microdeletions are quite heterogeneous, including
pulmonic stenosis, ventricular septal defect, aortic stenosis, atrial septal
defect, aortic stenosis, mitral valve prolapse or insufficiency, and hypertrophic
cardiomyopathy (Table <xref ref-type="table" rid="Tab2">2</xref>). Larger studies
are clearly required to ascertain the type and the frequency of heart defects in
patients with <italic>NF1</italic> microdeletions with more
precision.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Heart defects observed in patients with <italic>NF1</italic> microdeletions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Type of heart defect</th><th align="left">Number of <italic>NF1</italic>
microdeletion patients exhibiting the heart defect
(reference)<sup>a</sup>
</th></tr></thead><tbody><tr><td align="left">Pulmonic stenosis</td><td align="left">1 (Tonsgard et al. <xref ref-type="bibr" rid="CR218">1997</xref>)<break></break>2 (Dorschner et al. <xref ref-type="bibr" rid="CR44">2000</xref>)<break></break>2 (Riva et al. <xref ref-type="bibr" rid="CR181">2000</xref>)</td></tr><tr><td align="left">Ventricular septal defect</td><td align="left">1 (Tonsgard et al. <xref ref-type="bibr" rid="CR218">1997</xref>)<break></break>1 (Venturin et al. <xref ref-type="bibr" rid="CR232">2004b</xref>)<break></break>1 (Nguyen et al. <xref ref-type="bibr" rid="CR144">2013</xref>)</td></tr><tr><td align="left">Atrial septal defect</td><td align="left">1 (Kayes et al. <xref ref-type="bibr" rid="CR86">1994</xref>)<break></break>1 (Dorschner et al. <xref ref-type="bibr" rid="CR44">2000</xref>)</td></tr><tr><td align="left">Aortic stenosis</td><td align="left">1 (Nguyen et al. <xref ref-type="bibr" rid="CR144">2013</xref>)</td></tr><tr><td align="left">Aortic dissection</td><td align="left">1 (Leppig et al. <xref ref-type="bibr" rid="CR112">1997</xref>)</td></tr><tr><td align="left">Patent ductus arteriosus</td><td align="left">1 (Upadhyaya et al. <xref ref-type="bibr" rid="CR221">1996</xref>)</td></tr><tr><td align="left">Mitral valve prolapse</td><td align="left">1 (Wu et al. <xref ref-type="bibr" rid="CR252">1997</xref>)<break></break>3 (Mensink et al. <xref ref-type="bibr" rid="CR135">2006</xref>)<break></break>1 (Venturin et al. <xref ref-type="bibr" rid="CR232">2004b</xref>)<break></break>1 (Oktenli et al. <xref ref-type="bibr" rid="CR153">2003</xref>)</td></tr><tr><td align="left">Mitral valve insufficiency</td><td align="left">1 (Venturin et al. <xref ref-type="bibr" rid="CR232">2004b</xref>)<break></break>2 (Nguyen et al. <xref ref-type="bibr" rid="CR144">2013</xref>)</td></tr><tr><td align="left">Aortic valve insufficiency</td><td align="left">1 (Nguyen et al. <xref ref-type="bibr" rid="CR144">2013</xref>)<break></break>1 (Dorschner et al. <xref ref-type="bibr" rid="CR44">2000</xref>)</td></tr><tr><td align="left">Hypertrophic cardiomyopathy</td><td align="left">1 (Mensink et al. <xref ref-type="bibr" rid="CR135">2006</xref>)<break></break>1 (Venturin et al. <xref ref-type="bibr" rid="CR232">2004b</xref>)<break></break>3 (Nguyen et al. <xref ref-type="bibr" rid="CR144">2013</xref>)</td></tr><tr><td align="left">Intracardiac neurofibromas</td><td align="left">2 (Nguyen et al. <xref ref-type="bibr" rid="CR144">2013</xref>)</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>In the study of Nguyen et al. (<xref ref-type="bibr" rid="CR144">2013</xref>), 6 of 16 <italic>NF1</italic> microdeletion patients had major cardiac abnormalities.
Two of these patients exhibited several heart abnormalities: Patient 5a had
an aortic and a mitral valve insufficiency as well as a cardiac tumour
whereas patient 8a had aortic stenosis, mitral valve insufficiency and
hypertrophic cardiomyopathy</p></table-wrap-foot></table-wrap>
</p>
</sec>
</sec>
<sec id="Sec9">
<title>Co-deleted genes with the potential to influence the clinical phenotype in
patients with <italic>NF1</italic> microdeletions</title>
<p>In addition to the deletion of the <italic>NF1</italic> gene, hemizygosity of any one of a number of genes located within
the deletion interval at 17q11.2 may contribute to the clinical phenotype observed
in patients with <italic>NF1</italic> microdeletions. Some of
these genes may have tumour suppressive functions and their hemizygosity could
predispose to an increased tumour risk or might facilitate tumour progression. There
is certainly good evidence that biallelic <italic>SUZ12</italic>
loss promotes MPNST progression (De Raedt et al. <xref ref-type="bibr" rid="CR39">2014</xref>; Lee et al. <xref ref-type="bibr" rid="CR110">2014</xref>; Zhang et al. <xref ref-type="bibr" rid="CR260">2014</xref>). Haploinsufficiency of other genes during early embryonic
development and/or during later stages may, however, contribute to clinical sequelae
such as overgrowth, reduced cognitive capabilities, heart defects and dysmorphic
facial features. Thus, <italic>RNF135</italic> haploinsufficiency
is associated with dysmorphic facial features and overgrowth (Douglas et al.
<xref ref-type="bibr" rid="CR45">2007</xref>). The consequences of the
deletion of the other genes located within the 1.4-Mb <italic>NF1</italic> microdeletion region (listed in Table <xref ref-type="table" rid="Tab3">3</xref>) are less clear. This notwthstanding, the function, as well as
the expression pattern of some of these genes, renders it highly likely that their
loss impacts upon the <italic>NF1</italic>
microdeletion-associated phenotype. The haploinsufficiency of some of these genes
may even synergize with the loss of the <italic>NF1</italic> gene
to aggravate the clinical manifestations of patients with <italic>NF1</italic> microdeletions. To estimate the likely consequence of
haploinsufficiency of genes located within the <italic>NF1</italic> microdeletion region, the probability of loss-of-function (LoF)
intolerance may be considered as calculated from the ExAC data set (Lek et al.
<xref ref-type="bibr" rid="CR111">2016</xref>). The metric ‘probability of
being LoF intolerant (pLI)’ separates genes into LoF intolerant (pLI ≥ 0.9) or LoF
tolerant (pLI ≤ 0.1) categories. Importantly, <italic>ATAD5</italic>, <italic>RAB11FIP4</italic>, <italic>LRRC37B</italic> and <italic>SUZ12</italic>
reside in the category of LoF intolerant genes suggesting that their
haploinsufficiency in patients with <italic>NF1</italic>
microdeletions is highly likely to have pathological consequences. By contrast,
<italic>TEFM</italic>, <italic>ADAP2</italic>,
<italic>RNF135</italic>, <italic>EVI2A</italic> and <italic>UTP6</italic> are LoF tolerant
(Table <xref ref-type="table" rid="Tab3">3</xref>). It cannot, however, be excluded
that the hemizygosity of these latter genes may still contribute in one way or
another to the <italic>NF1</italic> microdeletion phenotype.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Protein-coding and microRNA genes located within the <italic>NF1</italic> microdeletion region at 17q11.2</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Official HGNC gene symbol</th><th align="left">Alternative names</th><th align="left">MIM#</th><th align="left">Official gene name</th><th align="left">Probability of loss of function intolerance<break></break>(pLI)</th></tr></thead><tbody><tr><td align="left">
<italic>CRLF3</italic>
</td><td align="left">
<italic>FRWS; CRLM9; p48.2;CYTOR4;
CREME</italic>-<italic>9</italic>
</td><td align="char" char=".">614853</td><td align="left">Cytokine receptor-like factor 3</td><td align="char" char=".">0.98</td></tr><tr><td align="left">
<italic>ATAD5</italic>
</td><td align="left">
<italic>ELG1; FRAG1; C17orf41</italic>
</td><td align="char" char=".">609534</td><td align="left">ATPase family, AAA domain containing 5</td><td align="char" char=".">1.00</td></tr><tr><td align="left">
<italic>TEFM</italic>
</td><td align="left">
<italic>C17orf42</italic>
</td><td align="char" char=".">616422</td><td align="left">Transcription elongation factor, mitochondrial</td><td align="char" char=".">0.04</td></tr><tr><td align="left">
<italic>ADAP2</italic>
</td><td align="left">
<italic>CENTA2; Cent</italic>-<italic>b; HSA272195</italic>
</td><td align="char" char=".">608635</td><td align="left">ArfGAP with dual PH domains 2</td><td align="char" char=".">0.00</td></tr><tr><td align="left">
<italic>RNF135</italic>
</td><td align="left">
<italic>L13; MMFD; REUL; Riplet</italic>
</td><td align="char" char=".">611358</td><td align="left">Ring finger protein 135p</td><td align="char" char=".">0.00</td></tr><tr><td align="left">
<italic>MIR4733</italic>
</td><td align="left">None</td><td align="left">—</td><td align="left">microRNA 4733</td><td align="left"></td></tr><tr><td align="left">
<italic>NF1</italic>
</td><td align="left">
<italic>WSS; NFNS; VRNF</italic>
</td><td align="char" char=".">162200</td><td align="left">neurofibromin 1</td><td align="char" char=".">1.00</td></tr><tr><td align="left">
<italic>OMG</italic>
</td><td align="left">
<italic>OMGP</italic>
</td><td align="char" char=".">164345</td><td align="left">Oligodendrocyte myelin glycoprotein</td><td align="char" char=".">0.86</td></tr><tr><td align="left">
<italic>EVI2B</italic>
</td><td align="left">
<italic>EVDB; CD361; D17S376</italic>
</td><td align="char" char=".">158381</td><td align="left">Ecotropic viral integration site 2B</td><td align="char" char=".">0.18</td></tr><tr><td align="left">
<italic>EVI2A</italic>
</td><td align="left">
<italic>EVDA; EVI2; EVI</italic>-<italic>2A</italic>
</td><td align="char" char=".">158380</td><td align="left">Ecotropic viral integration site 2A</td><td align="char" char=".">0.00</td></tr><tr><td align="left">
<italic>RAB11FIP4</italic>
</td><td align="left">
<italic>FIP4</italic>-<italic>Rab11;
RAB11</italic>-<italic>FIP4</italic>
</td><td align="char" char=".">611999</td><td align="left">RAB11 family-interacting protein 4</td><td align="char" char=".">0.99</td></tr><tr><td align="left">
<italic>MIR193A</italic>
</td><td align="left">
<italic>MIRN193; MIRN193A; mir</italic>-<italic>193a</italic>
</td><td align="char" char=".">614,733</td><td align="left">microRNA 193a</td><td align="left"></td></tr><tr><td align="left">
<italic>MIR365B</italic>
</td><td align="left">
<italic>MIR365</italic>-<italic>2;
mir</italic>-<italic>365b;
MIRN365</italic>-<italic>2;hsa</italic>-<italic>mir</italic>-<italic>365b</italic>
</td><td align="char" char=".">614,733</td><td align="left">microRNA 365b</td><td align="left"></td></tr><tr><td align="left">
<italic>MIR4725</italic>
</td><td align="left">
<italic>mir</italic>-<italic>4725</italic>
</td><td align="left">—</td><td align="left">microRNA 4725</td><td align="left"></td></tr><tr><td align="left">
<italic>COPRS</italic>
</td><td align="left">
<italic>TTP1; COPR5; C17orf79; HSA272196</italic>
</td><td align="char" char=".">616477</td><td align="left">Coordinator of PRMT5 and differentiation
stimulator</td><td align="char" char=".">0.83</td></tr><tr><td align="left">
<italic>UTP6</italic>
</td><td align="left">
<italic>HCA66; C17orf40</italic>
</td><td align="left">—</td><td align="left">UTP6, small subunit processome component</td><td align="char" char=".">0.00</td></tr><tr><td align="left">
<italic>SUZ12</italic>
</td><td align="left">
<italic>CHET9; JJAZ1</italic>
</td><td align="char" char=".">613675</td><td align="left">SUZ12 polycomb-repressive complex 2 subunit</td><td align="char" char=".">1.00</td></tr><tr><td align="left">
<italic>LRRC37B</italic>
</td><td align="left">None</td><td align="char" char=".">616558</td><td align="left">Leucine-rich repeat containing 37B</td><td align="char" char=".">0.95</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>The ExAC browser (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/">http://exac.broadinstitute.org/</ext-link>) provides the constraint metric termed “probability of loss of
function” (pLI). To determine the pLI metric, the observed and expected
variant counts for a given gene included in the ExAC dataset are considered.
The closer the pLI value is to one, the more loss of function-intolerant the
gene appears to be. A pLI value ≥ 0.9 is indicative of genes extremely
intolerant of loss function variants</p></table-wrap-foot></table-wrap>
</p>
<p>Our current knowledge of the genes located within the <italic>NF1</italic> microdeletion region that have the potential to
modify the clinical phenotype in patients with <italic>NF1</italic> microdeletions, as concluded from previously published studies, is
summarised below.</p>
<sec id="Sec10">
<title><italic>RNF135</italic> may be involved in overgrowth and
dysmorphic facial features</title>
<p>The <italic>RNF135</italic> gene located upstream
of <italic>NF1</italic> represents a good candidate to account
for the overgrowth phenotype observed in <italic>NF1</italic>
microdeletion patients. This conclusion derives directly from the findings of
Douglas et al. (<xref ref-type="bibr" rid="CR45">2007</xref>), who analysed a
cohort of 245 individuals with overgrowth, learning disability, dysmorphic facial
features and detected <italic>RNF135</italic> mutations in 6 of
them. The 245 patients investigated by Douglas et al. had been previously shown to
be negative for <italic>NSD1</italic> mutations, a frequent
cause of Sotos syndrome characterised by overgrowth, dysmorphic facial features
and learning disability (Tatton-Brown et al. <xref ref-type="bibr" rid="CR213">2005</xref>). Five of the six <italic>RNF135</italic>
mutation-positive patients identified by Douglas et al. harboured intragenic
<italic>RNF135</italic> mutations whereas the other patient
exhibited a microdeletion resulting from an NAHR event between NF1-REPa and
NF1-REPb which included <italic>RNF135</italic> plus five other
genes, but not <italic>NF1</italic> (Douglas et al. <xref ref-type="bibr" rid="CR45">2007</xref>). Inactivating mutations or entire gene
deletions of <italic>RNF135</italic> do not appear to be
frequent in patients with an overgrowth phenotype since <italic>RNF135</italic> mutations were not detected in another cohort of 160
<italic>NSD1</italic> mutation-negative patients with features
of Sotos syndrome (Visser et al. <xref ref-type="bibr" rid="CR239">2009</xref>). Remarkably, among these 160 patients with suggested Sotos
syndrome and overgrowth was a 4-year-old girl with dysmorphic facial features, two
CALS and developmental delay who was found to have an <italic>NF1</italic> microdeletion. This finding indicates that an <italic>NF1</italic> microdeletion should be considered in the
differential diagnosis of children with Sotos syndrome-associated features (Visser
et al. <xref ref-type="bibr" rid="CR239">2009</xref>).</p>
<p>
<italic>RNF135</italic> encodes an E3 ubiquitin ligase with an
N-terminal RING finger domain and C-terminal SPRY and PRY motifs. It is expressed
in many different tissues (Oshiumi et al. <xref ref-type="bibr" rid="CR155">2009</xref>). RNF135 ubiquitinates RIG-I (retinoic acid-inducible gene-I
protein) and promotes its signal transduction capacity so as to produce antiviral
type-I interferon 1 (Oshiumi et al. <xref ref-type="bibr" rid="CR156">2010</xref>). Owing to its ring finger domain and the PRY motif, RNF135
is likely to bind numerous proteins, suggestive of a wide range of functions. The
mechanism underlying the overgrowth phenotype mediated by the loss of one
<italic>RNF135</italic> copy is currently unclear and needs to
be further investigated.</p>
<p>Importantly, patients with <italic>RNF135</italic> mutations exhibit dysmorphic facial features including
hypertelorism, down-slanting palpebral fissures and a broad nasal tip giving rise
to a facial appearance similar to that observed in patients with <italic>NF1</italic> microdeletions (Douglas et al. <xref ref-type="bibr" rid="CR45">2007</xref>). These findings suggest that <italic>RNF135</italic> haploinsufficiency may be responsible for the
dysmorphic facial features observed in patients with <italic>NF1</italic> microdeletions. However, since only five patients with
intragenic <italic>RNF135</italic> mutations but lacking
<italic>NF1</italic> microdeletions have so far been reported,
more extended genotype/phenotype studies are necessary to assess whether the
dysmorphic facial features are indeed caused by <italic>RNF135</italic> mutations.</p>
</sec>
<sec id="Sec11">
<title><italic>SUZ12</italic> and its role in MPNST development in
patients with <italic>NF1</italic> microdeletions</title>
<p>The increased risk of MPNSTs in patients with large <italic>NF1</italic> microdeletions is probably associated with
hemizygosity of the <italic>SUZ12</italic> gene, located
telomeric to <italic>NF1</italic> within the <italic>NF1</italic> microdeletion region (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). <italic>SUZ12</italic> is
frequently bi-allelically inactivated in MPNSTs suggestive of a tumour suppressor
function in this tumour type (De Raedt et al. <xref ref-type="bibr" rid="CR39">2014</xref>; Lee et al. <xref ref-type="bibr" rid="CR110">2014</xref>; Zhang et al. <xref ref-type="bibr" rid="CR260">2014</xref>). As a component of the Polycomb repressive complex 2
(PRC2), the SUZ12 protein is involved in the epigenetic silencing of many
different genes by establishing di- and tri-methylation of histone H3 lysine 27
(reviewed by Di Croce and Helin <xref ref-type="bibr" rid="CR42">2013</xref>). Loss of histone H3 lysine 27 trimethylation has been
observed in 50–70% of MPNSTs. By contrast, H3 lysine 27 trimethylation is retained
in benign neurofibromas and hence serves as a diagnostic marker for malignant
transformation (Asano et al. <xref ref-type="bibr" rid="CR4">2017</xref>;
Cleven et al. <xref ref-type="bibr" rid="CR26">2016</xref>; Prieto-Granada et
al. <xref ref-type="bibr" rid="CR172">2016</xref>; Schaefer et al.
<xref ref-type="bibr" rid="CR191">2016</xref>; Röhrich et al. <xref ref-type="bibr" rid="CR184">2016</xref>). The genes targeted by PRC2 regulate cell
cycle progression, stem cell self-renewal, cell fate decisions and cellular
identity. The expression changes of some of these genes consequent to the loss of
PRC2 function appear likely to contribute to tumorigenesis (reviewed by Conway et
al. <xref ref-type="bibr" rid="CR29">2015</xref>; Laugesen et al.
<xref ref-type="bibr" rid="CR105">2016</xref>). Thus, PRC2 loss has been
shown to amplify Ras-driven gene expression through epigenetic changes (De Raedt
et al. <xref ref-type="bibr" rid="CR39">2014</xref>). Somatic inactivating
mutations of <italic>SUZ12</italic> or other genes encoding PRC2
components have been detected in MPNSTs but not in benign neurofibromas and
atypical neurofibromas. The latter are considered to be premalignant tumours with
high potential to transform into MPNSTs (De Raedt et al. <xref ref-type="bibr" rid="CR39">2014</xref>; Lee et al. <xref ref-type="bibr" rid="CR110">2014</xref>; Zhang et al. <xref ref-type="bibr" rid="CR260">2014</xref>; Pemov et al. <xref ref-type="bibr" rid="CR164">2016</xref>). Consequently, loss of PRC2 function is important during
malignant transformation and/or progression of MPNSTs. In patients with germline
<italic>NF1</italic> microdeletions, one <italic>SUZ12</italic> allele is deleted in all cells and the
probability of acquiring a somatic mutation of the remaining <italic>SUZ12</italic> allele is clearly going to be higher than
acquiring two independent somatic <italic>SUZ12</italic>
mutations (as would be necessary in NF1 patients with intragenic <italic>NF1</italic> mutations, or in patients without NF1 who exhibit
sporadic MPNSTs). Hence, the constitutional deletion of one <italic>SUZ12</italic> allele represents a predisposing factor that
contributes to the increased risk of MPNSTs in patients with <italic>NF1</italic> microdeletions.</p>
</sec>
<sec id="Sec12">
<title>Other genes with known tumour suppressor function within the <italic>NF1</italic> microdeletion region</title>
<p>In addition to the <italic>NF1</italic> and
<italic>SUZ12</italic> genes, patients with <italic>NF1</italic> microdeletions are also hemizygous for three other
genes with putative tumour suppressor function: <italic>ATAD5</italic> and the microRNA genes <italic>MIR193A</italic> and <italic>MIR365B</italic>. Whilst the
importance of <italic>SUZ12</italic> loss in MPNST progression
has now been well documented, rather less is known about the co-deleted genes
<italic>ATAD5</italic>, <italic>MIR193A</italic>, <italic>MIR365B</italic> and their
involvement in MPNST pathogenesis. However, as deduced from their function, it is
not unreasonable to suppose that haploinsufficiency of these genes could promote
MPNST development in patients with <italic>NF1</italic>
microdeletions as discussed below.</p>
<sec id="Sec13">
<title>
<italic>ATAD5</italic>
</title>
<p>Another tumour suppressor gene located within the <italic>NF1</italic> microdeletion region is <italic>ATAD5</italic> (ATPase family AAA domain–containing protein 5)
(Fig. <xref ref-type="fig" rid="Fig1">1</xref>). The ATAD5 protein is
involved in the stabilisation of stalled DNA replication forks by regulating
proliferating cell nuclear antigen (PCNA) ubiquitination during DNA damage
bypass, thereby promoting the exchange of a low-fidelity translesion polymerase
back to a high-fidelity replication polymerase (Lee et al. <xref ref-type="bibr" rid="CR107">2010</xref>, <xref ref-type="bibr" rid="CR109">2013</xref>). Mice haploinsufficient for Atad5
(Atad5<sup>+/m</sup>) display high levels of genomic
instability (Bell et al. <xref ref-type="bibr" rid="CR13">2011</xref>).
Embryonic fibroblasts from Atad5<sup>+/m</sup> mice exhibit
molecular defects in PCNA deubiquitination in response to DNA damage, as well as
DNA damage hypersensitivity, high levels of genomic instability and aneuploidy.
More than 90% of haploinsufficient Atad5<sup>+/m</sup> mice
developed tumours such as sarcomas, carcinomas and adenocarcinomas that
exhibited high levels of genomic instability (Bell et al. <xref ref-type="bibr" rid="CR13">2011</xref>). Furthermore, somatic <italic>ATAD5</italic> mutations were identified in a subset of
sporadic human endometrial tumours (Bell et al. <xref ref-type="bibr" rid="CR13">2011</xref>) as well as breast and ovarian tumour cell lines (Abaan et
al. <xref ref-type="bibr" rid="CR1">2013</xref>). Hence, <italic>ATAD5</italic> is regarded as a tumour suppressor gene (Bell
et al. <xref ref-type="bibr" rid="CR13">2011</xref>; Kubota et al.
<xref ref-type="bibr" rid="CR101">2013</xref>). Rare germline missense
variants of <italic>ATAD5</italic> with predicted
pathogenicity have been reported to be enriched in patients with ovarian cancer
as compared with controls (Maleva Kostovska et al. <xref ref-type="bibr" rid="CR126">2016</xref>). Targeted knockdown of <italic>ATAD5</italic> expression in human cell lines has been shown
to confer sensitivity to DNA damaging agents and cause severe genomic
instability (Sikdar et al. <xref ref-type="bibr" rid="CR200">2009</xref>).
Consequently, we may surmise that ATAD5 functions as an important regulator of
genome instability (Gazy et al. <xref ref-type="bibr" rid="CR59">2015</xref>). Taken together, <italic>ATAD5</italic>
haploinsufficiency is likely to contribute to tumorigenesis in patients with
<italic>NF1</italic> microdeletions, in particular MPNST
pathogenesis, since these tumours exhibit a high degree of genome instability
including numerous copy number variants as well as chromosomal rearrangements
(Mantripragada et al. <xref ref-type="bibr" rid="CR128">2009</xref>; Beert
et al. <xref ref-type="bibr" rid="CR12">2011</xref> and references
therein).</p>
</sec>
<sec id="Sec14">
<title>MicroRNA genes</title>
<p>MicroRNAs (miRNAs) can play a critical role during tumorigenesis
by directly interacting with the 3′UTRs of specific target mRNAs and inhibiting
their translation (reviewed by Lovat et al. <xref ref-type="bibr" rid="CR122">2011</xref>). MicroRNAs have also been implicated in NF1-associated
tumorigenesis (Sedani et al. <xref ref-type="bibr" rid="CR192">2012</xref>). Four microRNA genes are located within the 1.4-Mb
<italic>NF1</italic> microdeletion region, <italic>MIR193A</italic>, <italic>MIR365B,
MIR4725</italic> and <italic>MIR4733</italic>
(Fig. <xref ref-type="fig" rid="Fig1">1</xref>). One of these, <italic>MIR193A,</italic> encodes two mature miRNAs with well-known
tumour suppressor functions; miR193a-3p and miR193a-5p are generated from the
primary transcript by means of several maturation steps. The expression
preference of miR193a-5p and miR193a-3p is likely to be determined by the Ago
protein (reviewed by Tsai et al. <xref ref-type="bibr" rid="CR219">2016</xref>). According to the mirbase database (<ext-link ext-link-type="uri" xlink:href="http://www.mirbase.org/">http://www.mirbase.org/</ext-link>), miR193a-3p is more abundantly expressed in human tissues than
miR193a-5p. Several studies have indicated that miR193a-3p suppresses tumour
development by silencing multiple target genes including <italic>SRSF2</italic>, <italic>HIC2, HOXC9, PSEN1, LOXL4,
ING5</italic>, <italic>KIT</italic>, <italic>PLAU</italic> and <italic>MCL1</italic>
(Tsai et al. <xref ref-type="bibr" rid="CR219">2016</xref>). miR193a-3p has
been found to be down-regulated by hypermethylation in oral squamous cell
carcinoma cell lines (Kozaki et al. <xref ref-type="bibr" rid="CR99">2008</xref>), non-small cell lung cancer (Heller et al. <xref ref-type="bibr" rid="CR69">2012</xref>; Wang et al. <xref ref-type="bibr" rid="CR246">2013</xref>; Liang et al. <xref ref-type="bibr" rid="CR115">2015</xref>; Ren et al. <xref ref-type="bibr" rid="CR176">2015</xref>), bladder cancer (Deng et al.
<xref ref-type="bibr" rid="CR40">2014</xref>; Lv et al. <xref ref-type="bibr" rid="CR124">2014</xref>; Li et al. <xref ref-type="bibr" rid="CR114">2015</xref>), hepatocellular carcinoma (Salvi et al.
<xref ref-type="bibr" rid="CR189">2013</xref>), <italic>BRAF</italic> mutation-positive malignant melanoma (Caramuta et al.
<xref ref-type="bibr" rid="CR22">2010</xref>), acute myeloid leukaemia
(Xing et al. <xref ref-type="bibr" rid="CR254">2015</xref>) and pleural
mesothelioma (Williams et al. <xref ref-type="bibr" rid="CR250">2015</xref>). However, it is unclear whether the down-regulation of
miR193a-3p is a cause or a consequence of tumorigenesis. Decreased expression of
miR193a-3p has been found to be correlated with metastasis, apoptosis and
proliferation in breast cancer cell lines (Iliopoulos et al. <xref ref-type="bibr" rid="CR76">2011</xref>; Tsai et al. <xref ref-type="bibr" rid="CR219">2016</xref>) and ovarian tumour tissue (Nakano et
al. <xref ref-type="bibr" rid="CR141">2013</xref>). Moreover, miR193a-5p is
known to possess tumour suppressor functions since it inhibits the growth of
breast cancer cells (Tsai et al. <xref ref-type="bibr" rid="CR219">2016</xref>) and endometrioid endometrial carcinoma cells by
down-regulation of the transcription factor YY1 (Yang et al. <xref ref-type="bibr" rid="CR256">2013</xref>). Both miR193a-5p and miR193a-3p
suppress lung cancer cell migration and invasion by co-regulating the
ERBB4/PIK3R3/mTOR/S6K2 signalling pathway (Yu et al. <xref ref-type="bibr" rid="CR258">2015</xref>). These findings indicate that
miR193a-3p and miR193a-5p play a tumour suppressor role in many different tumour
types. In particular, the putative tumour suppressor function of miR193a-3p in
breast cancer cell lines is noteworthy since breast cancer occurs at an
increased frequency in patients with NF1 (Sharif et al. <xref ref-type="bibr" rid="CR197">2007</xref>; Seminog and Goldacre <xref ref-type="bibr" rid="CR193">2013</xref>, <xref ref-type="bibr" rid="CR194">2015</xref>; Uusitalo et al. <xref ref-type="bibr" rid="CR225">2016</xref>). However, it is unknown whether the breast cancer risk is
higher in patients with <italic>NF1</italic> microdeletions
than in patients with intragenic <italic>NF1</italic>
mutations.</p>
<p>The <italic>MIR365B</italic> gene, located
within the <italic>NF1</italic> microdeletion region
(Fig. <xref ref-type="fig" rid="Fig1">1</xref>), also encodes an miRNA with
known tumour suppressor function, as evidenced by its ability to target specific
transcription factors, such as NKX2-1 and TTF1, in non-small cell lung cancer
(Qi et al. <xref ref-type="bibr" rid="CR173">2012</xref>; Kang et al.
<xref ref-type="bibr" rid="CR83">2013</xref>; Sun et al. <xref ref-type="bibr" rid="CR209">2015</xref>). miR365 is down-regulated in colon
cancer (Nie et al. <xref ref-type="bibr" rid="CR146">2012</xref>),
cutaneous squamous cell carcinoma (Zhou et al. <xref ref-type="bibr" rid="CR262">2014</xref>, <xref ref-type="bibr" rid="CR263">2015</xref>),
hepatocellular carcinoma (Chen et al. <xref ref-type="bibr" rid="CR24">2015</xref>), gastric cancer (Guo et al. <xref ref-type="bibr" rid="CR66">2013</xref>) and malignant melanoma (Bai et al.
<xref ref-type="bibr" rid="CR6">2015a</xref>, <xref ref-type="bibr" rid="CR7">b</xref>). By contrast, putative tumour suppressor
functions of the other two miRNAs located within the <italic>NF1</italic> microdeletion region, encoded by <italic>MIR4725</italic> and <italic>MIR4733,</italic>
respectively, have not so far been reported.</p>
<p>Taken together, the loss of the <italic>MIR193A</italic> and <italic>MIR365B</italic> genes in
patients with <italic>NF1</italic> microdeletions may well
contribute to tumorigenesis in these patients. However, miRNAs are not only
involved in tumour development; they also play a role as key regulators of
metabolic homeostasis and tissue differentiation (reviewed by Vienberg et al.
<xref ref-type="bibr" rid="CR236">2017</xref>). Additional studies are
necessary to investigate the influence of the hemizygous loss of the miRNA genes
on the clinical phenotype associated with <italic>NF1</italic>
microdeletions.</p>
</sec>
</sec>
<sec id="Sec15">
<title>Other genes that may contribute to tumour development in patients with
<italic>NF1</italic> microdeletions</title>
<p>In addition to the deletion of <italic>SUZ12</italic> and <italic>ATAD5</italic>, hemizygosity for
the genes <italic>COPRS</italic>, <italic>UTP6</italic> and <italic>RNF135</italic> may also
contribute to the increased tumour risk associated with <italic>NF1</italic> microdeletions. Current knowledge about the function of these
genes is summarised in the following paragraphs.</p>
<sec id="Sec16">
<title>
<italic>COPRS</italic>
</title>
<p>
<italic>COPRS</italic> is another gene located within the
<italic>NF1</italic> microdeletion interval that may well
play a role in MPNST development. <italic>COPRS</italic>
encodes an adaptor protein that binds strongly to protein-arginine
methyltransferase 5 (PRTM5) and to histone H4. By these means, COPRS recruits
PRMT5 to chromatin and also modulates PRMT5 substrate specificity since PRMT5
bound to COPRS preferentially methylates histone H4 instead of histone H3
(Lacroix et al. <xref ref-type="bibr" rid="CR103">2008</xref>). COPRS
binding to PRMT5 is essential for myogenic differentiation, possibly through
altered targeting of PRMT5 to specific gene promoters (Paul et al. <xref ref-type="bibr" rid="CR163">2012</xref>). These observations suggest that the
COPRS–PRMT5 complex regulates cell differentiation, a process that is frequently
perturbed during tumorigenesis. MPNSTs often exhibit regions of divergent
differentiation possibly including rhabdomyosarcomatous, chondral, glandular,
neuroendocrine, gangliocytic and liposarcomatous components. These regions of
divergent differentiation may be focal on a background of typical spindle-shaped
tumour cells. For example, in some cases, rhabdomyosarcomatous differentiation
may become predominant rendering even differential diagnosis very difficult (Guo
et al. <xref ref-type="bibr" rid="CR65">2012</xref>). Aberrant regulation
of the COPRS–PRMT5 complex due to COPRS haploinsufficiency may contribute to
these divergent differentiation patterns. Increased expression of PRMT5 has been
noted in a wide variety of cancer types (reviewed by Stopa et al. <xref ref-type="bibr" rid="CR207">2015</xref>), but further studies are necessary to
investigate how <italic>COPRS</italic> haploinsufficiency in
patients with <italic>NF1</italic> microdeletions could alter
PRMT5 function, thereby contributing to tumorigenesis.</p>
<p>Analysis of the expression level of <italic>COPRS</italic> in MPNST cell lines has yielded inconsistent results both
within and between studies (Bartelt-Kirbach et al. <xref ref-type="bibr" rid="CR10">2009</xref>; Pasmant et al. <xref ref-type="bibr" rid="CR161">2011</xref>). Overexpression of <italic>COPRS</italic> (five to 10-fold) was observed in two MPNST
tissue samples from patients with intragenic <italic>NF1</italic> mutations as compared with cutaneous neurofibroma tissue
(Bartelt-Kirbach et al. <xref ref-type="bibr" rid="CR10">2009</xref>).
However, by contrast, these authors detected low expression of <italic>COPRS</italic> in an MPNST cell line, which was as low as the
<italic>COPRS</italic> expression level in
neurofibroma-derived fibroblast cell cultures. The MPNST cell line analysed by
these authors was derived from an NF1 patient but the germline <italic>NF1</italic> mutation in this patient had not been determined.
In similar vein, whilst Pasmant et al. (<xref ref-type="bibr" rid="CR161">2011</xref>) observed high <italic>COPRS</italic>
expression in a series of MPNST cell lines as compared with plexiform and
cutaneous neurofibroma samples, in other MPNST cell lines, <italic>COPRS</italic> expression levels were as low as in plexiform
and cutaneous neurofibromas (Pasmant et al. <xref ref-type="bibr" rid="CR161">2011</xref>). Unfortunately, these authors failed to specify the
origin of the MPNST cell lines analysed, whether they were derived from NF1
patients and if so, whether they harboured <italic>NF1</italic> microdeletions. The inconsistent findings regarding the
<italic>COPRS</italic> expression level in MPNSTs reported
by Bartelt-Kirbach et al. (<xref ref-type="bibr" rid="CR10">2009</xref>)
and Pasmant et al. (<xref ref-type="bibr" rid="CR161">2011</xref>) are
difficult to interpret. It may be that MPNST cell lines are an inappropriate
system in which to investigate <italic>COPRS</italic>
expression, perhaps because these cell lines have been subject to massive in
vitro selection and hence may not be representative of key stages of MPNST
development in vivo. Thus, the analysis of <italic>COPRS</italic> expression should be performed using primary MPNST samples
(with high proportions of tumour cells) from patients with <italic>NF1</italic> microdeletions to explore the role of <italic>COPRS</italic> during MPNST development or progression in
<italic>NF1</italic> microdeletion patients.</p>
</sec>
<sec id="Sec17">
<title>
<italic>UTP6</italic>
</title>
<p>Tumorigenesis in patients with <italic>NF1</italic> microdeletions may also be influenced by haploinsufficiency of
<italic>UTP6,</italic> located telomeric to <italic>NF1</italic> within the <italic>NF1</italic>
microdeletion region (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). The
protein encoded by UTP6 is involved in apoptosome-dependent apoptosis and it has
been suggested that UTP6 haploinsufficiency could render cells with <italic>NF1</italic> microdeletions less susceptible to apoptosis
(Piddubnyak et al. <xref ref-type="bibr" rid="CR167">2007</xref>). UTP6 is
required for ribosome synthesis (Bonnart et al. <xref ref-type="bibr" rid="CR19">2012</xref>) and is, as a component of the centrosome, required for
centriole duplication and the establishment of a bipolar spindle ensuring proper
chromosome segregation during mitosis (Fant et al. <xref ref-type="bibr" rid="CR50">2009</xref>; Ferraro et al. <xref ref-type="bibr" rid="CR55">2011</xref>). Somatic loss of the remaining <italic>UTP6</italic> allele in tumours of patients with <italic>NF1</italic> microdeletions may contribute to malignant
transformation by increasing chromosome instability and aneuploidy.</p>
</sec>
<sec id="Sec18">
<title>
<italic>RNF135</italic>
</title>
<p>In addition to its influence on the childhood overgrowth
phenotype and the dysmorphic facial features observed in patients with <italic>NF1</italic> microdeletions, <italic>RNF135</italic> haploinsufficiency may also promote tumorigenesis. The
<italic>RNF135</italic> gene has been shown to be
down-regulated in cells from malignant peripheral nerve sheath tumours (MPNSTs)
and MPNST cell lines suggesting that <italic>RNF135</italic>
loss is involved in conferring the increased MPNST risk characteristic of NF1
microdeletion patients (Pasmant et al. <xref ref-type="bibr" rid="CR161">2011</xref>). In glioblastomas, however, <italic>RNF135</italic> has been found to be upregulated and promotes the
proliferation of human glioblastoma cells in vivo and in vitro via the ERK
pathway (Liu et al. <xref ref-type="bibr" rid="CR118">2016</xref>).
Furthermore, <italic>RNF135</italic> would appear to promote
the expression of <italic>PTEN</italic> and <italic>TP53</italic> in tongue cancer SCC25 cells and <italic>RNF135</italic> overexpression inhibits the viability,
proliferation, and invasion of these cells (Jin et al. <xref ref-type="bibr" rid="CR82">2016</xref>). Taken together, these findings suggest
that changes in the dosage of <italic>RNF135</italic> might
contribute to tumorigenesis although further studies are necessary to clarify
this postulate.</p>
</sec>
</sec>
<sec id="Sec19">
<title>Haploinsufficiency of genes in <italic>NF1</italic>
microdeletion patients and intellectual disability</title>
<sec id="Sec20">
<title>
<italic>OMG</italic>
</title>
<p>Hemizygosity of a gene (or several genes) located within the
<italic>NF1</italic> microdeletion region may contribute to
the intellectual disability noted in patients with large <italic>NF1</italic> deletions (Venturin et al. <xref ref-type="bibr" rid="CR234">2006</xref>). A good candidate is the <italic>OMG</italic> gene which encodes the oligodendrocyte myelin glycoprotein
(OMgp) involved in the regulation of synaptic plasticity (reviewed by Mironova
and Giger <xref ref-type="bibr" rid="CR138">2013</xref>). Synaptic
plasticity and structural changes of the synapse have been suggested to cause
cognitive and functional defects observed in intellectual disability, autism
spectrum disorders and schizophrenia (Bernardinelli et al. <xref ref-type="bibr" rid="CR16">2014</xref>).</p>
<p>OMgp is anchored to the myelin membrane through a
glycosylphosphatidyl inositol lipid molecule and is expressed in neurons as well
as oligodendrocytes (Habib et al. <xref ref-type="bibr" rid="CR67">1998</xref>; Raiker et al. <xref ref-type="bibr" rid="CR174">2010</xref> and references therein). OMgp belongs to the group of
myelin-associated inhibitor proteins (MAIPs) which act as central nervous system
(CNS) regeneration inhibitors by preventing injured axons from regenerating
beyond the injury site. Prototypical MAIPs, including OMgp, are expressed in the
healthy as well as the injured brain and bind to the Nogo-66 receptor (NgR1) and
the paired Ig-like receptor B (PirB) which appear to inhibit neurite outgrowth
in the adult CNS (Atwal et al. <xref ref-type="bibr" rid="CR5">2008</xref>;
Akbik et al. <xref ref-type="bibr" rid="CR2">2012</xref>; Geoffroy and
Zheng <xref ref-type="bibr" rid="CR60">2014</xref>; Baldwin and Giger
<xref ref-type="bibr" rid="CR9">2015</xref>). However, in the adult CNS,
OMgp and other MAIPs also regulate neuronal morphology, dendritic spine shape
and activity-driven synaptic plasticity by binding to their receptors as
determined both by NgR1 and PirB knockout mouse models and human cell lines
(McGee et al. <xref ref-type="bibr" rid="CR134">2005</xref>; Syken et al.
<xref ref-type="bibr" rid="CR210">2006</xref>; Lee et al. <xref ref-type="bibr" rid="CR106">2008</xref>; Raiker et al. <xref ref-type="bibr" rid="CR174">2010</xref>; reviewed by Mironova and Giger
<xref ref-type="bibr" rid="CR138">2013</xref>).</p>
<p>In addition to its function in the adult CNS, OMgp plays
important roles during early stages of brain development before the onset of
myelination, possibly by regulating neurogenesis (Martin et al. <xref ref-type="bibr" rid="CR129">2009</xref>). During normal mouse development,
neuronal OMgp is expressed, from embryonic day E14 on, in growing axons during
axonal tract formation following the maturation of cortical connexions (Gil et
al. <xref ref-type="bibr" rid="CR62">2010</xref>). In primary hippocampal
cultures of adult normal mice, OMgp is present in the neuronal membrane,
synaptosomal fractions and axonal varicosities (Gil et al. <xref ref-type="bibr" rid="CR62">2010</xref>). OMgp-null mice show impaired
myelination and thalamo-cortical projection (Gil et al. <xref ref-type="bibr" rid="CR62">2010</xref>) as well as hypomyelination of the spinal
cord that correlates with lower propagation of ascending and descending
electrical impulses (Lee et al. <xref ref-type="bibr" rid="CR108">2011</xref>). Even although OMgp-null mice may not represent a wholly
appropriate model with which to ascertain the consequences of <italic>OMG</italic> haploinsufficiency in humans, data derived from
this system are consistent with the view that OMgp plays a key role in axonal
target specification and synaptic plasticity.</p>
<p>Many studies have indicated that dysfunction of synapse
formation, shape or density and synaptic plasticity cause intellectual
disability and neuropsychiatric disorders (reviewed by Pittenger <xref ref-type="bibr" rid="CR169">2013</xref>; Srivastava and Schwartz <xref ref-type="bibr" rid="CR204">2014</xref>). Since MAIPs and their receptors play
important roles in regulating synapse formation and plasticity, altered
expression or function of these proteins may contribute to intellectual
disability and other brain disorders (Sinibaldi et al. <xref ref-type="bibr" rid="CR201">2004</xref>; Budel et al. <xref ref-type="bibr" rid="CR21">2008</xref>; Tews et al. <xref ref-type="bibr" rid="CR216">2013</xref>; Llorens et al. <xref ref-type="bibr" rid="CR119">2011</xref>; Willi and Schwab, <xref ref-type="bibr" rid="CR249">2013</xref>; Petrasek et al. <xref ref-type="bibr" rid="CR166">2014</xref>). Consequently, OMgp haploinsufficiency
may well contribute to the intellectual disability observed in patients with
<italic>NF1</italic> microdeletions. The negative effects of
OMgp haploinsufficiency on synaptic plasticity could be additive in relation to
the consequences of the loss of the <italic>NF1</italic> gene
product neurofibromin, an important regulator of Ras signalling in the brain. At
least 50% of the patients with intragenic <italic>NF1</italic>
mutations suffer from intellectual disabilities manifesting as cognitive
slowing, memory disturbances, difficulties in solving strategic problems,
visuospatial impairment and deficits in motor coordination (Diggs-Andrews and
Gutmann <xref ref-type="bibr" rid="CR43">2013</xref>; Violante et al.
<xref ref-type="bibr" rid="CR237">2013</xref>). These symptoms are
further aggravated in patients with <italic>NF1</italic>
microdeletions who exhibit a significantly lower mean FSIQ than patients with
intragenic <italic>NF1</italic> mutations (Descheemaeker et
al. <xref ref-type="bibr" rid="CR41">2004</xref>).</p>
<p>Similar to the phenotype observed in patients with NF1,
behavioural studies in Nf1-deficient mouse models indicated deficits in spatial
learning and motor coordination (Shilyansky et al. <xref ref-type="bibr" rid="CR198">2010a</xref>, <xref ref-type="bibr" rid="CR199">b</xref>; van der Vaart et al. <xref ref-type="bibr" rid="CR228">2011</xref>). These mouse models also revealed that increased Ras/MAPK
(mitogen-activated protein kinases) signalling results in higher GABA
(gamma-aminobutyric acid) release during learning causing deficits in
hippocampal long-term potentiation (LTP) that could account for the spatial
learning and memory deficits of these mutant mice (Costa et al. <xref ref-type="bibr" rid="CR31">2002</xref>; Cui et al. <xref ref-type="bibr" rid="CR34">2008</xref>). Hence, neurofibromin is an important
Ras regulator in interneurons influencing hippocampal-dependent learning. Ras
signalling in dendritic spines of pyramidal neurons is required for many forms
of synaptic plasticity, including LTP, spine structural plasticity, and new
spine formation (reviewed by Oliveira and Yasuda <xref ref-type="bibr" rid="CR154">2014</xref>). Consequently, <italic>NF1</italic> and
<italic>OMG</italic> haploinsufficiency are likely to exert
additive negative effects that are causally associated with the cognitive
deficit evident in many patients with <italic>NF1</italic>
microdeletions. Loss-of-function mutations in the <italic>OMG</italic> gene have not, however, been observed in patients with
idiopathic intellectual disability (Venturin et al. <xref ref-type="bibr" rid="CR234">2006</xref>).</p>
</sec>
<sec id="Sec21">
<title>
<italic>RNF135</italic>
</title>
<p>
<italic>RNF135</italic> haploinsufficiency may also contribute
to the reduced cognitive capabilities observed in patients with <italic>NF1</italic> microdeletions. As mentioned earlier, <italic>RNF135</italic> encodes an E3 ubiquitin ligase; other
ubiquitin ligase genes have already been implicated in the development of
intellectual disability and autism (Tenorio et al. <xref ref-type="bibr" rid="CR215">2014</xref>; reviewed by Tastet et al. <xref ref-type="bibr" rid="CR212">2015</xref>).</p>
<p>A significantly increased frequency of genotypes carrying the
rare allele of the <italic>RNF135</italic> missense variant
rs111902263 (p.R115 K) has been observed in patients with autism as compared
with healthy controls (<italic>P</italic> = 0.0019, odds
ratio: 4.23, 95% confidence interval: 1.87–9.57) (Tastet et al. <xref ref-type="bibr" rid="CR212">2015</xref>). These authors also showed that the
<italic>RNF135</italic> gene is expressed in the cerebral
cortex of humans and mice. The <italic>RNF135</italic>-encoded
protein, termed ‘Riplet’, regulates the cytosolic viral RNA receptors RIG-I by
ubiquitination (Oshiumi et al. <xref ref-type="bibr" rid="CR155">2009</xref>, <xref ref-type="bibr" rid="CR156">2010</xref>,
<xref ref-type="bibr" rid="CR157">2013</xref>). RIG-I and other
RIG-I-like receptors contribute to innate antiviral immunity by inducing
antiviral responses such as the production of type I interferons (IFNs) and
proinflammatory cytokines (reviewed by Yoneyama et al. <xref ref-type="bibr" rid="CR257">2015</xref>). RIG-1 is upregulated in neurons upon
viral infection and is an important component of the intrinsic antiviral
pathways in the CNS (Nazmi et al. <xref ref-type="bibr" rid="CR142">2011</xref>). RIG-I knockdown in a mouse model was associated with
reduced neural stem/progenitor cell proliferation (Mukherjee et al. <xref ref-type="bibr" rid="CR140">2015</xref>), suggesting that the RNF135 protein
plays a role in neurogenesis. Further studies will be necessary to determine the
role of RNF135/Riplet in neural stem/progenitor cells and during brain
development, roles which may yet prove to be relevant in the context of
<italic>RNF135</italic> haploinsufficiency and cognitive
disability in patients with <italic>NF1</italic>
microdeletions.</p>
<p>Intriguingly, the <italic>ADAP2</italic> gene,
which is also located within the <italic>NF1</italic>
microdeletion region, encodes another key regulator of RIG-I signalling. ADAP2,
an ADP-ribosylation factor GTPase-activating protein (ArfGAP) with dual PH
domains 2, plays an important role as a scaffold protein that couples different
modules of RIG-I signalling, leading to the up-regulation of type-I interferon
gene transcription in response to viral infection (Bist et al. <xref ref-type="bibr" rid="CR18">2016</xref>). The potential role of ADAP2 in the
aetiology of cardiovascular malformations is discussed below.</p>
</sec>
</sec>
<sec id="Sec22">
<title><italic>ADAP2</italic> and cardiovascular malformations in
patients with <italic>NF1</italic> microdeletions</title>
<p>Hemizygosity of the <italic>ADAP2</italic> gene
may contribute to the cardiovascular malformations observed in patients with
<italic>NF1</italic> microdeletions. This conclusion is drawn
from the observation that <italic>ADAP2</italic> is highly
expressed during early stages of heart development in both mouse and human
(Venturin et al. <xref ref-type="bibr" rid="CR233">2005</xref>, <xref ref-type="bibr" rid="CR235">2014</xref>). In zebrafish, <italic>ADAP2</italic> loss of function leads to circulatory deficiencies and heart
shape defects or defective valvulogenesis (Venturin et al. <xref ref-type="bibr" rid="CR235">2014</xref>). The <italic>ADAP</italic>2-encoded protein acts as a GTPase-activating protein (GAP) of
the ADP-ribosylation factor 6 (ARF6), a small GTPase involved in actin
cytoskeleton remodelling. ADAP2 (centaurin-alpha2) is located in the cytoplasm but
after EGF stimulation, it binds to the plasma membrane via phosphatidylinositols.
Plasma membrane association of ADAP2 prevents ARF6 translocation to the plasma
membrane. By these means, ADAP2 negatively regulates ARF6-mediated actin
cytoskeleton reorganisation (Venkateswarlu et al. <xref ref-type="bibr" rid="CR230">2007</xref>). ADAP2 also interacts with beta-tubulin and stabilises
microtubules (Zuccotti et al. <xref ref-type="bibr" rid="CR265">2012</xref>).
As a microtubulin-associated protein expressed during early embryonic development
in the central nervous system and in the heart, ADAP2 is likely to mediate
microtubule cytoskeleton reorganisation during cell differentiation and migration.
It is well known that the interaction between microtubules and the actin
cytoskeleton in association with membrane-associated proteins regulates cell shape
and cellular remodelling (reviewed by Basu and Chang <xref ref-type="bibr" rid="CR11">2007</xref>; Bezanilla et al. <xref ref-type="bibr" rid="CR17">2015</xref>). Since ADAP2 interacts with the
microtubule/actin cytoskeleton, it may function as a cytoskeleton cross-talker
that increases microtubule stability and modulates actin reorganisation and hence
cellular morphology (Zucotti et al. <xref ref-type="bibr" rid="CR264">2012</xref>). Disturbances of the cytoskeletal organisation in myocytes
during embryonal development may be responsible for the cardiovascular
malformations observed in patients with <italic>NF1</italic>
microdeletions. This postulate was reinforced by the findings of Venturin et al.
(<xref ref-type="bibr" rid="CR235">2014</xref>) who showed that in
zebrafish, <italic>ADAP2</italic> is required for normal cardiac
morphogenesis.</p>
<p>The protein product of the <italic>NF1</italic>
gene, neurofibromin, is essential for embryonic cardiac valve formation and the
study of mouse models has indicated that neurofibromin loss leads to
cardiovascular lethality during early embryonic development; Nf1 regulation of Ras
in the developing endothelium is required for regular development of endocardial
cushions and the ventricular myocardium (Gitler et al. <xref ref-type="bibr" rid="CR63">2003</xref>; Ismat et al. <xref ref-type="bibr" rid="CR77">2006</xref>; Xu et al. <xref ref-type="bibr" rid="CR255">2009</xref>; Bajaj et al. <xref ref-type="bibr" rid="CR8">2012</xref>; Yzaguirre et al. <xref ref-type="bibr" rid="CR259">2015</xref>). Haploinsufficiency for both <italic>NF1</italic> and <italic>ADAP2</italic> may contribute
either cooperatively or additively to the increased frequency of heart defects in
patients with <italic>NF1</italic> microdeletions. Further,
<italic>SUZ12</italic> and <italic>UTP6</italic> are highly expressed during the development of the human heart;
it follows that their haploinsufficiency may also contribute to the increased
prevalence of congenital heart defects in patients with <italic>NF1</italic> microdeletions (Venturin et al. <xref ref-type="bibr" rid="CR233">2005</xref>).</p>
</sec>
</sec>
<sec id="Sec23">
<title>Clinical phenotype in patients with <italic>NF1</italic>
microdeletions: influence of mosaicism and deletion size</title>
<p>The presence of normal cells not harbouring an <italic>NF1</italic> microdeletion exerts a major influence on disease
severity in patients with mosaic large <italic>NF1</italic>
deletions. Depending upon the proportion of cells harbouring the deletion, the
clinical phenotype can be very mild or may affect only certain body segments
(Tinschert et al. <xref ref-type="bibr" rid="CR217">2000</xref>; Maertens et
al. <xref ref-type="bibr" rid="CR125">2007</xref>). The frequency of somatic
mosaicism is strongly associated with the type of <italic>NF1</italic> microdeletion. Type-2 <italic>NF1</italic>
deletions, caused by NAHR between <italic>SUZ12</italic> and
<italic>SUZ12P1</italic>, are frequently of postzygotic origin.
Patients with postzygotic type-2 <italic>NF1</italic> deletions
exhibit somatic mosaicism of cells with the deletion and normal cells not harbouring
the deletion (Kehrer-Sawatzki et al. <xref ref-type="bibr" rid="CR89">2004</xref>; Steinmann et al. <xref ref-type="bibr" rid="CR205">2007</xref>; Vogt et al. <xref ref-type="bibr" rid="CR242">2012</xref>). It has been estimated that at least 63% of all type-2
<italic>NF1</italic> deletions are associated with somatic
mosaicism (Vogt et al. <xref ref-type="bibr" rid="CR242">2012</xref>). Atypical
<italic>NF1</italic> deletions are also frequently mosaic; among
the 17 atypical <italic>NF1</italic> deletion patients
investigated by Vogt et al. (<xref ref-type="bibr" rid="CR243">2014</xref>), 10
patients (59%) exhibited somatic mosaicism with normal cells. By contrast, only a
very low proportion (2–4%) of type-1 <italic>NF1</italic>
microdeletions is associated with somatic mosaicism (Messiaen et al. <xref ref-type="bibr" rid="CR136">2011</xref>). Remarkably, patients with type-2 deletions
exhibit tissue-specific differences in the proportion of cells with the deletion
(termed del<sup>(+/−)</sup> cells), whereas the proportion of
del<sup>(+/−)</sup> cells is very high (94–99%) in the blood of
these patients, and much lower proportions of del<sup>(+/−)</sup>
cells are evident in urine samples (24–82%) (Roehl et al. <xref ref-type="bibr" rid="CR183">2012</xref>). Since mosaic type-2 <italic>NF1</italic> microdeletions occur in most instances during early
embryonic development, the tissue-specific differences in the proportion of
del<sup>(+/−)</sup> cells should result from cell type-specific
selection.</p>
<p>Genotype–phenotype correlations in patients with mosaic <italic>NF1</italic> microdeletions are difficult to perform because the
variable proportion of normal cells in different tissues is likely to influence the
expression of clinical symptoms. The proportion of normal cells is difficult to
assess and may vary from tissue to tissue and from patient to patient.
Unfortunately, only a small number of patients with mosaic <italic>NF1</italic> deletions have been analysed in any detail. None of the eight
patients with mosaic type-2 <italic>NF1</italic> microdeletions
exhibited facial dysmorphism, nor was there any evidence of delayed cognitive
development and/or learning disabilities, cognitive impairment, congenital heart
disease, hyperflexibility of joints, large hands and feet, muscular hypotonia or
bone cysts, all of which are frequently observed in patients with germline type-1
<italic>NF1</italic> microdeletions (Table <xref ref-type="table" rid="Tab1">1</xref>). Furthermore, externally visible and internal
plexiform neurofibromas were significantly less prevalent in patients with mosaic
type-2 <italic>NF1</italic> microdeletions as compared with
patients carrying constitutional (germline) type-1 <italic>NF1</italic> microdeletions (Kehrer-Sawatzki et al. <xref ref-type="bibr" rid="CR92">2012</xref>). These differences in clinical phenotype are
unlikely to be caused by the differing extent of type-1 and type-2 deletions. Even
although only two patients with non-mosaic type-2 <italic>NF1</italic> microdeletions have so far been analysed in terms of their
clinical phenotype (Vogt et al. <xref ref-type="bibr" rid="CR241">2011</xref>),
it may be concluded that patients with non-mosaic type-2 deletions exhibit most of
the clinical features that have been reported in individuals with germline type-1
<italic>NF1</italic> deletions. Thus, a severe disease
manifestation is not confined to patients with type-1 <italic>NF1</italic> deletions but may also occur in individuals with non-mosaic type-2
<italic>NF1</italic> deletions. The loss of the <italic>LRRC37B</italic> gene, associated with type-1 microdeletions but
not with type-2 microdeletions, is unlikely to exert a major influence on the
clinical phenotype. We conclude that the less severe clinical phenotype observed in
patients with mosaic type-2 <italic>NF1</italic> microdeletions is
unrelated to the extent of the deletion but is instead associated with the presence
of normal cells that lack the microdeletion. Nevertheless, an increased risk of
MPNSTs may also exist for patients with mosaic type-2 <italic>NF1</italic> microdeletions and plexiform neurofibromas, since most MPNSTs
develop from pre-existing plexiform neurofibromas (Tucker et al. <xref ref-type="bibr" rid="CR220">2005</xref>) and the concomitant loss of <italic>NF1</italic> and <italic>SUZ12</italic> in
plexiform neurofibroma cells harbouring the type-2 <italic>NF1</italic> microdeletion increases the likelihood of malignant
transformation.</p>
<p>The extent of the deletion may nevertheless be important in the
context of genotype-phenotype relationships in patients with <italic>NF1</italic> microdeletions. It has been noted that patients with very large
atypical <italic>NF1</italic> deletions that encompass several Mb,
much larger than the classical 1.4-Mb spanning type-1 <italic>NF1</italic> deletions, exhibit very severe disease manifestations associated
with many additional clinical features that are not generally found to be associated
with type-1 <italic>NF1</italic> deletions (Upadhyaya et al.
<xref ref-type="bibr" rid="CR221">1996</xref>; Cnossen et al. <xref ref-type="bibr" rid="CR27">1997</xref>; Dorschner et al. <xref ref-type="bibr" rid="CR44">2000</xref>; Kehrer-Sawatzki et al. <xref ref-type="bibr" rid="CR88">2003</xref>; Pasmant et al. <xref ref-type="bibr" rid="CR158">2008</xref>). However, these deletions were very
heterogeneous in size and hence genotype–phenotype analyses are scarcely feasible.
More interesting in this regard are shorter deletions with recurrent breakpoints
such as type-3 <italic>NF1</italic> microdeletions. These
deletions encompass only 1-Mb and do not include the five functional genes
(<italic>CRLF3</italic>, <italic>ATAD5, TEFM,
ADAP2</italic> and <italic>RNF135</italic>) located
centromeric to NF1-REPb (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). However,
only eight type-3 <italic>NF1</italic> deletions have so far been
identified by means of high-resolution breakpoint analysis (Bengesser et al.
<xref ref-type="bibr" rid="CR14">2010</xref>; Pasmant et al. <xref ref-type="bibr" rid="CR160">2010</xref>; Messiaen et al. <xref ref-type="bibr" rid="CR136">2011</xref>). Unfortunately, the clinical data from
these eight patients are far from comprehensive or completely unavailable.
Intellectual disability or cognitive impairment was observed in four of these eight
patients with type-3 <italic>NF1</italic> microdeletions.
Consequently, a gene (or genes) influencing the cognitive capabilities in these
patients is located either within the <italic>NF1</italic> gene
itself (e.g. <italic>OMG</italic>) or located telomeric to
<italic>NF1</italic>; <italic>OMG</italic> is
probably the best candidate for such an influence, by virtue of its function.
Remarkably, dysmorphic facial features were observed in six patients from whom
clinical phenotypic data were available (Bengesser et al. <xref ref-type="bibr" rid="CR14">2010</xref>; Pasmant et al. <xref ref-type="bibr" rid="CR160">2010</xref>). Since the <italic>RNF135</italic> gene was not deleted in these patients, it would appear that
<italic>RNF135</italic> haploinsufficiency cannot be held
responsible for the dysmorphic facial features in these individuals. The <italic>RNF135</italic> gene is located 46-kb upstream of the centromeric
breakpoint of type-3 <italic>NF1</italic> deletions. However, it
cannot be unequivocally excluded that a regulatory element which influences
<italic>RNF135</italic> expression has been deleted in patients
with type-3 <italic>NF1</italic> deletions. The deletion of such a
regulatory element could have impaired <italic>RNF135</italic>
expression in those patients with type-3 deletions, a postulate which remains to be
investigated. Unfortunately, since it is not yet known if patients with type-3
<italic>NF1</italic> deletions are affected by childhood
overgrowth or tall stature as adults, no further conclusions can be drawn concerning
<italic>RN135</italic> haploinsufficieny and its role in height
determination in patients with <italic>NF1</italic> deletions.
Detailed clinical characterisation of a larger number of patients with type-3
<italic>NF1</italic> deletions would be necessary to assess the
contribution of the genes listed in Table <xref ref-type="table" rid="Tab1">1</xref>
to the clinical phenotype associated with large <italic>NF1</italic> deletions.</p>
</sec>
<sec id="Sec24">
<title>The clinical phenotype in <italic>NF1</italic>
microdeletion vs. <italic>NF1</italic> microduplication
patients</title>
<p>For many disease-associated microdeletions encompassing several
hundred kb, the reciprocal microduplications have been identified. In most
instances, microdeletions and the reciprocal microduplications differ in terms of
the associated clinical phenotype (reviewed by Vissers and Stankiewicz <xref ref-type="bibr" rid="CR240">2012</xref>; Weise et al. <xref ref-type="bibr" rid="CR247">2012</xref>). Microduplications reciprocal to <italic>NF1</italic> microdeletions are not associated with a classical
NF1 phenotype but instead with developmental delay and learning disabilities as the
major clinical features. So far, 29 <italic>NF1</italic>
microduplication carriers have been reported, 18 of them were unrelated cases (Lu et
al. <xref ref-type="bibr" rid="CR123">2007</xref>; Grisart et al. <xref ref-type="bibr" rid="CR64">2008</xref>; Moles et al. <xref ref-type="bibr" rid="CR139">2012</xref>; Coe et al. <xref ref-type="bibr" rid="CR28">2014</xref>;
Kehrer-Sawatzki et al. <xref ref-type="bibr" rid="CR93">2014</xref>). None of
the individuals with an <italic>NF1</italic> microduplication so
far reported exhibited neurofibromas or other NF1-associated tumours. Only two of
the 29 <italic>NF1</italic> microduplication carriers had CALS.
However, these CALS were atypical, with irregular borders and nonhomogeneous
pigmentation which is not generally characteristic of those CALS typically seen in
patients with NF1 (Kehrer-Sawatzki et al. <xref ref-type="bibr" rid="CR93">2014</xref>). One of the two <italic>NF1</italic>
microduplication patients with CALS fulfilled the diagnostic criteria for NF1
because he not only had ten CALS but also Lisch nodules. Since only blood cells from
this patients were available for investigation, it could not be excluded that the
<italic>NF1</italic> microduplication observed in this patient
was of postzygotic origin and that the patient might also harbour cells in his body
that contained the reciprocal <italic>NF1</italic> microdeletion
(rather than the <italic>NF1</italic> microduplication). The
potential co-occurrence of cells with the reciprocal <italic>NF1</italic> microdeletion could have been responsible for the CALS and Lisch
nodules observed in this patient. Furthermore, it could not be excluded that
somatically acquired <italic>NF1</italic> mutations in melanocyte
progenitor cells contributed to the occurrence of CALS and Lisch nodules in this
individual. Since melanocytes from CALS of this patient could not be investigated,
his clinical manifestations are difficult to interpret with regard to the underlying
mutation (Kehrer-Sawatzki et al. <xref ref-type="bibr" rid="CR93">2014</xref>).
Nevertheless, the analysis of the other 28 <italic>NF1</italic>
microduplication carriers reported to date implies that these duplications do not
cause a classical NF1 phenotype.</p>
<p>Importantly, the clinical phenotype associated with <italic>NF1</italic> microdeletions is fully penetrant; clinically
unaffected individuals with germline <italic>NF1</italic>
microdeletions have not been reported. By contrast, three carriers of familial
<italic>NF1</italic> microduplications have been observed who,
according to the authors, do not exhibit any obvious clinical signs (Grisart et al.
<xref ref-type="bibr" rid="CR64">2008</xref>; Moles et al. <xref ref-type="bibr" rid="CR139">2012</xref>). However, <italic>NF1</italic> microduplications are very unlikely to be frequent neutral copy
number variants since they have not been observed in a total of 30,134 control
individuals (Shaikh et al. <xref ref-type="bibr" rid="CR196">2009</xref>;
Cooper et al. <xref ref-type="bibr" rid="CR30">2011</xref>; Moles et al.
<xref ref-type="bibr" rid="CR139">2012</xref>; Coe et al. <xref ref-type="bibr" rid="CR28">2014</xref>). In a disease context, <italic>NF1</italic> microduplications have been observed in 14 unrelated
individuals identified from among a total of 77,902 patients who were investigated
by array CGH due to developmental delay (Moles et al. <xref ref-type="bibr" rid="CR139">2012</xref>; Coe et al. <xref ref-type="bibr" rid="CR28">2014</xref>).</p>
<p>
<italic>NF1</italic> microdeletions are estimated to occur with a
frequency of approximately 1 in 60,000 individuals, calculated on the basis that
large <italic>NF1</italic> deletions are observed in ~5% of all
patients with NF1 which occurs with an incidence of ~1 in 3000. <italic>NF1</italic> microduplications were not observed in 30,134 control
individuals analysed by array CGH (Shaikh et al. <xref ref-type="bibr" rid="CR196">2009</xref>; Cooper et al. <xref ref-type="bibr" rid="CR30">2011</xref>; Moles et al. <xref ref-type="bibr" rid="CR139">2012</xref>; Coe et al. <xref ref-type="bibr" rid="CR28">2014</xref>), but this number of individuals is still too low to estimate
the frequency of <italic>NF1</italic> microduplications in the
general population or to assess whether <italic>NF1</italic>
microdeletions are more frequent than <italic>NF1</italic>
microduplications.</p>
</sec>
<sec id="Sec25">
<title>Conclusions</title>
<p>
<italic>NF1</italic> microdeletions are often associated with a
severe clinical phenotype characterised by features not observed at all (or at
significantly lower frequency) in patients with intragenic <italic>NF1</italic> mutations. Although many published studies have described the
<italic>NF1</italic> microdeletion-associated phenotype, what is
lacking are large studies comparing NF1 patients with and without <italic>NF1</italic> microdeletions according to standardised evaluation
criteria to ensure that the same analytical methods are identically applied in the
investigation of both patient groups. Ideally, such studies should be performed by
comparing patients with <italic>NF1</italic> microdeletions and
patients with intragenic loss-of-function <italic>NF1</italic>
mutations to minimise the effects of mutation severity. Further, these studies
should include sufficiently high numbers of patients to perform meaningful
statistical analysis whilst the age of the patients should be matched since many
NF1-associated features are age-related. This would be best performed as a
multicenter collaborative study to collect large numbers of patients with different
<italic>NF1</italic> microdeletion types to analyse the
different deletion types separately. Comprehensive comparative analyses of this kind
could help to answer several open questions that have not so far been systematically
addressed, e.g., whether an early (pre-pubertal) onset of growth of multiple
cutaneous neurofibromas is significantly more prevalent in children with <italic>NF1</italic> microdeletions as compared to children with
intragenic <italic>NF1</italic> mutations. In addition, a
comparative analysis including a large number of age-matched adult patients is
urgently required to ascertain whether high numbers of cutaneous neurofibromas
(<italic>N</italic> &gt; 1000) occur significantly more often in
patients with <italic>NF1</italic> microdeletions than in patients
with intragenic mutations. Clearly, these and other analyses of the
genotype–phenotype relationship should be performed so as to include patients with
non-mosaic <italic>NF1</italic> microdeletions with well
characterised deletion breakpoints to assess the number and identity of the
co-deleted genes. The most frequently occurring type-1 <italic>NF1</italic> deletions are important with regard to extended genotype-phenotype
correlations since they are the easiest group in which to discern such correlations;
however, the less frequent but recurrent type-3 <italic>NF1</italic> deletions are also of interest. Analyses of a larger number of
patients with type-3 <italic>NF1</italic> microdeletions would be
necessary to determine the influence of genes such as <italic>RNF135</italic> on the overgrowth and dysmorphic facial features, or the
influence on the deletion-associated phenotype of other genes not rendered
hemizygous by the type-3 <italic>NF1</italic> deletions
(Fig. <xref ref-type="fig" rid="Fig1">1</xref>). Although the deletion of
<italic>SUZ12</italic> may well predispose patients with
<italic>NF1</italic> microdeletions to malignancy, in particular
to the development of MPNSTs, the reasons for the disproportionately higher
frequency of benign plexiform, subcutaneous and spinal neurofibromas in patients
with <italic>NF1</italic> microdeletions is still unclear. It is
possible that deleted genes other than <italic>NF1</italic> may
also promote tumorigenesis and such additive effects could be investigated by the
targeted knockout of individual genes located within the <italic>NF1</italic> microdeletion interval using the CRISPR/Cas9 system in human
cells. Similar experiments might also be performed with mouse cells but it should be
appreciated that the genomic region on mouse chromosome 11 orthologous to the
<italic>NF1</italic> microdeletion region exhibits differences
in both the number and arrangement of genes as compared with the human genomic
region at 17q11.2 (Jenne et al. <xref ref-type="bibr" rid="CR80">2003</xref>).</p>
<p>Although <italic>NF1</italic> microdeletion
patients as a group exhibit a more severe clinical phenotype than that generally
exhibited by patients with <italic>NF1</italic> intragenic
lesions, a certain degree of variability in terms of the expression of clinical
symptoms is observed when individual patients with <italic>NF1</italic> microdeletions are compared, even in cases where their germline
deletions are identical. In patients with intragenic <italic>NF1</italic> mutations, the level of expression of the wild-type <italic>NF1</italic> allele has been suggested to impact upon the clinical
phenotype since skewed allele-specific expression of the <italic>NF1</italic> gene has been observed in healthy individuals (Hoffmeyer et al.
<xref ref-type="bibr" rid="CR71">1995</xref>; Cowley et al. <xref ref-type="bibr" rid="CR32">1998</xref>; Jentarra et al. <xref ref-type="bibr" rid="CR81">2012</xref>). It would be important to investigate
whether the phenotypic variability observed between patients with <italic>NF1</italic> microdeletions might also be caused by differences in
expression of the wild-type alleles of the genes that are present in only one copy
owing to the large <italic>NF1</italic> deletion. Such analyses,
as well as an extended comparative analysis of the clinical phenotype of NF1
patients with and without <italic>NF1</italic> microdeletions,
would be necessary to improve our understanding of the mechanisms involved as well
as to characterise the deletion-associated phenotype in a more systematic and
comprehensive manner.</p>
</sec>
</body>
<back>
<notes notes-type="COI-statement">
<title>Compliance with ethical standards</title>
<sec id="FPar1">
<title>Conflict of interest</title>
<p>On behalf of all authors, the corresponding author states that
there is no conflict of interest.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abaan</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Polley</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Bilke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Pineda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gindin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Reinhold</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Holbeck</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Doroshow</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Pommier</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>PS</given-names>
</name>
</person-group>
<article-title>The exomes of the NCI-60 panel: a genomic resource for
cancer biology and systems pharmacology</article-title>
<source/>Cancer Res
          <year>2013</year>
<volume>73</volume>
<fpage>4372</fpage>
<lpage>4382</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-3342</pub-id>
<pub-id pub-id-type="pmid">23856246</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbik</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cafferty</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Strittmatter</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Myelin associated inhibitors: a link between
injury-induced and experience-dependent plasticity</article-title>
<source/>Exp Neurol
          <year>2012</year>
<volume>235</volume>
<fpage>43</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2011.06.006</pub-id>
<pub-id pub-id-type="pmid">21699896</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alivuotila</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hakokari</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Visnapuu</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Korpijaakko-Huuhka</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Aaltonen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Happonen</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Peltonen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Peltonen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Speech characteristics in neurofibromatosis type
1</article-title>
<source/>Am J Med Genet A
          <year>2010</year>
<volume>152A</volume>
<fpage>42</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.33178</pub-id>
<pub-id pub-id-type="pmid">20034087</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asano</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ichikawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hiraoka</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Immunohistochemistry for trimethylated H3K27 in the
diagnosis of malignant peripheral nerve sheath tumours</article-title>
<source/>Histopathology
          <year>2017</year>
<volume>70</volume>
<issue>30</issue>
<fpage>385</fpage>
<lpage>393</lpage>
<pub-id pub-id-type="doi">10.1111/his.13072</pub-id>
<pub-id pub-id-type="pmid">27580378</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atwal</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Pinkston-Gosse</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Syken</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stawicki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shatz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tessier-Lavigne</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>PirB is a functional receptor for myelin inhibitors of
axonal regeneration</article-title>
<source/>Science
          <year>2008</year>
<volume>322</volume>
<fpage>967</fpage>
<lpage>970</lpage>
<pub-id pub-id-type="doi">10.1126/science.1161151</pub-id>
<pub-id pub-id-type="pmid">18988857</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>MicroRNA-365 inhibits growth, invasion and metastasis
of malignant melanoma by targeting NRP1 expression</article-title>
<source/>Int J Clin Exp Pathol
          <year>2015</year>
<volume>8</volume>
<fpage>4913</fpage>
<lpage>4922</lpage>
<pub-id pub-id-type="pmid">26191184</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>MicroRNA-365 inhibits growth, invasion and metastasis
of malignant melanoma by targeting NRP1 expression</article-title>
<source/>Cancer Biomark
          <year>2015</year>
<volume>15</volume>
<fpage>599</fpage>
<lpage>608</lpage>
<pub-id pub-id-type="doi">10.3233/CBM-150500</pub-id>
<pub-id pub-id-type="pmid">26406949</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bajaj</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>QF</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Pumiglia</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Loss of <italic>NF1</italic>
expression in human endothelial cells promotes autonomous proliferation and
altered vascular morphogenesis</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e49222</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0049222</pub-id>
<pub-id pub-id-type="pmid">23145129</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldwin</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Giger</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Insights into the physiological role of CNS
regeneration inhibitors</article-title>
<source/>Front Mol Neurosci
          <year>2015</year>
<volume>8</volume>
<fpage>23</fpage>
<pub-id pub-id-type="doi">10.3389/fnmol.2015.00023</pub-id>
<pub-id pub-id-type="pmid">26113809</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartelt-Kirbach</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wuepping</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dodrimont-Lattke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Expression analysis of genes lying in the <italic>NF1</italic> microdeletion interval points to four candidate
modifiers for neurofibroma formation</article-title>
<source/>Neurogenetics
          <year>2009</year>
<volume>10</volume>
<fpage>79</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-008-0154-0</pub-id>
<pub-id pub-id-type="pmid">18850118</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Shaping the actin cytoskeleton using microtubule
tips</article-title>
<source/>Curr Opin Cell Biol
          <year>2007</year>
<volume>19</volume>
<fpage>88</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/j.ceb.2006.12.012</pub-id>
<pub-id pub-id-type="pmid">17194581</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beert</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brems</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Daniëls</surname>
<given-names>B</given-names>
</name>
<name>
<surname>De Wever</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Van Calenbergh</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schoenaers</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Debiec-Rychter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gevaert</surname>
<given-names>O</given-names>
</name>
<name>
<surname>De Raedt</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Van Den Bruel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Ravel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cichowski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sciot</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Atypical neurofibromas in neurofibromatosis type 1 are
premalignant tumors</article-title>
<source/>Genes Chromosomes Cancer
          <year>2011</year>
<volume>50</volume>
<fpage>1021</fpage>
<lpage>1032</lpage>
<pub-id pub-id-type="doi">10.1002/gcc.20921</pub-id>
<pub-id pub-id-type="pmid">21987445</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bell</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Sikdar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ishiai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rudd</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Pollock</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Fogoros</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Mohamed</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hanigan</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cruz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Renaud</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>NF</given-names>
</name>
<name>
<surname>Cherukuri</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Borate</surname>
<given-names>B</given-names>
</name>
<name>
<surname>McManus</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Stoepel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sipahimalani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Godwin</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Sgroi</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Merino</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Elliot</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Elkahloun</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vinson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Takata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mullikin</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Wolfsberg</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Hieter</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Myung</surname>
<given-names>K</given-names>
</name>
<collab>NISC Comparative Sequencing
Program</collab>
</person-group>
<article-title>Predisposition to cancer caused by genetic and
functional defects of mammalian <italic>Atad5</italic></article-title>
<source/>PLoS Genet
          <year>2011</year>
<volume>7</volume>
<fpage>e1002245</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1002245</pub-id>
<pub-id pub-id-type="pmid">21901109</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bengesser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Steinmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chuzhanova</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Wimmer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tatagiba</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tinschert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>A novel third type of recurrent <italic>NF1</italic> microdeletion mediated by nonallelic homologous
recombination between <italic>LRRC37B</italic>-containing
low-copy repeats in 17q11.2</article-title>
<source/>Hum Mutat
          <year>2010</year>
<volume>31</volume>
<fpage>742</fpage>
<lpage>751</lpage>
<pub-id pub-id-type="doi">10.1002/humu.21254</pub-id>
<pub-id pub-id-type="pmid">20506354</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bengesser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mussotter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Messiaen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Analysis of crossover breakpoints yields new insights
into the nature of the gene conversion events associated with large <italic>NF1</italic> deletions mediated by nonallelic homologous
recombination</article-title>
<source/>Hum Mutat
          <year>2014</year>
<volume>35</volume>
<fpage>215</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22473</pub-id>
<pub-id pub-id-type="pmid">24186807</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernardinelli</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nikonenko</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Structural plasticity: mechanisms and contribution to
developmental psychiatric disorders</article-title>
<source/>Front Neuroanat
          <year>2014</year>
<volume>8</volume>
<fpage>123</fpage>
<pub-id pub-id-type="doi">10.3389/fnana.2014.00123</pub-id>
<pub-id pub-id-type="pmid">25404897</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bezanilla</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gladfelter</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Kovar</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>WL</given-names>
</name>
</person-group>
<article-title>Cytoskeletal dynamics: a view from the
membrane</article-title>
<source/>J Cell Biol
          <year>2015</year>
<volume>209</volume>
<fpage>329</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.201502062</pub-id>
<pub-id pub-id-type="pmid">25963816</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<mixed-citation publication-type="other">Bist P, Kim SY, Pulloor NK, McCaffrey K, Nair SK, Liu Y, Lin R,
Krishnan MN (2016) ArfGAP domain containing protein 2 (ADAP2) integrates upstream
and downstream modules of RIG-I signaling, and facilitates Type I interferon
production. Mol Cell Biol Dec 12. pii: MCB.00537-16. doi: 10.1128/MCB.00537-16 (Epub ahead of print)</mixed-citation>
</ref>
<ref id="CR19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonnart</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gérus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hoareau-Aveilla</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kiss</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Caizergues-Ferrer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Henras</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Mammalian HCA66 protein is required for both ribosome
synthesis and centriole duplication</article-title>
<source/>Nucleic Acids Res
          <year>2012</year>
<volume>40</volume>
<fpage>6270</fpage>
<lpage>6289</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gks234</pub-id>
<pub-id pub-id-type="pmid">22434888</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brewer</surname>
<given-names>VR</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>BD</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Hiscock</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Learning disability subtypes in children with
neurofibromatosis</article-title>
<source/>J Learn Disabil
          <year>1997</year>
<volume>30</volume>
<fpage>521</fpage>
<lpage>533</lpage>
<pub-id pub-id-type="doi">10.1177/002221949703000508</pub-id>
<pub-id pub-id-type="pmid">9293234</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Budel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Padukkavidana</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lauren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>McGee</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stillman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>BZ</given-names>
</name>
<name>
<surname>Sodi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gelernter</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hisama</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Arnsten</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Strittmatter</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Genetic variants of Nogo-66 receptor with possible
association to schizophrenia block myelin inhibition of axon
growth</article-title>
<source/>J Neurosci
          <year>2008</year>
<volume>28</volume>
<fpage>13161</fpage>
<lpage>13172</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3828-08.2008</pub-id>
<pub-id pub-id-type="pmid">19052207</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caramuta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Egyházi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rodolfo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Witten</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hansson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lui</surname>
<given-names>WO</given-names>
</name>
</person-group>
<article-title>MicroRNA expression profiles associated with
mutational status and survival in malignant melanoma</article-title>
<source/>J Invest Dermatol
          <year>2010</year>
<volume>130</volume>
<fpage>2062</fpage>
<lpage>2070</lpage>
<pub-id pub-id-type="doi">10.1038/jid.2010.63</pub-id>
<pub-id pub-id-type="pmid">20357817</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castle</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Baser</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Huson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Evaluation of genotype/phenotype correlations in
neurofibromatosis type 1</article-title>
<source/>J Med Genet
          <year>2003</year>
<volume>40</volume>
<fpage>e109</fpage>
<pub-id pub-id-type="doi">10.1136/jmg.40.10.e109</pub-id>
<pub-id pub-id-type="pmid">14569132</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Ming</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Prognostic significance and anti-proliferation effect
of microRNA-365 in hepatocellular carcinoma</article-title>
<source/>Int J Clin Exp Pathol
          <year>2015</year>
<volume>8</volume>
<fpage>1705</fpage>
<lpage>1711</lpage>
<pub-id pub-id-type="pmid">25973057</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clementi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Milani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mammi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Boni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Monciotti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tenconi</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis type 1 growth charts</article-title>
<source/>Am J Med Genet
          <year>1999</year>
<volume>87</volume>
<fpage>317</fpage>
<lpage>323</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19991203)87:4&lt;317::AID-AJMG7&gt;3.0.CO;2-X</pub-id>
<pub-id pub-id-type="pmid">10588837</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cleven</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Sannaa</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Briaire-de Bruijn</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ingram</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>van de Rijn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rubin</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>van Duinen</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Hogendoorn</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Lazar</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Bovée</surname>
<given-names>JV</given-names>
</name>
</person-group>
<article-title>Loss of H3K27 tri-methylation is a diagnostic marker
for malignant peripheral nerve sheath tumors and an indicator for an inferior
survival</article-title>
<source/>Mod Pathol
          <year>2016</year>
<volume>29</volume>
<fpage>582</fpage>
<lpage>590</lpage>
<pub-id pub-id-type="doi">10.1038/modpathol.2016.45</pub-id>
<pub-id pub-id-type="pmid">26990975</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cnossen</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>van der Est</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Breuning</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>van Asperen</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Breslau-Siderius</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>van der Ploeg</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>de Goede-Bolder</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van den Ouweland</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Halley</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Niermeijer</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Deletions spanning the neurofibromatosis type 1 gene:
implications for genotype-phenotype correlations in neurofibromatosis type
1?</article-title>
<source/>Hum Mutat
          <year>1997</year>
<volume>9</volume>
<fpage>458</fpage>
<lpage>464</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1098-1004(1997)9:5&lt;458::AID-HUMU13&gt;3.0.CO;2-1</pub-id>
<pub-id pub-id-type="pmid">9143927</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coe</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Witherspoon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>van Bon</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Vulto-van Silfhout</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Bosco</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Friend</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Buono</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vissers</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Schuurs-Hoeijmakers</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Hoischen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pfundt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Krumm</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Carvill</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lockhart</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</name>
<name>
<surname>Alberti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pettinato</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tervo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>de Leeuw</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Reijnders</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Torchia</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Peeters</surname>
<given-names>H</given-names>
</name>
<name>
<surname>O’Roak</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Fichera</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hehir-Kwa</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Shendure</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mefford</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Haan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gécz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>EE</given-names>
</name>
</person-group>
<article-title>Refining analyses of copy number variation identifies
specific genes associated with developmental delay</article-title>
<source/>Nat Genet
          <year>2014</year>
<volume>46</volume>
<fpage>1063</fpage>
<lpage>1071</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3092</pub-id>
<pub-id pub-id-type="pmid">25217958</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conway</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Healy</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bracken</surname>
<given-names>AP</given-names>
</name>
</person-group>
<article-title>PRC2 mediated H3K27 methylations in cellular identity
and cancer</article-title>
<source/>Curr Opin Cell Biol
          <year>2015</year>
<volume>37</volume>
<fpage>42</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1016/j.ceb.2015.10.003</pub-id>
<pub-id pub-id-type="pmid">26497635</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Girirajan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Vu</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Stalker</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hamid</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hannig</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Abdel-Hamid</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bader</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McCracken</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Niyazov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Leppig</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Thiese</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hummel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gorski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kussmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shashi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rehder</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ballif</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Shaffer</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>EE</given-names>
</name>
</person-group>
<article-title>A copy number variation morbidity map of developmental
delay</article-title>
<source/>Nat Genet
          <year>2011</year>
<volume>43</volume>
<fpage>838</fpage>
<lpage>846</lpage>
<pub-id pub-id-type="doi">10.1038/ng.909</pub-id>
<pub-id pub-id-type="pmid">21841781</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costa</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Federov</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Kogan</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kucherlapati</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jacks</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Mechanism for the learning deficits in a mouse model
of neurofibromatosis type 1</article-title>
<source/>Nature
          <year>2002</year>
<volume>415</volume>
<fpage>526</fpage>
<lpage>530</lpage>
<pub-id pub-id-type="doi">10.1038/nature711</pub-id>
<pub-id pub-id-type="pmid">11793011</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cowley</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Murthy</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Parry</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>P</given-names>
</name>
<name>
<surname>MacCollin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bernards</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gusella</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>Genetic variation in the 3′ untranslated region of the
neurofibromatosis 1 gene: application to unequal allelic
expression</article-title>
<source/>Somat Cell Mol Genet
          <year>1998</year>
<volume>24</volume>
<fpage>107</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1023/B:SCAM.0000007113.28381.53</pub-id>
<pub-id pub-id-type="pmid">9919310</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Crowe</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>Schull</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>JV</given-names>
</name>
</person-group>
<source/>A clinical, pathological and genetic study of multiple
neurofibromatosis
          <year>1956</year>
<publisher-loc>Springfield</publisher-loc>
<publisher-name>Charles C Thomas</publisher-name>
</element-citation>
</ref>
<ref id="CR34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Elgersma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Mody</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Neurofibromin regulation of ERK signaling modulates
GABA release and learning</article-title>
<source/>Cell
          <year>2008</year>
<volume>135</volume>
<fpage>549</fpage>
<lpage>560</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2008.09.060</pub-id>
<pub-id pub-id-type="pmid">18984165</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunha</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Rozza-de-Menezes</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Theos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Luiz</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Geller</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Validity and interexaminer reliability of a new method
to quantify skin neurofibromas of neurofibromatosis 1 using paper
frames</article-title>
<source/>Orphanet J Rare Dis
          <year>2014</year>
<volume>9</volume>
<fpage>202</fpage>
<pub-id pub-id-type="doi">10.1186/s13023-014-0202-9</pub-id>
<pub-id pub-id-type="pmid">25475340</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Luca</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bottillo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dasdia</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Morella</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lanari</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bernardini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Divona</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Giustini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sinibaldi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Novelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Torrente</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Schirinzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dallapiccola</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Deletions of <italic>NF1</italic>
gene and exons detected by multiplex ligation-dependent probe
amplification</article-title>
<source/>J Med Genet
          <year>2007</year>
<volume>44</volume>
<fpage>800</fpage>
<lpage>808</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2007.053785</pub-id>
<pub-id pub-id-type="pmid">18055911</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Raedt</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Brems</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wolkenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pilotti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Perrone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Frahm</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sciot</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Elevated risk for MPNST in <italic>NF1</italic> microdeletion patients</article-title>
<source/>Am J Hum Genet
          <year>2003</year>
<volume>72</volume>
<fpage>1288</fpage>
<lpage>1292</lpage>
<pub-id pub-id-type="doi">10.1086/374821</pub-id>
<pub-id pub-id-type="pmid">12660952</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Raedt</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heyns</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Brems</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Thijs</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Messiaen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lazaro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wimmer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Marynen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Conservation of hotspots for recombination in low-copy
repeats associated with the <italic>NF1</italic>
microdeletion</article-title>
<source/>Nat Genet
          <year>2006</year>
<volume>38</volume>
<fpage>1419</fpage>
<lpage>1423</lpage>
<pub-id pub-id-type="doi">10.1038/ng1920</pub-id>
<pub-id pub-id-type="pmid">17115058</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Raedt</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Beert</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pasmant</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Luscan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brems</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ortonne</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Helin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hornick</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Clapp</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bradner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cichowski</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>PRC2 loss amplifies Ras-driven transcription and
confers sensitivity to BRD4-based therapies</article-title>
<source/>Nature
          <year>2014</year>
<volume>514</volume>
<fpage>247</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="pmid">25119042</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>miR-193a-3p regulates the multi-drug resistance of
bladder cancer by targeting the <italic>LOXL4</italic> gene
and the oxidative stress pathway</article-title>
<source/>Mol Cancer
          <year>2014</year>
<volume>13</volume>
<fpage>234</fpage>
<pub-id pub-id-type="doi">10.1186/1476-4598-13-234</pub-id>
<pub-id pub-id-type="pmid">25311867</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Descheemaeker</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Roelandts</surname>
<given-names>K</given-names>
</name>
<name>
<surname>De Raedt</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Brems</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fryns</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Intelligence in individuals with a neurofibromatosis
type 1 microdeletion</article-title>
<source/>Am J Med Genet A
          <year>2004</year>
<volume>131</volume>
<fpage>325</fpage>
<lpage>326</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.30346</pub-id>
<pub-id pub-id-type="pmid">15472997</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Croce</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Helin</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Transcriptional regulation by Polycomb group
proteins</article-title>
<source/>Nat Struct Mol Biol
          <year>2013</year>
<volume>20</volume>
<fpage>1147</fpage>
<lpage>1155</lpage>
<pub-id pub-id-type="doi">10.1038/nsmb.2669</pub-id>
<pub-id pub-id-type="pmid">24096405</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diggs-Andrews</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Modeling cognitive dysfunction in
neurofibromatosis-1</article-title>
<source/>Trends Neurosci
          <year>2013</year>
<volume>36</volume>
<fpage>237</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2012.12.002</pub-id>
<pub-id pub-id-type="pmid">23312374</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dorschner</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Sybert</surname>
<given-names>VP</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pletcher</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title><italic>NF1</italic> microdeletion breakpoints are clustered
at flanking repetitive sequences</article-title>
<source/>Hum Mol Genet
          <year>2000</year>
<volume>9</volume>
<fpage>35</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/9.1.35</pub-id>
<pub-id pub-id-type="pmid">10587576</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Douglas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cilliers</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Coleman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tatton-Brown</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bernhard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Burn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Josifova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lacombe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mansour</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cormier-Daire</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Collaboration</surname>
<given-names>Childhood Overgrowth</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Mutations in <italic>RNF135</italic>, a gene within the <italic>NF1</italic>
microdeletion region, cause phenotypic abnormalities including
overgrowth</article-title>
<source/>Nat Genet
          <year>2007</year>
<volume>39</volume>
<fpage>963</fpage>
<lpage>965</lpage>
<pub-id pub-id-type="doi">10.1038/ng2083</pub-id>
<pub-id pub-id-type="pmid">17632510</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ducatman</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Scheithauer</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Piepgras</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Reiman</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Ilstrup</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Malignant peripheral nerve sheath tumors. A
clinicopathologic study of 120 cases</article-title>
<source/>Cancer
          <year>1986</year>
<volume>57</volume>
<fpage>2006</fpage>
<lpage>2021</lpage>
<pub-id pub-id-type="doi">10.1002/1097-0142(19860515)57:10&lt;2006::AID-CNCR2820571022&gt;3.0.CO;2-6</pub-id>
<pub-id pub-id-type="pmid">3082508</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duong</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Sbidian</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Valeyrie-Allanore</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vialette</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ferkal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hadj-Rabia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Glorion</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lyonnet</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zerah</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kemlin</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bastuji-Garin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wolkenstein</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Mortality associated with neurofibromatosis 1: a
cohort study of 1895 patients in 1980-2006 in France</article-title>
<source/>Orphanet J Rare Dis
          <year>2011</year>
<volume>6</volume>
<fpage>18</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1172-6-18</pub-id>
<pub-id pub-id-type="pmid">21542925</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Baser</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>McGaughran</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sharif</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Malignant peripheral nerve sheath tumours in
neurofibromatosis 1</article-title>
<source/>J Med Genet
          <year>2002</year>
<volume>39</volume>
<fpage>311</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.39.5.311</pub-id>
<pub-id pub-id-type="pmid">12011145</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Huson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Birch</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Malignant peripheral nerve sheath tumours in inherited
disease</article-title>
<source/>Clin Sarcoma Res
          <year>2012</year>
<volume>2</volume>
<fpage>17</fpage>
<pub-id pub-id-type="doi">10.1186/2045-3329-2-17</pub-id>
<pub-id pub-id-type="pmid">23036231</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fant</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gnadt</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Haren</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Merdes</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Stability of the small gamma-tubulin complex requires
HCA66, a protein of the centrosome and the nucleolus</article-title>
<source/>J Cell Sci
          <year>2009</year>
<volume>122</volume>
<fpage>1134</fpage>
<lpage>1144</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.035238</pub-id>
<pub-id pub-id-type="pmid">19299467</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferner</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>International consensus statement on malignant
peripheral nerve sheath tumors in neurofibromatosis</article-title>
<source/>Cancer Res
          <year>2002</year>
<volume>62</volume>
<fpage>1573</fpage>
<lpage>1577</lpage>
<pub-id pub-id-type="pmid">11894862</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferner</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Chaudhuri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bingham</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>MRI in neurofibromatosis 1. The nature and evolution
of increased intensity T2 weighted lesions and their relationship to
intellectual impairment</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>1993</year>
<volume>56</volume>
<fpage>492</fpage>
<lpage>495</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.56.5.492</pub-id>
<pub-id pub-id-type="pmid">8505641</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferner</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Weinman</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Intellectual impairment in neurofibromatosis
1</article-title>
<source/>J Neurol Sci
          <year>1996</year>
<volume>138</volume>
<fpage>125</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1016/0022-510X(96)00022-6</pub-id>
<pub-id pub-id-type="pmid">8791250</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferner</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Huson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Willshaw</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Towers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gleeson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Steiger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kirby</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Guidelines for the diagnosis and management of
individuals with neurofibromatosis 1</article-title>
<source/>J Med Genet
          <year>2007</year>
<volume>44</volume>
<fpage>81</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2006.045906</pub-id>
<pub-id pub-id-type="pmid">17105749</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferraro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pesaresi</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>De Zio</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cencioni</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Gortat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cozzolino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berghella</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Salvatore</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Oettinghaus</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Scorrano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pérez-Payà</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cecconi</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Apaf1 plays a pro-survival role by regulating
centrosome morphology and function</article-title>
<source/>J Cell Sci
          <year>2011</year>
<volume>124</volume>
<fpage>3450</fpage>
<lpage>3463</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.086298</pub-id>
<pub-id pub-id-type="pmid">21984814</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forbes</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Dorschner</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Genomic context of paralogous recombination hotspots
mediating recurrent <italic>NF1</italic> region
microdeletion</article-title>
<source/>Genes Chromosomes Cancer
          <year>2004</year>
<volume>41</volume>
<fpage>12</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1002/gcc.20065</pub-id>
<pub-id pub-id-type="pmid">15236313</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>JM</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Friedman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>MacCollin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>VM</given-names>
</name>
</person-group>
<article-title>Evaluation and management</article-title>
<source/>Neurofibromatosis: phenotype, natural history and
pathogenesis
          <year>1999</year>
<edition>3</edition>
<publisher-loc>Baltimore</publisher-loc>
<publisher-name>Johns Hopkins University Press</publisher-name>
<fpage>90</fpage>
<lpage>91</lpage>
</element-citation>
</ref>
<ref id="CR58">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Birch</surname>
<given-names>PH</given-names>
</name>
</person-group>
<article-title>Type 1 neurofibromatosis: a descriptive analysis of
the disorder in 1,728 patients</article-title>
<source/>Am J Med Genet
          <year>1997</year>
<volume>70</volume>
<fpage>138</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19970516)70:2&lt;138::AID-AJMG7&gt;3.0.CO;2-U</pub-id>
<pub-id pub-id-type="pmid">9128932</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gazy</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Liefshitz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Parnas</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kupiec</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Elg1, a central player in genome
stability</article-title>
<source/>Mutat Res Rev Mutat Res
          <year>2015</year>
<volume>763</volume>
<fpage>267</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.1016/j.mrrev.2014.11.007</pub-id>
<pub-id pub-id-type="pmid">25795125</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geoffroy</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Myelin-associated inhibitors in axonal growth after
CNS injury</article-title>
<source/>Curr Opin Neurobiol
          <year>2014</year>
<volume>27</volume>
<fpage>31</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.conb.2014.02.012</pub-id>
<pub-id pub-id-type="pmid">24608164</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gervasini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Venturin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Orzan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Friso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Clementi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tenconi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Larizza</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Uncommon <italic>Alu</italic>-mediated <italic>NF1</italic> microdeletion
with a breakpoint inside the <italic>NF1</italic>
gene</article-title>
<source/>Genomics
          <year>2005</year>
<volume>85</volume>
<fpage>273</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygeno.2004.10.014</pub-id>
<pub-id pub-id-type="pmid">15676286</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gil</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bichler</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Seira</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Llorens</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bribian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Claverol-Tinture</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Soriano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sumoy</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Del Río</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Developmental expression of the oligodendrocyte myelin
glycoprotein in the mouse telencephalon</article-title>
<source/>Cereb Cortex
          <year>2010</year>
<volume>20</volume>
<fpage>1769</fpage>
<lpage>1779</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bhp246</pub-id>
<pub-id pub-id-type="pmid">19892785</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gitler</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ismat</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Yamauchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Nf1 has an essential role in endothelial
cells</article-title>
<source/>Nat Genet
          <year>2003</year>
<volume>33</volume>
<fpage>75</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1038/ng1059</pub-id>
<pub-id pub-id-type="pmid">12469121</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grisart</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rack</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Vidrequin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hilbert</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Deltenre</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Verellen-Dumoulin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Destrée</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title><italic>NF1</italic> microduplication first clinical report:
association with mild mental retardation, early onset of baldness and dental
enamel hypoplasia?</article-title>
<source/>Eur J Hum Genet
          <year>2008</year>
<volume>16</volume>
<fpage>305</fpage>
<lpage>311</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ejhg.5201978</pub-id>
<pub-id pub-id-type="pmid">18183042</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Malignant peripheral nerve sheath tumors:
differentiation patterns and immunohistochemical features—a mini-review and our
new findings</article-title>
<source/>J Cancer
          <year>2012</year>
<volume>3</volume>
<fpage>303</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="doi">10.7150/jca.4179</pub-id>
<pub-id pub-id-type="pmid">22773934</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>XB</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>ZZ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to
gastric tumorigenesis induced by PTEN deficiency</article-title>
<source/>Nat Commun
          <year>2013</year>
<volume>4</volume>
<fpage>2544</fpage>
<pub-id pub-id-type="pmid">24149576</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Habib</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Marton</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Allwardt</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gulcher</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Mikol</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Högnason</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chattopadhyay</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Stefansson</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Expression of the oligodendrocyte-myelin glycoprotein
by neurons in the mouse central nervous system</article-title>
<source/>J Neurochem
          <year>1998</year>
<volume>70</volume>
<fpage>1704</fpage>
<lpage>1711</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1998.70041704.x</pub-id>
<pub-id pub-id-type="pmid">9523589</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hegedus</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Emnett</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Neurofibromin regulates somatic growth through the
hypothalamic-pituitary axis</article-title>
<source/>Hum Mol Genet
          <year>2008</year>
<volume>17</volume>
<fpage>2956</fpage>
<lpage>2966</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddn194</pub-id>
<pub-id pub-id-type="pmid">18614544</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heller</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Weinzierl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Noll</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Babinsky</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Altenberger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Minichsdorfer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Döme</surname>
<given-names>B</given-names>
</name>
<name>
<surname>End-Pfützenreuter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arns</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Grin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Klepetko</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zielinski</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Zöchbauer-Müller</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Genome-wide miRNA expression profiling identifies
miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung
cancers</article-title>
<source/>Clin Cancer Res
          <year>2012</year>
<volume>18</volume>
<fpage>1619</fpage>
<lpage>1629</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2450</pub-id>
<pub-id pub-id-type="pmid">22282464</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hillmer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Summerer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Daiber</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Messiaen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Fine mapping of meiotic NAHR-associated crossovers
causing large <italic>NF1</italic> deletions</article-title>
<source/>Hum Mol Genet
          <year>2016</year>
<volume>25</volume>
<fpage>484</fpage>
<lpage>496</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddv487</pub-id>
<pub-id pub-id-type="pmid">26614388</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmeyer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Assum</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Griesser</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nürnberg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Krone</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>On unequal allelic expression of the neurofibromin
gene in neurofibromatosis type 1</article-title>
<source/>Hum Mol Genet
          <year>1995</year>
<volume>4</volume>
<fpage>1267</fpage>
<lpage>1272</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/4.8.1267</pub-id>
<pub-id pub-id-type="pmid">7581363</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Compston</surname>
<given-names>DAS</given-names>
</name>
</person-group>
<article-title>von Recklinghausen neurofibromatosis: a clinical and
population study in South East Wales</article-title>
<source/>Brain
          <year>1988</year>
<volume>111</volume>
<fpage>1355</fpage>
<lpage>1381</lpage>
<pub-id pub-id-type="doi">10.1093/brain/111.6.1355</pub-id>
<pub-id pub-id-type="pmid">3145091</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Shores</surname>
<given-names>A</given-names>
</name>
<name>
<surname>North</surname>
<given-names>KN</given-names>
</name>
</person-group>
<article-title>The nature and frequency of cognitive deficits in
children with neurofibromatosis type 1</article-title>
<source/>Neurology
          <year>2005</year>
<volume>65</volume>
<fpage>1037</fpage>
<lpage>1044</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000179303.72345.ce</pub-id>
<pub-id pub-id-type="pmid">16217056</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Arthur Shores</surname>
<given-names>E</given-names>
</name>
<name>
<surname>North</surname>
<given-names>KN</given-names>
</name>
</person-group>
<article-title>Learning disabilities in children with
neurofibromatosis type 1: subtypes, cognitive profile, and
attention-deficit-hyperactivity disorder</article-title>
<source/>Dev Med Child Neurol
          <year>2006</year>
<volume>48</volume>
<fpage>973</fpage>
<lpage>977</lpage>
<pub-id pub-id-type="doi">10.1017/S0012162206002131</pub-id>
<pub-id pub-id-type="pmid">17109785</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Gill</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Shores</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>North</surname>
<given-names>KN</given-names>
</name>
</person-group>
<article-title>T2 hyperintensities in children with neurofibromatosis
type 1 and their relationship to cognitive functioning</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2007</year>
<volume>78</volume>
<fpage>1088</fpage>
<lpage>1091</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.2006.108134</pub-id>
<pub-id pub-id-type="pmid">17299016</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iliopoulos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rotem</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Struhl</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Inhibition of miR-193a expression by Max and RXRα
activates K-Ras and PLAU to mediate distinct aspects of cellular
transformation</article-title>
<source/>Cancer Res
          <year>2011</year>
<volume>71</volume>
<fpage>5144</fpage>
<lpage>5153</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-0425</pub-id>
<pub-id pub-id-type="pmid">21670079</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ismat</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>The neurofibromin GAP-related domain rescues
endothelial but not neural crest development in Nf1 mice</article-title>
<source/>J Clin Invest
          <year>2006</year>
<volume>116</volume>
<fpage>2378</fpage>
<lpage>2384</lpage>
<pub-id pub-id-type="pmid">16906226</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itoh</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Magnaldi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>White</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Denckla</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Hofman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Naidu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bryan</surname>
<given-names>RN</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis type 1: the evolution of deep gray
and white matter MR abnormalities</article-title>
<source/>Am J Neuroradiol
          <year>1994</year>
<volume>15</volume>
<fpage>1513</fpage>
<lpage>1519</lpage>
<pub-id pub-id-type="pmid">7985572</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jenne</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Tinschert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Reimann</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lasinger</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Thiel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hameister</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Molecular characterization and gene content of
breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2
microdeletions</article-title>
<source/>Am J Hum Genet
          <year>2001</year>
<volume>69</volume>
<fpage>516</fpage>
<lpage>527</lpage>
<pub-id pub-id-type="doi">10.1086/323043</pub-id>
<pub-id pub-id-type="pmid">11468690</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jenne</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Tinschert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dorschner</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Hameister</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Complete physical map and gene content of the human
<italic>NF1</italic> tumor suppressor region in human and
mouse</article-title>
<source/>Genes Chromosomes Cancer
          <year>2003</year>
<volume>37</volume>
<fpage>111</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="doi">10.1002/gcc.10206</pub-id>
<pub-id pub-id-type="pmid">12696059</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jentarra</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Olfers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rajan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Saffen</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Narayanan</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Skewed allele-specific expression of the <italic>NF1</italic> gene in normal subjects: a possible mechanism for
phenotypic variability in neurofibromatosis type 1</article-title>
<source/>J Child Neurol
          <year>2012</year>
<volume>27</volume>
<fpage>695</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1177/0883073811423439</pub-id>
<pub-id pub-id-type="pmid">22068829</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>The E3 ubiquitin ligase RNF135 regulates the
tumorigenesis activity of tongue cancer SCC25 cells</article-title>
<source/>Cancer Med
          <year>2016</year>
<volume>5</volume>
<fpage>3140</fpage>
<lpage>3146</lpage>
<pub-id pub-id-type="doi">10.1002/cam4.832</pub-id>
<pub-id pub-id-type="pmid">27709798</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>JY</given-names>
</name>
</person-group>
<article-title>MicroRNA-365 regulates NKX2-1, a key mediator of lung
cancer</article-title>
<source/>Cancer Lett
          <year>2013</year>
<volume>335</volume>
<fpage>487</fpage>
<lpage>494</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2013.03.006</pub-id>
<pub-id pub-id-type="pmid">23507558</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karajannis</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Ferner</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis-related tumors: emerging biology and
therapies</article-title>
<source/>Curr Opin Pediatr
          <year>2015</year>
<volume>27</volume>
<fpage>26</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1097/MOP.0000000000000169</pub-id>
<pub-id pub-id-type="pmid">25490687</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kayes</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Large <italic>de novo</italic> DNA
deletion in a patient with sporadic neurofibromatosis 1, mental retardation, and
dysmorphism</article-title>
<source/>J Med Genet
          <year>1992</year>
<volume>29</volume>
<fpage>686</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.29.10.686</pub-id>
<pub-id pub-id-type="pmid">1359144</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kayes</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ehrlich</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rubenstein</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Deletions spanning the neurofibromatosis 1 gene:
identification and phenotype of five patients</article-title>
<source/>Am J Hum Genet
          <year>1994</year>
<volume>54</volume>
<fpage>424</fpage>
<lpage>436</lpage>
<pub-id pub-id-type="pmid">8116612</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
</person-group>
<article-title>Mosaicism in sporadic neurofibromatosis type 1:
variations on a theme common to other hereditary cancer
syndromes?</article-title>
<source/>J Med Genet
          <year>2008</year>
<volume>45</volume>
<fpage>622</fpage>
<lpage>631</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2008.059329</pub-id>
<pub-id pub-id-type="pmid">18511569</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tinschert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jenne</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>Heterogeneity of breakpoints in non-LCR-mediated large
constitutional deletions of the 17q11.2 <italic>NF1</italic>
tumor suppressor region</article-title>
<source/>J Med Genet
          <year>2003</year>
<volume>40</volume>
<fpage>E116</fpage>
<pub-id pub-id-type="doi">10.1136/jmg.40.10.e116</pub-id>
<pub-id pub-id-type="pmid">14569139</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sandig</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kohn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wimmer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Krammer</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Peyrl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jenne</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Hansmann</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
</person-group>
<article-title>High frequency of mosaicism among patients with
neurofibromatosis type 1 (NF1) with microdeletions caused by somatic
recombination of the <italic>JJAZ1</italic>
gene</article-title>
<source/>Am J Hum Genet
          <year>2004</year>
<volume>75</volume>
<fpage>410</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1086/423624</pub-id>
<pub-id pub-id-type="pmid">15257518</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fünsterer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
</person-group>
<article-title>Extensively high load of internal tumors determined by
whole body MRI scanning in a patient with neurofibromatosis type 1 and a
non-LCR-mediated 2-Mb deletion in 17q11.2</article-title>
<source/>Hum Genet
          <year>2005</year>
<volume>116</volume>
<fpage>466</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-005-1265-4</pub-id>
<pub-id pub-id-type="pmid">15776250</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fünsterer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
</person-group>
<article-title>Absence of cutaneous neurofibromas in an NF1 patient
with an atypical deletion partially overlapping the common 1.4 Mb microdeleted
region</article-title>
<source/>Am J Med Genet A
          <year>2008</year>
<volume>146A</volume>
<fpage>691</fpage>
<lpage>699</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.32045</pub-id>
<pub-id pub-id-type="pmid">18265407</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mußotter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
</person-group>
<article-title>Dissecting the clinical phenotype associated with
mosaic type-2 <italic>NF1</italic>
microdeletions</article-title>
<source/>Neurogenetics
          <year>2012</year>
<volume>13</volume>
<fpage>229</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-012-0332-y</pub-id>
<pub-id pub-id-type="pmid">22581253</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bengesser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Callens</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mikhail</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hillmer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Saal</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Lacassie</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Messiaen</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Identification of large <italic>NF1</italic> duplications reciprocal to NAHR-mediated type-1 <italic>NF1</italic> deletions</article-title>
<source/>Hum Mutat
          <year>2014</year>
<volume>35</volume>
<fpage>1469</fpage>
<lpage>1475</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22692</pub-id>
<pub-id pub-id-type="pmid">25205021</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein-Tasman</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Janke</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Casnar</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Hunter</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Tonsgard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Trapane</surname>
<given-names>P</given-names>
</name>
<name>
<surname>van der Fluit</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kais</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>Cognitive and psychosocial phenotype of young children
with neurofibromatosis-1</article-title>
<source/>J Int Neuropsychol Soc
          <year>2014</year>
<volume>20</volume>
<fpage>88</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1017/S1355617713001227</pub-id>
<pub-id pub-id-type="pmid">24229851</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Siebert</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gesk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Friedrich</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Tinschert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
</person-group>
<article-title>Screening 500 unselected neurofibromatosis 1 patients
for deletions of the <italic>NF1</italic> gene</article-title>
<source/>Hum Mutat
          <year>2004</year>
<volume>23</volume>
<fpage>111</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1002/humu.10299</pub-id>
<pub-id pub-id-type="pmid">14722914</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bengesser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mussotter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Friedrich</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Jett</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
</person-group>
<article-title>Internal tumor burden in neurofibromatosis type I
patients with large <italic>NF1</italic>
deletions</article-title>
<source/>Genes Chromosomes Cancer
          <year>2012</year>
<volume>51</volume>
<fpage>447</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="doi">10.1002/gcc.21931</pub-id>
<pub-id pub-id-type="pmid">22294457</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Matsune</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ohashi</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Fused teeth, macrodontia and increased caries are
characteristic features of neurofibromatosis type 1 patients with <italic>NF1</italic> gene microdeletion</article-title>
<source/>J Pediatr Genet
          <year>2012</year>
<volume>1</volume>
<fpage>25</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="pmid">27625798</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korf</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Poussaint</surname>
<given-names>TY</given-names>
</name>
</person-group>
<article-title>Structural anomalies revealed by neuroimaging studies
in the brains of patients with neurofibromatosis type 1 and large
deletions</article-title>
<source/>Genet Med
          <year>1999</year>
<volume>1</volume>
<fpage>136</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="doi">10.1097/00125817-199905000-00004</pub-id>
<pub-id pub-id-type="pmid">11258348</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kozaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Imoto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mogi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Omura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Inazawa</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Exploration of tumor-suppressive microRNAs silenced by
DNA hypermethylation in oral cancer</article-title>
<source/>Cancer Res
          <year>2008</year>
<volume>68</volume>
<fpage>2094</fpage>
<lpage>2105</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5194</pub-id>
<pub-id pub-id-type="pmid">18381414</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krab</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Aarsen</surname>
<given-names>FK</given-names>
</name>
<name>
<surname>de Goede-Bolder</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Catsman-Berrevoets</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Arts</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Moll</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Elgersma</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Impact of neurofibromatosis type 1 on school
performance</article-title>
<source/>J Child Neurol
          <year>2008</year>
<volume>23</volume>
<fpage>1002</fpage>
<lpage>1010</lpage>
<pub-id pub-id-type="doi">10.1177/0883073808316366</pub-id>
<pub-id pub-id-type="pmid">18827266</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubota</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Myung</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Donaldson</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>Is PCNA unloading the central function of the
Elg1/ATAD5 replication factor C-like complex?</article-title>
<source/>Cell Cycle
          <year>2013</year>
<volume>12</volume>
<fpage>2570</fpage>
<lpage>2579</lpage>
<pub-id pub-id-type="doi">10.4161/cc.25626</pub-id>
<pub-id pub-id-type="pmid">23907118</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulkantrakorn</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Geller</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Seizures in neurofibromatosis 1</article-title>
<source/>Pediatr Neurol
          <year>1998</year>
<volume>19</volume>
<fpage>347</fpage>
<lpage>350</lpage>
<pub-id pub-id-type="doi">10.1016/S0887-8994(98)00075-7</pub-id>
<pub-id pub-id-type="pmid">9880138</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lacroix</surname>
<given-names>M</given-names>
</name>
<name>
<surname>El Messaoudi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rodier</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Le Cam</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sardet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fabbrizio</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The histone-binding protein COPR5 is required for
nuclear functions of the protein arginine methyltransferase PRMT5</article-title>
<source/>EMBO Rep
          <year>2008</year>
<volume>9</volume>
<fpage>452</fpage>
<lpage>458</lpage>
<pub-id pub-id-type="doi">10.1038/embor.2008.45</pub-id>
<pub-id pub-id-type="pmid">18404153</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lammert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
</person-group>
<article-title>Prevalence of neurofibromatosis 1 in German children
at elementary school enrolment</article-title>
<source/>Arch Dermatol
          <year>2005</year>
<volume>141</volume>
<fpage>71</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1001/archderm.141.1.71</pub-id>
<pub-id pub-id-type="pmid">15655144</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laugesen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Højfeldt</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Helin</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Role of the polycomb repressive complex 2 (PRC2) in
transcriptional regulation and cancer</article-title>
<source/>Cold Spring Harb Perspect Med
          <year>2016</year>
<volume>6</volume>
<fpage>a026575</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a026575</pub-id>
<pub-id pub-id-type="pmid">27449971</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Raiker</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Venkatesh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Geary</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Robak</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Shrager</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Giger</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Synaptic function for the Nogo-66 receptor NgR1:
regulation of dendritic spine morphology and activity-dependent synaptic
strength</article-title>
<source/>J Neurosci
          <year>2008</year>
<volume>28</volume>
<fpage>2753</fpage>
<lpage>2765</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5586-07.2008</pub-id>
<pub-id pub-id-type="pmid">18337405</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cohn</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Sikdar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>D’Andrea</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Myung</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Human ELG1 regulates the level of ubiquitinated
proliferating cell nuclear antigen (PCNA) through its interactions with PCNA and
USP1</article-title>
<source/>J Biol Chem
          <year>2010</year>
<volume>285</volume>
<fpage>10362</fpage>
<lpage>10369</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M109.092544</pub-id>
<pub-id pub-id-type="pmid">20147293</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pepinsky</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Mi</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Oligodendrocyte differentiation and myelination
defects in OMgp null mice</article-title>
<source/>Mol Cell Neurosci
          <year>2011</year>
<volume>46</volume>
<fpage>752</fpage>
<lpage>761</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2011.02.008</pub-id>
<pub-id pub-id-type="pmid">21352918</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Aladjem</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Myung</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>ATAD5 regulates the lifespan of DNA replication
factories by modulating PCNA level on the chromatin</article-title>
<source/>J Cell Biol
          <year>2013</year>
<volume>200</volume>
<fpage>31</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.201206084</pub-id>
<pub-id pub-id-type="pmid">23277426</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Teckie</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wiesner</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Prieto Granada</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sboner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tap</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Fletcher</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Huberman</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>LX</given-names>
</name>
<name>
<surname>Viale</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Antonescu</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>PRC2 is recurrently inactivated through <italic>EED</italic> or <italic>SUZ12</italic> loss
in malignant peripheral nerve sheath tumors</article-title>
<source/>Nat Genet
          <year>2014</year>
<volume>46</volume>
<fpage>1227</fpage>
<lpage>1232</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3095</pub-id>
<pub-id pub-id-type="pmid">25240281</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karczewski</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Minikel</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Samocha</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Banks</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fennell</surname>
<given-names>T</given-names>
</name>
<name>
<surname>O’Donnell-Luria</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Ware</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>Tukiainen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Birnbaum</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Kosmicki</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Estrada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pierce-Hoffman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Berghout</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Deflaux</surname>
<given-names>N</given-names>
</name>
<name>
<surname>DePristo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Flannick</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fromer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gauthier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Howrigan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kiezun</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kurki</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Moonshine</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Natarajan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Orozco</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Peloso</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Poplin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rivas</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Ruano-Rubio</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Ruderfer</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Shakir</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Stenson</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Tiao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tusie-Luna</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Weisburd</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Altshuler</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Ardissino</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Boehnke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Danesh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Donnelly</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Elosua</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Florez</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Gabriel</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Getz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Glatt</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Hultman</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Kathiresan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Laakso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McCarroll</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>McGovern</surname>
<given-names>D</given-names>
</name>
<name>
<surname>McPherson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Palotie</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Purcell</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Saleheen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Scharf</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sklar</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Tuomilehto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tsuang</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Daly</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>MacArthur</surname>
<given-names>DG</given-names>
</name>
<collab>Exome Aggregation Consortium</collab>
</person-group>
<article-title>Analysis of protein-coding genetic variation in 60,706
humans</article-title>
<source/>Nature
          <year>2016</year>
<volume>536</volume>
<fpage>285</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1038/nature19057</pub-id>
<pub-id pub-id-type="pmid">27535533</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leppig</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Viskochil</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ortenberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Familial neurofibromatosis 1 microdeletions:
cosegregation with distinct facial phenotype and early onset of cutaneous
neurofibromata</article-title>
<source/>Am J Med Genet
          <year>1997</year>
<volume>73</volume>
<fpage>197</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(1997)73:2&lt;197::AID-AJMG17&gt;3.0.CO;2-P</pub-id>
<pub-id pub-id-type="pmid">9409873</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Gerson</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Axelson</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Whitford</surname>
<given-names>RP</given-names>
</name>
</person-group>
<article-title>von Recklinghausen neurofibromatosis II. Incidence of
optic gliomata</article-title>
<source/>Ophthalmology
          <year>1984</year>
<volume>91</volume>
<fpage>929</fpage>
<lpage>935</lpage>
<pub-id pub-id-type="doi">10.1016/S0161-6420(84)34217-8</pub-id>
<pub-id pub-id-type="pmid">6436764</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The miR-193a-3p-regulated <italic>ING5</italic> gene activates the DNA damage response pathway and inhibits
multi-chemoresistance in bladder cancer</article-title>
<source/>Oncotarget
          <year>2015</year>
<volume>6</volume>
<fpage>10195</fpage>
<lpage>10206</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.3555</pub-id>
<pub-id pub-id-type="pmid">25991669</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>miR-193a-3p functions as a tumor suppressor in lung
cancer by down-regulating ERBB4</article-title>
<source/>J Biol Chem
          <year>2015</year>
<volume>290</volume>
<fpage>926</fpage>
<lpage>940</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M114.621409</pub-id>
<pub-id pub-id-type="pmid">25391651</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Birch</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Tenconi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Niimura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Poyhonen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Armfield Uhas</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sigorini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Virdis</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bonioli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wolkenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pivnick</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Lawrence</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Cardiovascular malformations and other cardiovascular
abnormalities in neurofibromatosis 1</article-title>
<source/>Am J Med Genet
          <year>2000</year>
<volume>95</volume>
<fpage>108</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1002/1096-8628(20001113)95:2&lt;108::AID-AJMG4&gt;3.0.CO;2-0</pub-id>
<pub-id pub-id-type="pmid">11078559</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Listernick</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Packer</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Optic pathway gliomas in children with
neurofibromatosis 1: consensus statement from the NF1 optic pathway glioma task
force</article-title>
<source/>Ann Neurol
          <year>1997</year>
<volume>41</volume>
<fpage>143</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410410204</pub-id>
<pub-id pub-id-type="pmid">9029062</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>RNF135, RING finger protein, promotes the
proliferation of human glioblastoma cells in vivo and in vitro via the ERK
pathway</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>20642</fpage>
<pub-id pub-id-type="doi">10.1038/srep20642</pub-id>
<pub-id pub-id-type="pmid">26856755</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Llorens</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gil</surname>
<given-names>V</given-names>
</name>
<name>
<surname>del Río</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Emerging functions of myelin-associated proteins
during development, neuronal plasticity, and neurodegeneration</article-title>
<source/>FASEB J
          <year>2011</year>
<volume>25</volume>
<fpage>463</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="doi">10.1096/fj.10-162792</pub-id>
<pub-id pub-id-type="pmid">21059749</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>López-Correa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brems</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lázaro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Marynen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Unequal meiotic crossover: a frequent cause of
<italic>NF1</italic> microdeletions</article-title>
<source/>Am J Hum Genet
          <year>2000</year>
<volume>66</volume>
<fpage>1969</fpage>
<lpage>1974</lpage>
<pub-id pub-id-type="doi">10.1086/302920</pub-id>
<pub-id pub-id-type="pmid">10775528</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>López-Correa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dorschner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brems</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lázaro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Clementi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dooijes</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Moog</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rutkowski</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Fryns</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Marynen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Recombination hotspot in <italic>NF1</italic> microdeletion patients</article-title>
<source/>Hum Mol Genet
          <year>2001</year>
<volume>10</volume>
<fpage>1387</fpage>
<lpage>1392</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/10.13.1387</pub-id>
<pub-id pub-id-type="pmid">11440991</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lovat</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Valeri</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Croce</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>MicroRNAs in the pathogenesis of cancer</article-title>
<source/>Semin Oncol
          <year>2011</year>
<volume>38</volume>
<fpage>724</fpage>
<lpage>733</lpage>
<pub-id pub-id-type="doi">10.1053/j.seminoncol.2011.08.006</pub-id>
<pub-id pub-id-type="pmid">22082758</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Sahoo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yatsenko</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Bacino</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Stankiewicz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Chinault</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Beaudet</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Lupski</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title>Clinical implementation of chromosomal microarray
analysis: summary of 2513 postnatal cases</article-title>
<source/>PLoS One
          <year>2007</year>
<volume>2</volume>
<fpage>e327</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0000327</pub-id>
<pub-id pub-id-type="pmid">17389918</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The DNA methylation-regulated miR-193a-3p dictates the
multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2
expression</article-title>
<source/>Cell Death Dis
          <year>2014</year>
<volume>5</volume>
<fpage>e1402</fpage>
<pub-id pub-id-type="doi">10.1038/cddis.2014.367</pub-id>
<pub-id pub-id-type="pmid">25188512</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maertens</surname>
<given-names>O</given-names>
</name>
<name>
<surname>De Schepper</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vandesompele</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brems</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Heyns</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Janssens</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Speleman</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Messiaen</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Molecular dissection of isolated disease features in
mosaic neurofibromatosis type 1</article-title>
<source/>Am J Hum Genet
          <year>2007</year>
<volume>81</volume>
<fpage>243</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="doi">10.1086/519562</pub-id>
<pub-id pub-id-type="pmid">17668375</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maleva Kostovska</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bogdanova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schürmann</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bhuju</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Geffers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dürst</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liebrich</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Klapdor</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Christiansen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Park-Simon</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Hillemanns</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Plaseska-Karanfilska</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dörk</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Rare <italic>ATAD5</italic> missense
variants in breast and ovarian cancer patients</article-title>
<source/>Cancer Lett
          <year>2016</year>
<volume>376</volume>
<fpage>173</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2016.03.048</pub-id>
<pub-id pub-id-type="pmid">27045477</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantripragada</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Thuresson</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Piotrowski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Díaz de Ståhl</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Menzel</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Grigelionis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ferner</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bolund</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Nordling</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vetrie</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Messiaen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bruder</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Dumanski</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Identification of novel deletion breakpoints bordered
by segmental duplications in the <italic>NF1</italic> locus
using high resolution array-CGH</article-title>
<source/>J Med Genet
          <year>2006</year>
<volume>43</volume>
<fpage>28</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2005.033795</pub-id>
<pub-id pub-id-type="pmid">15944227</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantripragada</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Díaz de Ståhl</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Patridge</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Menzel</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chuzhanova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Guha</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dumanski</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Genome-wide high-resolution analysis of DNA copy
number alterations in NF1-associated malignant peripheral nerve sheath tumors
using 32 K BAC array</article-title>
<source/>Genes Chromosomes Cancer
          <year>2009</year>
<volume>48</volume>
<fpage>897</fpage>
<lpage>907</lpage>
<pub-id pub-id-type="doi">10.1002/gcc.20695</pub-id>
<pub-id pub-id-type="pmid">19603524</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Andres</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Védrine</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tabagh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Michelle</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jourdan</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Heuze-Vourc’h</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Corcia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Duittoz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vourc’h</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Effect of the oligodendrocyte myelin glycoprotein
(OMgp) on the expansion and neuronal differentiation of rat neural stem
cells</article-title>
<source/>Brain Res
          <year>2009</year>
<volume>1284</volume>
<fpage>22</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2009.05.070</pub-id>
<pub-id pub-id-type="pmid">19501059</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Thakker</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Leark</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Treatment of ADHD in neurofibromatosis type
1</article-title>
<source/>Dev Med Child Neurol
          <year>2002</year>
<volume>44</volume>
<fpage>164</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1017/S0012162201001876</pub-id>
<pub-id pub-id-type="pmid">12005317</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Asuagbor</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Dombi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fünsterer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wenzel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Widemann</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Assessment of benign tumor burden by whole-body MRI in
patients with neurofibromatosis 1</article-title>
<source/>Neuro Oncol
          <year>2008</year>
<volume>10</volume>
<fpage>593</fpage>
<lpage>598</lpage>
<pub-id pub-id-type="doi">10.1215/15228517-2008-011</pub-id>
<pub-id pub-id-type="pmid">18559970</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Friedrich</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Roehl</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Bammert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Högel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Spöri</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Clinical characterisation of 29 neurofibromatosis
type-1 patients with molecularly ascertained 1.4 Mb type-1 <italic>NF1</italic> deletions</article-title>
<source/>J Med Genet
          <year>2010</year>
<volume>47</volume>
<fpage>623</fpage>
<lpage>630</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2009.075937</pub-id>
<pub-id pub-id-type="pmid">20543202</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGaughran</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Donnai</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Teare</surname>
<given-names>D</given-names>
</name>
<name>
<surname>MacLeod</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Westerbeek</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kingston</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Super</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DG</given-names>
</name>
</person-group>
<article-title>A clinical study of type 1 neurofibromatosis in north
west England</article-title>
<source/>J Med Genet
          <year>1999</year>
<volume>36</volume>
<fpage>197</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="pmid">10204844</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGee</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>QS</given-names>
</name>
<name>
<surname>Daw</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Strittmatter</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Experience-driven plasticity of visual cortex limited
by myelin and Nogo receptor</article-title>
<source/>Science
          <year>2005</year>
<volume>309</volume>
<fpage>2222</fpage>
<lpage>2226</lpage>
<pub-id pub-id-type="doi">10.1126/science.1114362</pub-id>
<pub-id pub-id-type="pmid">16195464</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mensink</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Ketterling</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Flynn</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Knudson</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Lindor</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Heese</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Spinner</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Babovic-Vuksanovic</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Connective tissue dysplasia in five new patients with
<italic>NF1</italic> microdeletions: further expansion of
phenotype and review of the literature</article-title>
<source/>J Med Genet
          <year>2006</year>
<volume>43</volume>
<fpage>e8</fpage>
<pub-id pub-id-type="doi">10.1136/jmg.2005.034256</pub-id>
<pub-id pub-id-type="pmid">16467218</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messiaen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bengesser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mikhail</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Serra</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Garcia-Linares</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Lazaro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Mosaic type-1 <italic>NF1</italic>
microdeletions as a cause of both generalized and segmental neurofibromatosis
type-1 (NF1)</article-title>
<source/>Hum Mutat
          <year>2011</year>
<volume>32</volume>
<fpage>213</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1002/humu.21418</pub-id>
<pub-id pub-id-type="pmid">21280148</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millichap</surname>
<given-names>JG</given-names>
</name>
</person-group>
<article-title>MRI Screening for optic gliomas in neurofibromatosis
type 1</article-title>
<source/>Pediatr Neurol Briefs
          <year>2015</year>
<volume>29</volume>
<fpage>72</fpage>
<pub-id pub-id-type="doi">10.15844/pedneurbriefs-29-9-7</pub-id>
<pub-id pub-id-type="pmid">26933608</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mironova</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Giger</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Where no synapses go: gatekeepers of circuit
remodeling and synaptic strength</article-title>
<source/>Trends Neurosci
          <year>2013</year>
<volume>36</volume>
<fpage>363</fpage>
<lpage>373</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2013.04.003</pub-id>
<pub-id pub-id-type="pmid">23642707</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moles</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Gowans</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Gedela</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Beversdorf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Seaver</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Torchia</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Shaffer</surname>
<given-names>LG</given-names>
</name>
</person-group>
<article-title><italic>NF1</italic> microduplications: identification of
seven nonrelated individuals provides further characterization of the
phenotype</article-title>
<source/>Genet Med
          <year>2012</year>
<volume>14</volume>
<fpage>508</fpage>
<lpage>514</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2011.46</pub-id>
<pub-id pub-id-type="pmid">22241097</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukherjee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nazmi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Basu</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>RIG-I knockdown impedes neurogenesis in a murine model
of Japanese encephalitis</article-title>
<source/>Cell Biol Int
          <year>2015</year>
<volume>39</volume>
<fpage>224</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="doi">10.1002/cbin.10354</pub-id>
<pub-id pub-id-type="pmid">25077467</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakano</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Miyazawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Gain-of-function microRNA screens identify miR-193a
regulating proliferation and apoptosis in epithelial ovarian cancer
cells</article-title>
<source/>Int J Oncol
          <year>2013</year>
<volume>42</volume>
<fpage>1875</fpage>
<lpage>1882</lpage>
<pub-id pub-id-type="pmid">23588298</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nazmi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dutta</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Basu</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>RIG-I mediates innate immune response in mouse neurons
following Japanese encephalitis virus infection</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<fpage>e21761</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0021761</pub-id>
<pub-id pub-id-type="pmid">21738791</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dombi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Widemann</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Solomon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fuensterer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
</person-group>
<article-title>Growth dynamics of plexiform neurofibromas: a
retrospective cohort study of 201 patients with neurofibromatosis
1</article-title>
<source/>Orphanet J Rare Dis
          <year>2012</year>
<volume>7</volume>
<fpage>75</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1172-7-75</pub-id>
<pub-id pub-id-type="pmid">23035791</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mir</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jett</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kentsch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
</person-group>
<article-title>Cardiac characterization of 16 patients with large
<italic>NF1</italic> gene deletions</article-title>
<source/>Clin Genet
          <year>2013</year>
<volume>84</volume>
<fpage>344</fpage>
<lpage>349</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12072</pub-id>
<pub-id pub-id-type="pmid">23278345</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jett</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
</person-group>
<article-title>Benign whole body tumor volume is a risk factor for
malignant peripheral nerve sheath tumors in neurofibromatosis type
1</article-title>
<source/>J Neurooncol
          <year>2014</year>
<volume>116</volume>
<fpage>307</fpage>
<lpage>313</lpage>
<pub-id pub-id-type="doi">10.1007/s11060-013-1293-1</pub-id>
<pub-id pub-id-type="pmid">24166582</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>microRNA-365, down-regulated in colon cancer, inhibits
cell cycle progression and promotes apoptosis of colon cancer cells by probably
targeting cyclin D1 and Bcl-2</article-title>
<source/>Carcinogenesis
          <year>2012</year>
<volume>33</volume>
<fpage>220</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgr245</pub-id>
<pub-id pub-id-type="pmid">22072615</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ning</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Farschtschi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Growth in neurofibromatosis 1 microdeletion
patients</article-title>
<source/>Clin Genet
          <year>2016</year>
<volume>89</volume>
<fpage>351</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12632</pub-id>
<pub-id pub-id-type="pmid">26111455</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>North</surname>
<given-names>KN</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis type 1: review of the first 200
patients in an Australian clinic</article-title>
<source/>J Child Neurol
          <year>1993</year>
<volume>8</volume>
<fpage>395</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="doi">10.1177/088307389300800421</pub-id>
<pub-id pub-id-type="pmid">8228039</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>North</surname>
<given-names>KN</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Friedman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>MacCollin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>VM</given-names>
</name>
</person-group>
<article-title>Cognitive function and academic
performance</article-title>
<source/>Neurofibromatosis: phenotype, natural history and
pathogenesis
          <year>1999</year>
<edition>3</edition>
<publisher-loc>Baltimore</publisher-loc>
<publisher-name>Johns Hopkins University Press</publisher-name>
<fpage>168</fpage>
</element-citation>
</ref>
<ref id="CR150">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>North</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis type 1</article-title>
<source/>Am J Med Genet
          <year>2000</year>
<volume>97</volume>
<fpage>119</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1002/1096-8628(200022)97:2&lt;119::AID-AJMG3&gt;3.0.CO;2-3</pub-id>
<pub-id pub-id-type="pmid">11180219</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>North</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Joy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yuille</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cocks</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hutchins</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Cognitive function and academic performance in
children with neurofibromatosis type 1</article-title>
<source/>Dev Med Child Neurol
          <year>1995</year>
<volume>37</volume>
<fpage>427</fpage>
<lpage>436</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.1995.tb12026.x</pub-id>
<pub-id pub-id-type="pmid">7768342</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>North</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Samango-Sprouse</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ferner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ratner</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Denckla</surname>
<given-names>MB</given-names>
</name>
</person-group>
<article-title>Cognitive function and academic performance in
neurofibromatosis 1: consensus statement from the NF1 cognitive disorders task
force</article-title>
<source/>Neurology
          <year>1997</year>
<volume>48</volume>
<fpage>1121</fpage>
<lpage>1127</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.48.4.1121</pub-id>
<pub-id pub-id-type="pmid">9109916</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oktenli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Saglam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Demirbas</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Consoli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ulucan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Koz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Durukan</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Bozkurt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Koc</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kocar</surname>
<given-names>IH</given-names>
</name>
<name>
<surname>Gul</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A large deletion (1.5 Mb) encompassing the
neurofibromatosis type 1 gene in a patient with sporadic NF1 associated with
dysmorphism, mental retardation, and unusual ocular and skeletal
features</article-title>
<source/>Clin Dysmorphol
          <year>2003</year>
<volume>12</volume>
<fpage>199</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="pmid">14564162</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliveira</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Neurofibromin is the major ras inactivator in
dendritic spines</article-title>
<source/>J Neurosci
          <year>2014</year>
<volume>34</volume>
<fpage>776</fpage>
<lpage>783</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3096-13.2014</pub-id>
<pub-id pub-id-type="pmid">24431436</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oshiumi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hatakeyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Seya</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Riplet/RNF135, a RING finger protein, ubiquitinates
RIG-I to promote interferon-beta induction during the early phase of viral
infection</article-title>
<source/>J Biol Chem
          <year>2009</year>
<volume>284</volume>
<fpage>807</fpage>
<lpage>817</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M804259200</pub-id>
<pub-id pub-id-type="pmid">19017631</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oshiumi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Miyashita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Okabe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seya</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>The ubiquitin ligase Riplet is essential for
RIG-I-dependent innate immune responses to RNA virus infection</article-title>
<source/>Cell Host Microbe
          <year>2010</year>
<volume>8</volume>
<fpage>496</fpage>
<lpage>509</lpage>
<pub-id pub-id-type="doi">10.1016/j.chom.2010.11.008</pub-id>
<pub-id pub-id-type="pmid">21147464</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oshiumi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Miyashita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seya</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>A distinct role of Riplet-mediated K63-Linked
polyubiquitination of the RIG-I repressor domain in human antiviral innate
immune responses</article-title>
<source/>PLoS Pathog
          <year>2013</year>
<volume>9</volume>
<fpage>e1003533</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1003533</pub-id>
<pub-id pub-id-type="pmid">23950712</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasmant</surname>
<given-names>E</given-names>
</name>
<name>
<surname>de Saint-Trivier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Laurendeau</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dieux-Coeslier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Parfait</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bièche</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Characterization of a 7.6-Mb germline deletion
encompassing the <italic>NF1</italic> locus and about a
hundred genes in an NF1 contiguous gene syndrome patient</article-title>
<source/>Eur J Hum Genet
          <year>2008</year>
<volume>16</volume>
<fpage>1459</fpage>
<lpage>1466</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2008.134</pub-id>
<pub-id pub-id-type="pmid">18648396</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasmant</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sabbagh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Masliah-Planchon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Haddad</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hamel</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Laurendeau</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Soulier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Parfait</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wolkenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bièche</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Detection and characterization of <italic>NF1</italic> microdeletions by custom high resolution array
CGH</article-title>
<source/>J Mol Diagn
          <year>2009</year>
<volume>11</volume>
<fpage>524</fpage>
<lpage>529</lpage>
<pub-id pub-id-type="doi">10.2353/jmoldx.2009.090064</pub-id>
<pub-id pub-id-type="pmid">19767589</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasmant</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sabbagh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Spurlock</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Laurendeau</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Grillo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hamel</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Barbarot</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leheup</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lacombe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dollfus</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pasquier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Isidor</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ferkal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Soulier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sanson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dieux-Coeslier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bièche</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Parfait</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wolkenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>D</given-names>
</name>
<collab>Members of the NF France
Network</collab>
</person-group>
<article-title><italic>NF1</italic> microdeletions in neurofibromatosis type
1: from genotype to phenotype</article-title>
<source/>Hum Mutat
          <year>2010</year>
<volume>31</volume>
<fpage>E1506</fpage>
<lpage>1518</lpage>
<pub-id pub-id-type="doi">10.1002/humu.21271</pub-id>
<pub-id pub-id-type="pmid">20513137</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasmant</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Masliah-Planchon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lévy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Laurendeau</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ortonne</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Parfait</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Valeyrie-Allanore</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Leroy</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wolkenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bièche</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Identification of genes potentially involved in the
increased risk of malignancy in <italic>NF1</italic>-microdeleted patients</article-title>
<source/>Mol Med
          <year>2011</year>
<volume>17</volume>
<fpage>79</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.2119/molmed.2010.00079</pub-id>
<pub-id pub-id-type="pmid">20844836</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasmant</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wolkenstein</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis type 1: from genotype to
phenotype</article-title>
<source/>J Med Genet
          <year>2012</year>
<volume>49</volume>
<fpage>483</fpage>
<lpage>489</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2012-100978</pub-id>
<pub-id pub-id-type="pmid">22889851</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paul</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sardet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fabbrizio</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The histone- and PRMT5-associated protein COPR5 is
required for myogenic differentiation</article-title>
<source/>Cell Death Differ
          <year>2012</year>
<volume>19</volume>
<fpage>900</fpage>
<lpage>908</lpage>
<pub-id pub-id-type="doi">10.1038/cdd.2011.193</pub-id>
<pub-id pub-id-type="pmid">22193545</pub-id>
</element-citation>
</ref>
<ref id="CR164">
<mixed-citation publication-type="other">Pemov A, HansenNH, Patidar R, Boland JF, Chandrasekharappa S,
Mullikin JC,Wallace M, Khan J, Legius E, Widemann B, Stewart DR (2016) Comparative
genomic analysis of NF1-associated atypical neurofibromas (ANF) and malignant
peripheral nerve sheath tumors (MPNST). In: American Society of Human Genetics
66th Annual Meeting, 18–22 October 2016 Vancouver</mixed-citation>
</ref>
<ref id="CR165">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petek</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jenne</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Smolle</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Binder</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lasinger</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Windpassinger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kroisel</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Mitotic recombination mediated by the <italic>JJAZF1</italic> (<italic>KIAA0160</italic>)
gene causing somatic mosaicism and a new type of constitutional <italic>NF1</italic> microdeletion in two children of a mosaic female
with only few manifestations</article-title>
<source/>J Med Genet
          <year>2003</year>
<volume>40</volume>
<fpage>520</fpage>
<lpage>525</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.40.7.520</pub-id>
<pub-id pub-id-type="pmid">12843325</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrasek</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Prokopova</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Sladek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weissova</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Vojtechova</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bahnik</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zemanova</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schönig</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tews</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bartsch</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schwab</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Sumova</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stuchlik</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Nogo-A-deficient transgenic rats show deficits in
higher cognitive functions, decreased anxiety, and altered circadian activity
patterns</article-title>
<source/>Front Behav Neurosci
          <year>2014</year>
<volume>8</volume>
<fpage>90</fpage>
<pub-id pub-id-type="pmid">24672453</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piddubnyak</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Rigou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rain</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Geneste</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Wolkenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hickman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Mauviel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Poyet</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Positive regulation of apoptosis by HCA66, a new
Apaf-1 interacting protein, and its putative role in the physiopathology of
<italic>NF1</italic> microdeletion syndrome
patients</article-title>
<source/>Cell Death Differ
          <year>2007</year>
<volume>14</volume>
<fpage>1222</fpage>
<lpage>1233</lpage>
<pub-id pub-id-type="doi">10.1038/sj.cdd.4402122</pub-id>
<pub-id pub-id-type="pmid">17380155</pub-id>
</element-citation>
</ref>
<ref id="CR168">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinna</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lanari</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Daniele</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Consoli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Agolini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Margiotti</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bottillo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Torrente</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bruselles</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fusilli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ficcadenti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bargiacchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Trevisson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Forzan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giustini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leoni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zampino</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Digilio</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Dallapiccola</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Clementi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>De Luca</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>p.Arg1809Cys substitution in neurofibromin is
associated with a distinctive NF1 phenotype without neurofibromas</article-title>
<source/>Eur J Hum Genet
          <year>2015</year>
<volume>23</volume>
<fpage>1068</fpage>
<lpage>1071</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2014.243</pub-id>
<pub-id pub-id-type="pmid">25370043</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pittenger</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Disorders of memory and plasticity in psychiatric
disease</article-title>
<source/>Dialogues Clin Neurosci
          <year>2013</year>
<volume>15</volume>
<fpage>455</fpage>
<lpage>463</lpage>
<pub-id pub-id-type="pmid">24459412</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plotkin</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Bredella</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kassarjian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Esparza</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Merker</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Munn</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Muzikansky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Askenazi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wenzel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
</person-group>
<article-title>Quantitative assessment of whole-body tumor burden in
adult patients with neurofibromatosis</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e35711</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0035711</pub-id>
<pub-id pub-id-type="pmid">22558206</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prada</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Hufnagel</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Hummel</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Lovell</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Hopkin</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Saal</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Schorry</surname>
<given-names>EK</given-names>
</name>
</person-group>
<article-title>The use of magnetic resonance imaging screening for
optic pathway gliomas in children with neurofibromatosis type 1</article-title>
<source/>J Pediatr
          <year>2015</year>
<volume>167</volume>
<issue>851–856</issue>
<fpage>e1</fpage>
</element-citation>
</ref>
<ref id="CR172">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prieto-Granada</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Wiesner</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Messina</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Jungbluth</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Antonescu</surname>
<given-names>CR</given-names>
</name>
</person-group>
<article-title>Loss of H3K27me3 expression is a highly sensitive
marker for sporadic and radiation-induced MPNST</article-title>
<source/>Am J Surg Pathol
          <year>2016</year>
<volume>40</volume>
<fpage>479</fpage>
<lpage>489</lpage>
<pub-id pub-id-type="doi">10.1097/PAS.0000000000000564</pub-id>
<pub-id pub-id-type="pmid">26645727</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Salzberg</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Runkle</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zander</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>MiR-365 regulates lung cancer and developmental gene
thyroid transcription factor 1</article-title>
<source/>Cell Cycle
          <year>2012</year>
<volume>11</volume>
<fpage>177</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.4161/cc.11.1.18576</pub-id>
<pub-id pub-id-type="pmid">22185756</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raiker</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Baldwin</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shrager</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Giger</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Oligodendrocyte-myelin glycoprotein and Nogo
negatively regulate activity-dependent synaptic plasticity</article-title>
<source/>J Neurosci
          <year>2010</year>
<volume>30</volume>
<fpage>12432</fpage>
<lpage>12445</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0895-10.2010</pub-id>
<pub-id pub-id-type="pmid">20844138</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rasmussen</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Colman</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>VT</given-names>
</name>
<name>
<surname>Abernathy</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Arn</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Saul</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Constitutional and mosaic large <italic>NF1</italic> gene deletions in neurofibromatosis type
1</article-title>
<source/>J Med Genet
          <year>1998</year>
<volume>35</volume>
<fpage>468</fpage>
<lpage>471</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.35.6.468</pub-id>
<pub-id pub-id-type="pmid">9643287</pub-id>
</element-citation>
</ref>
<ref id="CR176">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Expression and clinicopathological significance of
miR-193a-3p and its potential target astrocyte elevated gene-1 in non-small lung
cancer tissues</article-title>
<source/>Cancer Cell Int
          <year>2015</year>
<volume>15</volume>
<fpage>80</fpage>
<pub-id pub-id-type="doi">10.1186/s12935-015-0227-8</pub-id>
<pub-id pub-id-type="pmid">26257582</pub-id>
</element-citation>
</ref>
<ref id="CR177">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Riccardi</surname>
<given-names>VM</given-names>
</name>
</person-group>
<source/>Neurofibromatosis: phenotype, natural history and
pathogenesis
          <year>1992</year>
<edition>2</edition>
<publisher-loc>Baltimore</publisher-loc>
<publisher-name>Johns Hopkins University Press</publisher-name>
<fpage>165</fpage>
<lpage>166</lpage>
</element-citation>
</ref>
<ref id="CR178">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Riccardi</surname>
<given-names>VM</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Friedman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>MacCollin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>VM</given-names>
</name>
</person-group>
<article-title>Skeletal system</article-title>
<source/>Neurofibromatosis: phenotype, natural history and
pathogenesis
          <year>1999</year>
<edition>3</edition>
<publisher-loc>Baltimore</publisher-loc>
<publisher-name>Johns Hopkins University Press</publisher-name>
<fpage>262</fpage>
<lpage>263</lpage>
</element-citation>
</ref>
<ref id="CR179">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Riccardi</surname>
<given-names>VM</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Friedman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>MacCollin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>VM</given-names>
</name>
</person-group>
<article-title>Skeletal system</article-title>
<source/>Neurofibromatosis: phenotype, natural history and
pathogenesis
          <year>1999</year>
<edition>3</edition>
<publisher-loc>Baltimore</publisher-loc>
<publisher-name>Johns Hopkins University Press</publisher-name>
<fpage>260</fpage>
</element-citation>
</ref>
<ref id="CR180">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riva</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Castorina</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Manoukian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dalprà</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Doneda</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>den Dunnen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Larizza</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Characterization of a cytogenetic 17q11.2 deletion in
an NF1 patient with a contiguous gene syndrome</article-title>
<source/>Hum Genet
          <year>1996</year>
<volume>98</volume>
<fpage>646</fpage>
<lpage>650</lpage>
<pub-id pub-id-type="doi">10.1007/s004390050277</pub-id>
<pub-id pub-id-type="pmid">8931693</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riva</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Corrado</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Natacci</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Castorina</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Clementi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tenconi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Larizza</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title><italic>NF1</italic> microdeletion syndrome: refined FISH
characterization of sporadic and familial deletions with locus-specific
probes</article-title>
<source/>Am J Hum Genet
          <year>2000</year>
<volume>66</volume>
<fpage>100</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1086/302709</pub-id>
<pub-id pub-id-type="pmid">10631140</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roehl</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mussotter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zickler</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Spöti</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Högel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chuzhanova</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Wimmer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Intrachromosomal mitotic nonallelic homologous
recombination is the major molecular mechanism underlying type-2 <italic>NF1</italic> deletions</article-title>
<source/>Hum Mutat
          <year>2010</year>
<volume>31</volume>
<fpage>1163</fpage>
<lpage>1173</lpage>
<pub-id pub-id-type="doi">10.1002/humu.21340</pub-id>
<pub-id pub-id-type="pmid">20725927</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roehl</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Mussotter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wimmer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Högel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zetzmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Tissue-specific differences in the proportion of
mosaic large <italic>NF1</italic> deletions are suggestive of
a selective growth advantage of hematopoietic del(±) stem cells</article-title>
<source/>Hum Mutat
          <year>2012</year>
<volume>33</volume>
<fpage>541</fpage>
<lpage>550</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22013</pub-id>
<pub-id pub-id-type="pmid">22190464</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Röhrich</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koelsche</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schrimpf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Capper</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sahm</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kratz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reuss</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hovestadt</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Bewerunge-Hudler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mawrin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mittelbronn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Mechtersheimer</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Okuducu</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Arp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seiz-Rosenhagen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hänggi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Heim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Paulus</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Schittenhelm</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ahmadi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Herold-Mende</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Unterberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pfister</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>von Deimling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reuss</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>Methylation-based classification of benign and
malignant peripheral nerve sheath tumors</article-title>
<source/>Acta Neuropathol
          <year>2016</year>
<volume>131</volume>
<fpage>877</fpage>
<lpage>887</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-016-1540-6</pub-id>
<pub-id pub-id-type="pmid">26857854</pub-id>
</element-citation>
</ref>
<ref id="CR185">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rojnueangnit</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Callens</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cochran</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abbott</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Atkin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Babovic-Vuksanovic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Barnett</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Crenshaw</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bartholomew</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Basel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bellus</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ben-Shachar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bialer</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Bick</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Blumberg</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cortes</surname>
<given-names>F</given-names>
</name>
<name>
<surname>David</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Destree</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Duat-Rodriguez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Earl</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Escobar</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Eswara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ezquieta</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Frayling</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Frydman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gripp</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Hernández-Chico</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Heyrman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Janssens</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Keena</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Llano-Rivas</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Leppig</surname>
<given-names>K</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Misra</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Mulbury</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Narayanan</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Orenstein</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Galvin-Parton</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pedro</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pivnick</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Randolph</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Raskin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rosell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rubin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Seashore</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schaaf</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Scheuerle</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schorry</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schnur</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Siqveland</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tkachuk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tonsgard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zackai</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zonana</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lazaro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Messiaen</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>High incidence of Noonan syndrome features including
short stature and pulmonic stenosis in patients carrying<italic>
NF1</italic> missense mutations affecting p.Arg1809: genotype-phenotype
correlation</article-title>
<source/>Hum Mutat
          <year>2015</year>
<volume>36</volume>
<fpage>1052</fpage>
<lpage>1063</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22832</pub-id>
<pub-id pub-id-type="pmid">26178382</pub-id>
</element-citation>
</ref>
<ref id="CR186">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruggieri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Polizzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Spalice</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Salpietro</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Caltabiano</surname>
<given-names>R</given-names>
</name>
<name>
<surname>D’Orazi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Pavone</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pirrone</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Magro</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Platania</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cavallaro</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Muglia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nicita</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>The natural history of spinal neurofibromatosis: a
critical review of clinical and genetic features</article-title>
<source/>Clin Genet
          <year>2015</year>
<volume>87</volume>
<fpage>401</fpage>
<lpage>410</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12498</pub-id>
<pub-id pub-id-type="pmid">25211147</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabbagh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pasmant</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Laurendeau</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Parfait</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Barbarot</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Guillot</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Combemale</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ferkal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aubourg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vidaud</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wolkenstein</surname>
<given-names>P</given-names>
</name>
<collab>Members of the NF France
Network</collab>
</person-group>
<article-title>Unravelling the genetic basis of variable clinical
expression in neurofibromatosis 1</article-title>
<source/>Hum Mol Genet
          <year>2009</year>
<volume>18</volume>
<fpage>2768</fpage>
<lpage>2778</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddp212</pub-id>
<pub-id pub-id-type="pmid">19417008</pub-id>
</element-citation>
</ref>
<ref id="CR188">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salamon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Adam</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Derlin</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Multimodal imaging in neurofibromatosis type
1-associated nerve sheath tumors</article-title>
<source/>Rofo
          <year>2015</year>
<volume>187</volume>
<fpage>1084</fpage>
<lpage>1092</lpage>
<pub-id pub-id-type="doi">10.1055/s-0035-1551330</pub-id>
<pub-id pub-id-type="pmid">26333104</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salvi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Conde</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Abeni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Arici</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Grossi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Specchia</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Portolani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Barlati</surname>
<given-names>S</given-names>
</name>
<name>
<surname>De Petro</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Effects of miR-193a and sorafenib on hepatocellular
carcinoma cells</article-title>
<source/>Mol Cancer
          <year>2013</year>
<volume>12</volume>
<fpage>162</fpage>
<pub-id pub-id-type="doi">10.1186/1476-4598-12-162</pub-id>
<pub-id pub-id-type="pmid">24330766</pub-id>
</element-citation>
</ref>
<ref id="CR190">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sbidian</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hadj-Rabia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Valeyrie-Allanore</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Barbarot</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chosidow</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ferkal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wolkenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bastuji-Garin</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Clinical characteristics predicting internal
neurofibromas in 357 children with neurofibromatosis-1: results from a
cross-selectional study</article-title>
<source/>Orphanet J Rare Dis
          <year>2012</year>
<volume>7</volume>
<fpage>62</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1172-7-62</pub-id>
<pub-id pub-id-type="pmid">22943186</pub-id>
</element-citation>
</ref>
<ref id="CR191">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaefer</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Fletcher</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Hornick</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Loss of H3K27 trimethylation distinguishes malignant
peripheral nerve sheath tumors from histologic mimics</article-title>
<source/>Mod Pathol
          <year>2016</year>
<volume>29</volume>
<fpage>4</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1038/modpathol.2015.134</pub-id>
<pub-id pub-id-type="pmid">26585554</pub-id>
</element-citation>
</ref>
<ref id="CR192">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sedani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>An emerging role for microRNAs in NF1
tumorigenesis</article-title>
<source/>Hum Genom
          <year>2012</year>
<volume>6</volume>
<fpage>23</fpage>
<pub-id pub-id-type="doi">10.1186/1479-7364-6-23</pub-id>
</element-citation>
</ref>
<ref id="CR193">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seminog</surname>
<given-names>OO</given-names>
</name>
<name>
<surname>Goldacre</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Risk of benign tumours of nervous system, and of
malignant neoplasms, in people with neurofibromatosis: population-based
record-linkage study</article-title>
<source/>Br J Cancer
          <year>2013</year>
<volume>108</volume>
<fpage>193</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="doi">10.1038/bjc.2012.535</pub-id>
<pub-id pub-id-type="pmid">23257896</pub-id>
</element-citation>
</ref>
<ref id="CR194">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seminog</surname>
<given-names>OO</given-names>
</name>
<name>
<surname>Goldacre</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Age-specific risk of breast cancer in women with
neurofibromatosis type 1</article-title>
<source/>Br J Cancer
          <year>2015</year>
<volume>112</volume>
<fpage>1546</fpage>
<lpage>1548</lpage>
<pub-id pub-id-type="doi">10.1038/bjc.2015.78</pub-id>
<pub-id pub-id-type="pmid">25742481</pub-id>
</element-citation>
</ref>
<ref id="CR195">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sevick</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Barkovich</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lempert</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Evolution of white matter lesions in neurofibromatosis
type 1: MR findings</article-title>
<source/>Am J Roentgenol
          <year>1992</year>
<volume>159</volume>
<fpage>171</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.2214/ajr.159.1.1609692</pub-id>
<pub-id pub-id-type="pmid">1609692</pub-id>
</element-citation>
</ref>
<ref id="CR196">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaikh</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Gai</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Perin</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Glessner</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>K</given-names>
</name>
<name>
<surname>O’Hara</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Casalunovo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Conlin</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>D’Arcy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Frackelton</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Geiger</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Haldeman-Englert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Imielinski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Medne</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Annaiah</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bradfield</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Dabaghyan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Eckert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Onyiah</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Ostapenko</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Otieno</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Santa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Shaner</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Skraban</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Elia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goldmuntz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Spinner</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Zackai</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Chiavacci</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Grundmeier</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rappaport</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>White</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Hakonarson</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>High-resolution mapping and analysis of copy number
variations in the human genome: a data resource for clinical and research
applications</article-title>
<source/>Genome Res
          <year>2009</year>
<volume>19</volume>
<fpage>1682</fpage>
<lpage>1690</lpage>
<pub-id pub-id-type="doi">10.1101/gr.083501.108</pub-id>
<pub-id pub-id-type="pmid">19592680</pub-id>
</element-citation>
</ref>
<ref id="CR197">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharif</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Iddenden</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shenton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DG</given-names>
</name>
</person-group>
<article-title>Women with neurofibromatosis 1 are at a moderately
increased risk of developing breast cancer and should be considered for early
screening</article-title>
<source/>J Med Genet
          <year>2007</year>
<volume>44</volume>
<fpage>481</fpage>
<lpage>484</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2007.049346</pub-id>
<pub-id pub-id-type="pmid">17369502</pub-id>
</element-citation>
</ref>
<ref id="CR198">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shilyansky</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Molecular and cellular mechanisms of learning
disabilities: a focus on NF1</article-title>
<source/>Annu Rev Neurosci
          <year>2010</year>
<volume>33</volume>
<fpage>221</fpage>
<lpage>243</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-neuro-060909-153215</pub-id>
<pub-id pub-id-type="pmid">20345245</pub-id>
</element-citation>
</ref>
<ref id="CR199">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shilyansky</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Karlsgodt</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Sidiropoulou</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hardt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>James</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Ehninger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bearden</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Poirazi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jentsch</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Neurofibromin regulates corticostriatal inhibitory
networks during working memory performance</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2010</year>
<volume>107</volume>
<fpage>13141</fpage>
<lpage>13146</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1004829107</pub-id>
<pub-id pub-id-type="pmid">20624961</pub-id>
</element-citation>
</ref>
<ref id="CR200">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sikdar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Wincovitch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pak</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jasin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dutra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Myung</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>DNA damage responses by human ELG1 in S phase are
important to maintain genomic integrity</article-title>
<source/>Cell Cycle
          <year>2009</year>
<volume>8</volume>
<fpage>3199</fpage>
<lpage>3207</lpage>
<pub-id pub-id-type="doi">10.4161/cc.8.19.9752</pub-id>
<pub-id pub-id-type="pmid">19755857</pub-id>
</element-citation>
</ref>
<ref id="CR201">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinibaldi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>De Luca</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bellacchio</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Conti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pasini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Paloscia</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Spalletta</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Caltagirone</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pizzuti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dallapiccola</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Mutations of the Nogo-66 receptor (<italic>RTN4R</italic>) gene in schizophrenia</article-title>
<source/>Hum Mutat
          <year>2004</year>
<volume>24</volume>
<fpage>534</fpage>
<lpage>535</lpage>
<pub-id pub-id-type="doi">10.1002/humu.9292</pub-id>
<pub-id pub-id-type="pmid">15532024</pub-id>
</element-citation>
</ref>
<ref id="CR202">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soucy</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>van Oppen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nejedly</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Hollander</surname>
<given-names>AS</given-names>
</name>
</person-group>
<article-title>Height assessments in children with neurofibromatosis
type 1</article-title>
<source/>J Child Neurol
          <year>2013</year>
<volume>28</volume>
<fpage>303</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="doi">10.1177/0883073812446310</pub-id>
<pub-id pub-id-type="pmid">22752476</pub-id>
</element-citation>
</ref>
<ref id="CR203">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spiegel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oexle</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Horn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Windt</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Buske</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Albrecht</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Prott</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Seemanová</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Seidel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rosenbaum</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jenne</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tinschert</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Childhood overgrowth in patients with common <italic>NF1</italic> microdeletions</article-title>
<source/>Eur J Hum Genet
          <year>2005</year>
<volume>13</volume>
<fpage>883</fpage>
<lpage>888</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ejhg.5201419</pub-id>
<pub-id pub-id-type="pmid">15856072</pub-id>
</element-citation>
</ref>
<ref id="CR204">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srivastava</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>CE</given-names>
</name>
</person-group>
<article-title>Intellectual disability and autism spectrum disorders:
causal genes and molecular mechanisms</article-title>
<source/>Neurosci Biobehav Rev
          <year>2014</year>
<volume>2</volume>
<fpage>161</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.02.015</pub-id>
</element-citation>
</ref>
<ref id="CR205">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chuzhanova</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Senger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Serra</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lazaro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gilaberte</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wimmer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Type 2 <italic>NF1</italic>
deletions are highly unusual by virtue of the absence of nonallelic homologous
recombination hotspots and an apparent preference for female mitotic
recombination</article-title>
<source/>Am J Hum Genet
          <year>2007</year>
<volume>81</volume>
<fpage>1201</fpage>
<lpage>1220</lpage>
<pub-id pub-id-type="doi">10.1086/522089</pub-id>
<pub-id pub-id-type="pmid">17999360</pub-id>
</element-citation>
</ref>
<ref id="CR206">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Brems</surname>
<given-names>H</given-names>
</name>
<name>
<surname>De Raedt</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Copy number variations in the <italic>NF1</italic> gene region are infrequent and do not predispose to recurrent
type-1 deletions</article-title>
<source/>Eur J Hum Genet
          <year>2008</year>
<volume>16</volume>
<fpage>572</fpage>
<lpage>580</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ejhg.5202002</pub-id>
<pub-id pub-id-type="pmid">18212816</pub-id>
</element-citation>
</ref>
<ref id="CR207">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stopa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Krebs</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Shechter</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The PRMT5 arginine methyltransferase: many roles in
development, cancer and beyond</article-title>
<source/>Cell Mol Life Sci
          <year>2015</year>
<volume>72</volume>
<fpage>2041</fpage>
<lpage>2059</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-015-1847-9</pub-id>
<pub-id pub-id-type="pmid">25662273</pub-id>
</element-citation>
</ref>
<ref id="CR208">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Streubel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Latta</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Fonatsch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rehder</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Somatic mosaicism of a greater than 1.7-Mb deletion of
genomic DNA involving the entire <italic>NF1</italic> gene as
verified by FISH: further evidence for a contiguous gene syndrome in
17q11.2</article-title>
<source/>Am J Med Genet
          <year>1999</year>
<volume>87</volume>
<fpage>12</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19991105)87:1&lt;12::AID-AJMG3&gt;3.0.CO;2-O</pub-id>
<pub-id pub-id-type="pmid">10528240</pub-id>
</element-citation>
</ref>
<ref id="CR209">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Associations of deregulation of mir-365 and its target
mRNA TTF-1 and survival in patients with NSCLC</article-title>
<source/>Int J Clin Exp Pathol
          <year>2015</year>
<volume>8</volume>
<fpage>2392</fpage>
<lpage>2399</lpage>
<pub-id pub-id-type="pmid">26045746</pub-id>
</element-citation>
</ref>
<ref id="CR210">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Syken</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grandpre</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kanold</surname>
<given-names>PO</given-names>
</name>
<name>
<surname>Shatz</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>PirB restricts ocular-dominance plasticity in visual
cortex</article-title>
<source/>Science
          <year>2006</year>
<volume>313</volume>
<fpage>1795</fpage>
<lpage>1800</lpage>
<pub-id pub-id-type="doi">10.1126/science.1128232</pub-id>
<pub-id pub-id-type="pmid">16917027</pub-id>
</element-citation>
</ref>
<ref id="CR211">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szudek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Birch</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Growth in North American white children with
neurofibromatosis 1 (NF1)</article-title>
<source/>J Med Genet
          <year>2000</year>
<volume>37</volume>
<fpage>933</fpage>
<lpage>938</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.37.12.933</pub-id>
<pub-id pub-id-type="pmid">11106357</pub-id>
</element-citation>
</ref>
<ref id="CR212">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tastet</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Decalonne</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Marouillat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Malvy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thépault</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Toutain</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Paubel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tabagh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bénédetti</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Laumonnier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Barthélémy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bonnet-Brilhault</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Andres</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Vourc’h</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Mutation screening of the ubiquitin ligase gene
<italic>RNF135</italic> in French patients with
autism</article-title>
<source/>Psychiatr Genet
          <year>2015</year>
<volume>25</volume>
<fpage>263</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="doi">10.1097/YPG.0000000000000100</pub-id>
<pub-id pub-id-type="pmid">26368817</pub-id>
</element-citation>
</ref>
<ref id="CR213">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatton-Brown</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Douglas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Coleman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Baujat</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Horn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Temple</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Faravelli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Waggoner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Turkmen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cormier-Daire</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Irrthum</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Collaboration</surname>
<given-names>Childhood Overgrowth</given-names>
</name>
</person-group>
<article-title>Genotype-phenotype associations in Sotos syndrome: an
analysis of 266 individuals with <italic>NSD1</italic>
aberrations</article-title>
<source/>Am J Hum Genet
          <year>2005</year>
<volume>77</volume>
<fpage>193</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1086/432082</pub-id>
<pub-id pub-id-type="pmid">15942875</pub-id>
</element-citation>
</ref>
<ref id="CR214">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor Tavares</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Willatt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Simonic</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Mosaic deletion of the <italic>NF1</italic> gene in a patient with cognitive disability and dysmorphic
features but without diagnostic features of NF1</article-title>
<source/>Am J Med Genet A
          <year>2013</year>
<volume>161A</volume>
<fpage>1185</fpage>
<lpage>1188</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.35853</pub-id>
<pub-id pub-id-type="pmid">23532973</pub-id>
</element-citation>
</ref>
<ref id="CR215">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tenorio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mansilla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Valencia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martínez-Glez</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Romanelli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Arias</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Castrejón</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Poletta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Guillén-Navarro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gordo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mansilla</surname>
<given-names>E</given-names>
</name>
<name>
<surname>García-Santiago</surname>
<given-names>F</given-names>
</name>
<name>
<surname>González-Casado</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Vallespín</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Palomares</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Santos-Simarro</surname>
<given-names>F</given-names>
</name>
<name>
<surname>García-Miñaur</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fernández</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mena</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Benito-Sanz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>del Pozo</surname>
<given-names>Á</given-names>
</name>
<name>
<surname>Silla</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Ibañez</surname>
<given-names>K</given-names>
</name>
<name>
<surname>López-Granados</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Martín-Trujillo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Montaner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Campos-Barros</surname>
<given-names>Á</given-names>
</name>
<name>
<surname>Dopazo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nevado</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Monk</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ruiz-Pérez</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Lapunzina</surname>
<given-names>P</given-names>
</name>
<collab>SOGRI Consortium</collab>
</person-group>
<article-title>A new overgrowth syndrome is due to mutations in
<italic>RNF125</italic></article-title>
<source/>Hum Mutat
          <year>2014</year>
<volume>35</volume>
<fpage>1436</fpage>
<lpage>1441</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22689</pub-id>
<pub-id pub-id-type="pmid">25196541</pub-id>
</element-citation>
</ref>
<ref id="CR216">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tews</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schönig</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Arzt</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Clementi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rioult-Pedotti</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Zemmar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Enkel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Weinmann</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kasper</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schwab</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Bartsch</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Synthetic microRNA-mediated downregulation of Nogo-A
in transgenic rats reveals its role as regulator of synaptic plasticity and
cognitive function</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2013</year>
<volume>110</volume>
<fpage>6583</fpage>
<lpage>6588</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1217665110</pub-id>
<pub-id pub-id-type="pmid">23576723</pub-id>
</element-citation>
</ref>
<ref id="CR217">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tinschert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Naumann</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Stegmann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Buske</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thiel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jenne</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>Segmental neurofibromatosis is caused by somatic
mutation of the neurofibromatosis type 1 (<italic>NF1</italic>) gene</article-title>
<source/>Eur J Hum Genet
          <year>2000</year>
<volume>8</volume>
<fpage>455</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ejhg.5200493</pub-id>
<pub-id pub-id-type="pmid">10878667</pub-id>
</element-citation>
</ref>
<ref id="CR218">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tonsgard</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Yelavarthi</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Cushner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Short</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Lindgren</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Do <italic>NF1</italic> gene
deletions result in a characteristic phenotype?</article-title>
<source/>Am J Med Genet
          <year>1997</year>
<volume>73</volume>
<fpage>80</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19971128)73:1&lt;80::AID-AJMG16&gt;3.0.CO;2-N</pub-id>
<pub-id pub-id-type="pmid">9375928</pub-id>
</element-citation>
</ref>
<ref id="CR219">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Ger</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>HT</given-names>
</name>
</person-group>
<article-title>Arm selection preference of microRNA-193a varies in
breast cancer</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>28176</fpage>
<pub-id pub-id-type="doi">10.1038/srep28176</pub-id>
<pub-id pub-id-type="pmid">27307030</pub-id>
</element-citation>
</ref>
<ref id="CR220">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tucker</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wolkenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Revuz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zeller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Association between benign and malignant peripheral
nerve sheath tumors in NF1</article-title>
<source/>Neurology
          <year>2005</year>
<volume>65</volume>
<fpage>205</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000168830.79997.13</pub-id>
<pub-id pub-id-type="pmid">16043787</pub-id>
</element-citation>
</ref>
<ref id="CR221">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Maynard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sorour</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Vaughan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wilkie</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>HE</given-names>
</name>
</person-group>
<article-title>A cytogenetic deletion, del(17)(q11.22q21.1), in a
patient with sporadic neurofibromatosis type 1 (NF1) associated with dysmorphism
and developmental delay</article-title>
<source/>J Med Genet
          <year>1996</year>
<volume>33</volume>
<fpage>148</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.33.2.148</pub-id>
<pub-id pub-id-type="pmid">8929953</pub-id>
</element-citation>
</ref>
<ref id="CR222">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ruggieri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maynard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Osborn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hartog</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mudd</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Penttinen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cordeiro</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ponder</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ponder</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Krawczak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
</person-group>
<article-title>Gross deletions of the neurofibromatosis type 1
(<italic>NF1</italic>) gene are predominantly of maternal
origin and commonly associated with a learning disability, dysmorphic features
and developmental delay</article-title>
<source/>Hum Genet
          <year>1998</year>
<volume>102</volume>
<fpage>591</fpage>
<lpage>597</lpage>
<pub-id pub-id-type="doi">10.1007/s004390050746</pub-id>
<pub-id pub-id-type="pmid">9654211</pub-id>
</element-citation>
</ref>
<ref id="CR223">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Chuzhanova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Giovannini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Consoli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Side</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pierpont</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hachen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Barnicoat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Van Biervliet</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Stevenson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Viskochil</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Baralle</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Haan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Turnpenny</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lazaro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Messiaen</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>An absence of cutaneous neurofibromas associated with
a 3-bp inframe deletion in exon 17 of the <italic>NF1</italic>
gene (c.2970-2972 delAAT): evidence of a clinically significant NF1
genotype-phenotype correlation</article-title>
<source/>Am J Hum Genet
          <year>2007</year>
<volume>80</volume>
<fpage>140</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="doi">10.1086/510781</pub-id>
<pub-id pub-id-type="pmid">17160901</pub-id>
</element-citation>
</ref>
<ref id="CR224">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uusitalo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Leppävirta</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Koffert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Suominen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vahtera</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vahlberg</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pöyhönen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Peltonen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Peltonen</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Incidence and mortality of neurofibromatosis: a total
population study in Finland</article-title>
<source/>J Invest Dermatol
          <year>2015</year>
<volume>135</volume>
<fpage>904</fpage>
<lpage>906</lpage>
<pub-id pub-id-type="doi">10.1038/jid.2014.465</pub-id>
<pub-id pub-id-type="pmid">25354145</pub-id>
</element-citation>
</ref>
<ref id="CR225">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uusitalo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rantanen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kallionpää</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Pöyhönen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leppävirta</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ylä-Outinen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Pukkala</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pitkäniemi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Peltonen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Peltonen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Distinctive cancer associations in patients with
neurofibromatosis type 1</article-title>
<source/>J Clin Oncol
          <year>2016</year>
<volume>34</volume>
<fpage>1978</fpage>
<lpage>1986</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.2015.65.3576</pub-id>
<pub-id pub-id-type="pmid">26926675</pub-id>
</element-citation>
</ref>
<ref id="CR226">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valero</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Pascual-Castroviejo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Velasco</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hernández-Chico</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Identification of <italic>de
novo</italic> deletions at the <italic>NF1</italic> gene:
no preferential paternal origin and phenotypic analysis of
patients</article-title>
<source/>Hum Genet
          <year>1997</year>
<volume>99</volume>
<fpage>720</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="doi">10.1007/s004390050438</pub-id>
<pub-id pub-id-type="pmid">9187663</pub-id>
</element-citation>
</ref>
<ref id="CR227">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Asperen</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Overweg-Plandsoen</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Cnossen</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>van Tijn</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Hennekam</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Familial neurofibromatosis type 1 associated with an
overgrowth syndrome resembling Weaver syndrome</article-title>
<source/>J Med Genet
          <year>1998</year>
<volume>35</volume>
<fpage>323</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.35.4.323</pub-id>
<pub-id pub-id-type="pmid">9598729</pub-id>
</element-citation>
</ref>
<ref id="CR228">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Vaart</surname>
<given-names>T</given-names>
</name>
<name>
<surname>van Woerden</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Elgersma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>de Zeeuw</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Schonewille</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Motor deficits in neurofibromatosis type 1 mice: the
role of the cerebellum</article-title>
<source/>Genes Brain Behav
          <year>2011</year>
<volume>10</volume>
<fpage>404</fpage>
<lpage>409</lpage>
<pub-id pub-id-type="doi">10.1111/j.1601-183X.2011.00685.x</pub-id>
<pub-id pub-id-type="pmid">21352477</pub-id>
</element-citation>
</ref>
<ref id="CR229">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vassilopoulou-Sellin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Slopis</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>Growth hormone deficiency in children with
neurofibromatosis type 1 without suprasellar lesions</article-title>
<source/>Pediatr Neurol
          <year>2000</year>
<volume>22</volume>
<fpage>355</fpage>
<lpage>358</lpage>
<pub-id pub-id-type="doi">10.1016/S0887-8994(00)00123-5</pub-id>
<pub-id pub-id-type="pmid">10913726</pub-id>
</element-citation>
</ref>
<ref id="CR230">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venkateswarlu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brandom</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>PI-3-kinase-dependent membrane recruitment of
centaurin-alpha2 is essential for its effect on ARF6-mediated actin cytoskeleton
reorganisation</article-title>
<source/>J Cell Sci
          <year>2007</year>
<volume>120</volume>
<fpage>792</fpage>
<lpage>801</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.03373</pub-id>
<pub-id pub-id-type="pmid">17284522</pub-id>
</element-citation>
</ref>
<ref id="CR231">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venturin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gervasini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Orzan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bentivegna</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Corrado</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Colapietro</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Friso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tenconi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Larizza</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Evidence for non-homologous end joining and nonallelic
homologous recombination in atypical <italic>NF1</italic>
microdeletions</article-title>
<source/>Hum Genet
          <year>2004</year>
<volume>115</volume>
<fpage>69</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-004-1101-2</pub-id>
<pub-id pub-id-type="pmid">15103551</pub-id>
</element-citation>
</ref>
<ref id="CR232">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venturin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guarnieri</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Natacci</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Stabile</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tenconi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Clementi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Larizza</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Mental retardation and cardiovascular malformations in
<italic>NF1</italic> microdeleted patients point to
candidate genes in 17q11.2</article-title>
<source/>J Med Genet
          <year>2004</year>
<volume>41</volume>
<fpage>35</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2003.014761</pub-id>
<pub-id pub-id-type="pmid">14729829</pub-id>
</element-citation>
</ref>
<ref id="CR233">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venturin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bentivegna</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moroni</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Larizza</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Evidence by expression analysis of candidate genes for
congenital heart defects in the <italic>NF1</italic>
microdeletion interval</article-title>
<source/>Ann Hum Genet
          <year>2005</year>
<volume>69</volume>
<fpage>508</fpage>
<lpage>516</lpage>
<pub-id pub-id-type="doi">10.1111/j.1529-8817.2005.00203.x</pub-id>
<pub-id pub-id-type="pmid">16138909</pub-id>
</element-citation>
</ref>
<ref id="CR234">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venturin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moncini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Villa</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bonati</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Larizza</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Mutations and novel polymorphisms in coding regions
and UTRs of <italic>CDK5R1</italic> and <italic>OMG</italic> genes in patients with non-syndromic mental
retardation</article-title>
<source/>Neurogenetics
          <year>2006</year>
<volume>7</volume>
<fpage>59</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-005-0026-9</pub-id>
<pub-id pub-id-type="pmid">16425041</pub-id>
</element-citation>
</ref>
<ref id="CR235">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venturin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gaudenzi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brunelli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Moncini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cotelli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title><italic>ADAP2</italic> in heart development: a candidate gene
for the occurrence of cardiovascular malformations in <italic>NF1</italic> microdeletion syndrome</article-title>
<source/>J Med Genet
          <year>2014</year>
<volume>51</volume>
<fpage>436</fpage>
<lpage>443</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2013-102240</pub-id>
<pub-id pub-id-type="pmid">24711647</pub-id>
</element-citation>
</ref>
<ref id="CR236">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vienberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Geiger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dalgaard</surname>
<given-names>LT</given-names>
</name>
</person-group>
<article-title>MicroRNAs in metabolism</article-title>
<source/>Acta Physiol (Oxf)
          <year>2017</year>
<volume>219</volume>
<fpage>346</fpage>
<lpage>361</lpage>
<pub-id pub-id-type="doi">10.1111/apha.12681</pub-id>
<pub-id pub-id-type="pmid">27009502</pub-id>
</element-citation>
</ref>
<ref id="CR237">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Violante</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Castelo-Branco</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Gyrification, cortical and subcortical morphometry in
neurofibromatosis type 1: an uneven profile of developmental
abnormalities</article-title>
<source/>J Neurodev Disord
          <year>2013</year>
<volume>5</volume>
<fpage>3</fpage>
<pub-id pub-id-type="doi">10.1186/1866-1955-5-3</pub-id>
<pub-id pub-id-type="pmid">23406822</pub-id>
</element-citation>
</ref>
<ref id="CR238">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Viskochil</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Buchberg</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cawthon</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Culver</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Copeland</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>NA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deletions and a translocation interrupt a cloned gene
at the neurofibromatosis type 1 locus</article-title>
<source/>Cell
          <year>1990</year>
<volume>62</volume>
<fpage>187</fpage>
<lpage>192</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(90)90252-A</pub-id>
<pub-id pub-id-type="pmid">1694727</pub-id>
</element-citation>
</ref>
<ref id="CR239">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Visser</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Koelma</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vijfhuizen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>van der Wielen</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Kant</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Breuning</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Wit</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Losekoot</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title><italic>RNF135</italic> mutations are not present in patients
with Sotos syndrome-like features</article-title>
<source/>Am J Med Genet A
          <year>2009</year>
<volume>149A</volume>
<fpage>806</fpage>
<lpage>808</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.32694</pub-id>
<pub-id pub-id-type="pmid">19291764</pub-id>
</element-citation>
</ref>
<ref id="CR240">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vissers</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Stankiewicz</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Microdeletion and microduplication
syndromes</article-title>
<source/>Methods Mol Biol
          <year>2012</year>
<volume>838</volume>
<fpage>29</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1007/978-1-61779-507-7_2</pub-id>
<pub-id pub-id-type="pmid">22228006</pub-id>
</element-citation>
</ref>
<ref id="CR241">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schuhmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roehl</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Mußotter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Delineation of the clinical phenotype associated with
non-mosaic type-2 <italic>NF1</italic> deletions: two case
reports</article-title>
<source/>J Med Case Rep
          <year>2011</year>
<volume>5</volume>
<fpage>577</fpage>
<pub-id pub-id-type="doi">10.1186/1752-1947-5-577</pub-id>
<pub-id pub-id-type="pmid">22151963</pub-id>
</element-citation>
</ref>
<ref id="CR242">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mussotter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bengesser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Högel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chuzhanova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>van den Ende</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Messiaen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Identification of recurrent type-2 <italic>NF1</italic> microdeletions reveals a mitotic nonallelic
homologous recombination hotspot underlying a human genomic
disorder</article-title>
<source/>Hum Mutat
          <year>2012</year>
<volume>33</volume>
<fpage>1599</fpage>
<lpage>1609</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22171</pub-id>
<pub-id pub-id-type="pmid">22837079</pub-id>
</element-citation>
</ref>
<ref id="CR243">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bengesser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Wimmer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>van Minkelen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brems</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Högel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lazaro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rosenbaum</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bammert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Messiaen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>SVA retrotransposon insertion-associated deletion
represents a novel mutational mechanism underlying large genomic copy number
changes with non-recurrent breakpoints</article-title>
<source/>Genome Biol
          <year>2014</year>
<volume>15</volume>
<fpage>R80</fpage>
<pub-id pub-id-type="doi">10.1186/gb-2014-15-6-r80</pub-id>
<pub-id pub-id-type="pmid">24958239</pub-id>
</element-citation>
</ref>
<ref id="CR244">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waggoner</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Towbin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gottesman</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>A clinic-based study of plexiform neurofibromas in
neurofibromatosis 1</article-title>
<source/>Am J Med Genet
          <year>2000</year>
<volume>92</volume>
<fpage>132</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(20000515)92:2&lt;132::AID-AJMG10&gt;3.0.CO;2-6</pub-id>
<pub-id pub-id-type="pmid">10797438</pub-id>
</element-citation>
</ref>
<ref id="CR245">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wallace</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Fountain</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Odeh</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Viskochil</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Marchuk</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>O’Connell</surname>
<given-names>P</given-names>
</name>
<name>
<surname>White</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>FS</given-names>
</name>
</person-group>
<article-title>A chromosome jump crosses a translocation breakpoint
in the von Recklinghausen neurofibromatosis region</article-title>
<source/>Genes Chromosomes Cancer
          <year>1990</year>
<volume>2</volume>
<fpage>271</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="doi">10.1002/gcc.2870020404</pub-id>
<pub-id pub-id-type="pmid">2176541</pub-id>
</element-citation>
</ref>
<ref id="CR246">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Demethylation of miR-9-3 and miR-193a genes suppresses
proliferation and promotes apoptosis in non-small cell lung cancer cell
lines</article-title>
<source/>Cell Physiol Biochem
          <year>2013</year>
<volume>32</volume>
<fpage>1707</fpage>
<lpage>1719</lpage>
<pub-id pub-id-type="doi">10.1159/000356605</pub-id>
<pub-id pub-id-type="pmid">24356455</pub-id>
</element-citation>
</ref>
<ref id="CR247">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weise</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mrasek</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mulatinho</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Llerena</surname>
<given-names>JC</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Hardekopf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pekova</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bhatt</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kosyakova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Liehr</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Microdeletion and microduplication
syndromes</article-title>
<source/>J Histochem Cytochem
          <year>2012</year>
<volume>60</volume>
<fpage>346</fpage>
<lpage>358</lpage>
<pub-id pub-id-type="doi">10.1369/0022155412440001</pub-id>
<pub-id pub-id-type="pmid">22396478</pub-id>
</element-citation>
</ref>
<ref id="CR248">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wessel</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Albers</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>The association between hypotonia and brain tumors in
children with neurofibromatosis type 1</article-title>
<source/>J Child Neurol
          <year>2013</year>
<volume>28</volume>
<fpage>1664</fpage>
<lpage>1667</lpage>
<pub-id pub-id-type="doi">10.1177/0883073812460918</pub-id>
<pub-id pub-id-type="pmid">23071069</pub-id>
</element-citation>
</ref>
<ref id="CR249">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schwab</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Nogo and Nogo receptor: relevance to
schizophrenia?</article-title>
<source/>Neurobiol Dis
          <year>2013</year>
<volume>54</volume>
<fpage>150</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2013.01.011</pub-id>
<pub-id pub-id-type="pmid">23369871</pub-id>
</element-citation>
</ref>
<ref id="CR250">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kirschner</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Hanh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mugridge</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Linton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Edelman</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Vallely</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>McCaughan</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Klebe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Brahmbhatt</surname>
<given-names>H</given-names>
</name>
<name>
<surname>MacDiarmid</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Zandwijk</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>miR-193a-3p is a potential tumor suppressor in
malignant pleural mesothelioma</article-title>
<source/>Oncotarget
          <year>2015</year>
<volume>6</volume>
<fpage>23480</fpage>
<lpage>23495</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.4346</pub-id>
<pub-id pub-id-type="pmid">26125439</pub-id>
</element-citation>
</ref>
<ref id="CR251">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Boles</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>BR</given-names>
</name>
</person-group>
<article-title>Deletion of the entire <italic>NF1</italic> gene detected by the FISH: four deletion patients associated
with severe manifestations</article-title>
<source/>Am J Med Genet
          <year>1995</year>
<volume>59</volume>
<fpage>528</fpage>
<lpage>535</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320590427</pub-id>
<pub-id pub-id-type="pmid">8585580</pub-id>
</element-citation>
</ref>
<ref id="CR252">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>BR</given-names>
</name>
</person-group>
<article-title>Deletion of the entire <italic>NF1</italic> gene causing distinct manifestations in a
family</article-title>
<source/>Am J Med Genet
          <year>1997</year>
<volume>69</volume>
<fpage>98</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19970303)69:1&lt;98::AID-AJMG19&gt;3.0.CO;2-J</pub-id>
<pub-id pub-id-type="pmid">9066892</pub-id>
</element-citation>
</ref>
<ref id="CR253">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>López-Correa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rutkowski</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Baumbach</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Glover</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Germline mutations in NF1 patients with
malignancies</article-title>
<source/>Genes Chromosomes Cancer
          <year>1999</year>
<volume>26</volume>
<fpage>376</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1098-2264(199912)26:4&lt;376::AID-GCC13&gt;3.0.CO;2-O</pub-id>
<pub-id pub-id-type="pmid">10534774</pub-id>
</element-citation>
</ref>
<ref id="CR254">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xing</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>XQ</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>FY</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Bin-Zhou</surname>
<given-names>WuJB</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Long non-coding RNA HOTAIR modulates c-KIT expression
through sponging miR-193a in acute myeloid leukemia</article-title>
<source/>FEBS Lett
          <year>2015</year>
<volume>589</volume>
<fpage>1981</fpage>
<lpage>1987</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2015.04.061</pub-id>
<pub-id pub-id-type="pmid">25979172</pub-id>
</element-citation>
</ref>
<ref id="CR255">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ismat</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Antonucci</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Cardiomyocyte-specific loss of neurofibromin promotes
cardiac hypertrophy and dysfunction</article-title>
<source/>Circ Res
          <year>2009</year>
<volume>105</volume>
<fpage>304</fpage>
<lpage>311</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.201509</pub-id>
<pub-id pub-id-type="pmid">19574548</pub-id>
</element-citation>
</ref>
<ref id="CR256">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kwong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>A novel miR-193a-5p-YY1-APC regulatory axis in human
endometrioid endometrial adenocarcinoma</article-title>
<source/>Oncogene
          <year>2013</year>
<volume>32</volume>
<fpage>3432</fpage>
<lpage>3442</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2012.360</pub-id>
<pub-id pub-id-type="pmid">22907428</pub-id>
</element-citation>
</ref>
<ref id="CR257">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoneyama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Onomoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jogi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Akaboshi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Viral RNA detection by RIG-I-like
receptors</article-title>
<source/>Curr Opin Immunol
          <year>2015</year>
<volume>32</volume>
<fpage>48</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1016/j.coi.2014.12.012</pub-id>
<pub-id pub-id-type="pmid">25594890</pub-id>
</element-citation>
</ref>
<ref id="CR258">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>MicroRNA-193a-3p and -5p suppress the metastasis of
human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2
signaling pathway</article-title>
<source/>Oncogene
          <year>2015</year>
<volume>34</volume>
<fpage>413</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2013.574</pub-id>
<pub-id pub-id-type="pmid">24469061</pub-id>
</element-citation>
</ref>
<ref id="CR259">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yzaguirre</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Padmanabhan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Groh</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Engleka</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Speck</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Loss of neurofibromin Ras-GAP activity enhances the
formation of cardiac blood islands in murine embryos</article-title>
<source/>Elife
          <year>2015</year>
<volume>4</volume>
<fpage>e07780</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.07780</pub-id>
<pub-id pub-id-type="pmid">26460546</pub-id>
</element-citation>
</ref>
<ref id="CR260">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sausen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Belzberg</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Chaichana</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gallia</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Gokaslan</surname>
<given-names>ZL</given-names>
</name>
<name>
<surname>Riggins</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Wolinksy</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Hruban</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Kinzler</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Papadopoulos</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vogelstein</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bettegowda</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Somatic mutations of <italic>SUZ12</italic> in malignant peripheral nerve sheath tumors</article-title>
<source/>Nat Genet
          <year>2014</year>
<volume>46</volume>
<fpage>1170</fpage>
<lpage>1172</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3116</pub-id>
<pub-id pub-id-type="pmid">25305755</pub-id>
</element-citation>
</ref>
<ref id="CR261">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Molecular characterization of <italic>NF1</italic> and neurofibromatosis type 1 genotype-phenotype correlations
in a Chinese population</article-title>
<source/>Sci Rep
          <year>2015</year>
<volume>5</volume>
<fpage>11291</fpage>
<pub-id pub-id-type="doi">10.1038/srep11291</pub-id>
<pub-id pub-id-type="pmid">26056819</pub-id>
</element-citation>
</ref>
<ref id="CR262">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ou Ding</surname>
<given-names>CZ</given-names>
</name>
</person-group>
<article-title>miR-365 promotes cutaneous squamous cell carcinoma
(CSCC) through targeting nuclear factor I/B (NFIB)</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e100620</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0100620</pub-id>
<pub-id pub-id-type="pmid">24949940</pub-id>
</element-citation>
</ref>
<ref id="CR263">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>microRNA-365-targeted nuclear factor I/B
transcriptionally represses cyclin-dependent kinase 6 and 4 to inhibit the
progression of cutaneous squamous cell carcinoma</article-title>
<source/>Int J Biochem Cell Biol
          <year>2015</year>
<volume>65</volume>
<fpage>182</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2015.06.009</pub-id>
<pub-id pub-id-type="pmid">26072217</pub-id>
</element-citation>
</ref>
<ref id="CR264">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zickler</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Hampp</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Messiaen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bengesser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mussotter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Roehl</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Wimmer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pasmant</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chuzhanova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kestler</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Högel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Kehrer-Sawatzki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Characterization of the nonallelic homologous
recombination hotspot PRS3 associated with type-3 <italic>NF1</italic> deletions</article-title>
<source/>Hum Mutat
          <year>2012</year>
<volume>33</volume>
<fpage>372</fpage>
<lpage>383</lpage>
<pub-id pub-id-type="doi">10.1002/humu.21644</pub-id>
<pub-id pub-id-type="pmid">22045503</pub-id>
</element-citation>
</ref>
<ref id="CR265">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuccotti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cartelli</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Stroppi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pandini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Venturin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aliverti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Battaglioli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cappelletti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Centaurin-α<sub>2</sub> interacts with
β-tubulin and stabilizes microtubules</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e52867</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0052867</pub-id>
<pub-id pub-id-type="pmid">23285209</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>